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ABSTRACT 
The past thirty years have reported the introduction of multiple anticancer 
therapies targeting various aspects of the cancer hallmarks, which are essential for 
successful tumor propagation and dissemination. In this sense, the evolution of 
molecular-scale technology has been central to the identification of new cancer 
targets.  
The receptor tyrosine kinase (RTK) Hardy-Zuckerman 4 feline sarcoma virus 
homolog (c-KIT) is a critical regulator of growth, differentiation, migration and 
proliferation in the hematopoietic system, in germ cells and melanocytes. Since it 
activates a number of intracellular signaling pathways implicated in the tumor 
progression, it is one of the most studied proto-oncogenes as well as the target of 
drugs belonging to the family of tyrosine kinase inhibitors (TKIs). Actually, TKIs are 
employed for the treatment of human and canine c-KIT-dependent tumors as an 
alternative to standard chemotherapy. Nevertheless, multiple resistance phenomena 
frequently occur. 
Recently, the discovery of G-quadruplex (G4) structures highlighted a new role 
for DNA in cancer biology. DNA G4 are four-stranded globular nucleic acid 
secondary structures, formed in specific G-rich sequences with biological 
significance; among these ones, the human telomeres and the promotorial region of 
oncogenes such as c-KIT. 
In the first part of this dissertation, three compounds were proved to bind in 
silico c-KIT G4 and were tested in human and canine cell lines to check for their 
potential usefulness as therapeutic agents. Interesting results, e.g. c-KIT mRNA and 
protein inhibition, were obtained with an anthraquinone derivative (AQ1) that caused 
a block of cell proliferation. 
In another study, the occurrence of c-KIT mutations was investigated in 
matched primary and metastatic canine cutaneous mast cell tumor (MCT), to make a 
recommendation for the best therapeutic choice. In dogs, 10-30% of MCTs possess c-
KIT mutations, and the relevance of the mutational status for the therapy with TKIs is 
nowadays accepted also in this species; however, little is known on c-KIT mutational 
status in metastatic MCTs. In all analyzed dogs, there was a perfect concordance 
between c-KIT mutational status in primary MCT and the relative lymph node 
metastasis. This has a relevant implication for clinical practices. 
Finally, during the Ph.D. program, a collaboration was established with the 
Centre de Recherche en Cancérologie de Marseille, and particularly with Dr. Patrice 
Dubreuil. In his most recent articles, he discovered a set of genes that are frequently 
mutated in human systemic mastocytosis (SM) and cooperate with c-KIT in the 
disease malignant evolution. In the last study illustrated in this Ph.D. thesis, the 
mutational profile of these hotspot genes in canine MCTs samples has been screened, 
in order to find molecular similarities between the two diseases, thereby justifying the 
use of domestic dog as an animal model in comparative oncology. 
  
RIASSUNTO 
Negli ultimi trent’anni, l’evoluzione delle tecnologie in campo medico-
scientifico ha permesso la più profonda conoscenza dei meccanismi molecolari alla 
base dello sviluppo, della crescita e della diffusione del tumore. Tutto ciò ha 
permesso di sviluppare le cosiddette terapie mirate, identificando nuovi bersagli 
terapeutici.  
Il recettore tirosin-chinasico c-KIT è un fattore critico per la regolazione della 
crescita, differenziazione, migrazione e proliferazione delle cellule germinali, di 
quelle del sistema ematopoietico e dei melanociti. c-KIT è anche coinvolto 
nell’attivazione di numerosi meccanismi intracellulari implicati nella progressione 
tumorale e, allo stesso tempo, è uno dei proto-oncogeni più studiati ed il bersaglio di 
farmaci appartenenti alla famiglia degli inibitori tirosin-chinasici (TKIs). 
Attualmente, i TKIs sono approvati come trattamento alternativo alla chemioterapia 
tradizionale in tumori c-KIT dipendenti in uomo e cane tuttavia, fenomeni di 
resistenza a questi farmaci si verificano frequentemente. 
Negli ultimi anni, la scoperta di strutture secondarie del DNA chiamate G-
quadruplex (G4) ha evidenziato un nuovo ruolo degli acidi nucleici nella biologia 
tumorale. Tali conformazioni si formano in specifiche sequenze del DNA ricche in 
residui di guanina, localizzate principalmente nei telomeri e nelle regioni 
promotoriali di alcuni oncogeni come c-KIT. 
Nella prima parte di questa tesi di dottorato, tre composti scelti sulla base della 
loro capacità di legare e stabilizzare le conformazioni G4 sono stati testati in linee 
cellulari stabilizzate di uomo e cane al fine di determinare la loro efficacia come 
potenziali agenti terapeutici. In questo senso, alcuni risultati interessanti in termini di 
blocco della proliferazione nonché della trascrizione e traduzione di c-KIT si sono 
ottenuti con un derivato della famiglia degli antrachinoni chiamato AQ1. 
In un altro studio proposto, il profilo mutazionale di c-KIT è stato analizzato in 
una coorte di campioni di mastocitoma del cane composti da tumore primitivo e 
relativa metastasi linfonodale. Nel cane infatti, la percentuale tra il 10 ed il 30% dei 
mastocitomi presenta almeno una mutazione di c-KIT nel tumore primitivo, tuttavia, 
poche conoscenze si hanno relativamente al profilo mutazionale nelle metastasi. Dai 
risultati ottenuti, tutti i cani analizzati hanno dimostrato avere una perfetta 
concordanza tra tumore primitivo e metastasi in termini di status mutazionale di c-
KIT con rilevanti implicazioni cliniche per la scelta della miglior terapia da attuare da 
parte degli oncologi veterinari. 
Infine, nel corso del secondo anno di dottorato, è nata una collaborazione con il 
Dr. Patrice Dubreuil del Centre de Recherche en Cancérologie de Marseille, a 
Marsiglia. Nei suoi recenti articoli sulla mastocitosi dell’uomo, egli ha scoperto un 
set di geni che presentano mutazioni in talune percentuali di casi e cooperano con c-
KIT nello sviluppo delle forme più gravi ed aggressive della malattia. Nell’ultima 
pubblicazione illustrata in questa dissertazione, è stato eseguito lo screening del 
profilo mutazionale di questi nuovi geni in campioni di mastocitoma di cane al fine di 
trovare analogie molecolari che possano giustificare l’uso del cane come animale 
modello nell’oncologia comparata. 
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1. GENERAL INTRODUCTION 
 
1.1 CANCER TARGETED THERAPY 
In developed countries, cancer is a leading cause of death mainly associated 
with population ageing and lifestyle, with 14.1 million of new cases and 8.2 million 
of deaths worldwide in 2012. Despite this, early diagnosis, universal access to health 
cares and the development of even more innovative therapies resulted in a significant 
improvement of cancer survival (Urruticoechea et al., 2010). 
Among the therapeutic strategies, surgery is the oldest and remains an effective 
treatment for localized primary tumors and associated regional lymphatics 
(Urruticoechea et al., 2010).  
The advent of radiation therapy (1920s) and chemotherapy (1940s) permitted 
the cure and the control of the metastatic processes but, in contrast to surgery, they 
are efficient only against a fraction of tumor cells by each treatment. For these 
reasons, the three processes are complementary: as an example, radiotherapy 
protocols are today used pre- and post-surgery in a number of tumor locations such as 
rectal and esophageal carcinomas or breast and central nervous system tumors. Also 
intraoperative radiation therapy, consisting in the delivery of a single large fraction 
during surgery with either electrons or low energy photons, is occasionally used. 
Chemo- and radiotherapy combined approaches (the administration of chemotherapy 
prior to, during or following radiotherapy) have been shown to improve local control 
and eradicate micro-metastatic disease (Urruticoechea et al., 2010). 
For more than 50 years, the systemic therapy of cancer has been dominated by 
the use of cytotoxic chemotherapeutics. Most of these drugs are designed to kill or 
rapidly inhibit all dividing cells through the creation of DNA-damages. They are 
administered either in single doses or in short courses of therapy at the "Maximum 
Tolerated Dose" (MTD), which means the highest administrable doses without no 
life-threatening toxicity levels (Schrama et al., 2006). Owing to the high doses of 
these anticancer drugs, a wide treatment-free period is needed to permit normal host 
cells recovery. Moreover, it is nowadays clear that the genetic instability and high 
mutation rate of cancer cells resulting from chemotherapy carries a high risk of 
selection for drug-resistant cell clones (Urruticoechea et al., 2010). 
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The concept of tumor heterogeneity refers to the existence of cell 
subpopulations harboring distinct phenotypic profiles resulting from the integration, 
within and between tumors (intra- and inter-tumor heterogeneity), of both genetic and 
non-genetic influences (Huang et al., 2014). In this sense, the past decade has borne 
witness to a transformation in cancer treatment options. The elucidation of the 
molecular basis of cellular transformation, the concept that cancer is a genetic disease 
of somatic cells and that these genetic and epigenetic alterations underlie an aberrant 
transcription program has created a novel framework actually changing the clinical 
practice (Abou-Jawde et al., 2003). Furthermore, the realization that cancer cells need 
a microenvironment (i.e. fibroblasts, vessels, macrophages, lymphocytes, etc.) to 
survive and fully display their phenotype opened the door to new therapeutic 
strategies termed as ‘targeted therapy’. The new targets included signaling molecules, 
cell-cycle proteins, apoptosis modulators, growth factors, and molecules promoting 
angiogenesis. Although each cancer seems to have its own pattern of signature 
mutations, some common aberrations in signaling appear in several tumors. These 
looked as interesting targets for drug development and have changed the concept of 
therapy (Urruticoechea et al., 2010).  
Three main classes of targeted therapies are now routinely employed in a clinical 
setting: monoclonal antibodies, small molecule inhibitors and fusion proteins (Tobin 
et al., 2015). The first example of antibody used to cure cancer was trastuzumab 
(Herceptin
®
, Genentech) approved in 1998 as a second line treatment for metastatic 
breast cancer (Nahta et al., 2006; Huang et al., 2014). It is directed against the 
extracellular domain of the transmembrane Erb-B2 Receptor Tyrosine Kinase 2 
(ERBB2), which is overexpressed in 20-30% of breast cancer. This high expression 
is relatively homogeneous among ERBB2+ tumor cells, both in the primary tumor 
and metastatic sites, suggesting for its effectiveness in all disease locations and 
against most of cancer cells (Nahta et al., 2006). Trastuzumab is generally well 
tolerated but some infusion-related reactions are likely to occur, including fever, 
rigors, chills, nausea, dyspnea and hypotension. A cardiac toxicity was the most 
problematic adverse event ever noted in combination chemotherapy trials 
(trastuzumab plus standard chemotherapy; Stern and Herrmann, 2005). 
The use of the monoclonal chimeric IgG1 antibody IDEC-C2B8, also called 
Rituximab (Rituxan or MabThera or Zytux, distributed by different brands), 
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permitted the successful treatment of single patients with non-Hodgkin lymphoma 
(NHL). The antibody recognizes and binds the CD20 antigen, a transmembrane 
phosphoprotein essential for B-lymphocytes differentiation and proliferation. 
Rituximab does not severely compromise the immunity of the patience since 
immature precursor cells and the other components of the immune system do not 
possess CD20 (Adams and Weiner, 2005; Stern and Herrmann, 2005). Therefore, 
despite B-lymphopenia, rituximab has only infusion related toxicity. 
The bevacizumab (Avastin
®
, Genentech, Roche) is a monoclonal antibody that 
binds and neutralizes all the human vascular endothelial growth factor A (VEGF-A) 
isoforms. Firstly approved in 2004, it is used in combination with standard 
chemotherapy for metastatic colon cancer. It is used for treatment of other types of 
metastatic cancers as certain lung cancers, renal cancers, ovarian cancers, and 
glioblastoma multiforme of the brain. It acts inhibiting the growth and proliferation of 
blood vessels, which are part of the body's normal healing and maintenance. In this 
sense, the main side effects are hypertension and increased risk of bleeding. 
One example of fusion protein used against cancer is constituted by Aflibercept 
(VEGF-Trap; ziv-aflibercept; Zaltrap, Sanofi-Aventis SpA), an intravenously 
administered recombinant protein, designed to block angiogenesis promoters. 
Aflibercept is a fully human, recombinant fusion protein acting as a soluble decoy for 
VEGF receptor. It is formed by the second and the third extracellular binding 
domains of human VEGF receptors 1 and 2 (VEGFR-1 and VEGFR-2) fused to the 
crystallisable fragments (Fc) portion of a human immunoglobulin G1. Aflibercept 
binds to VEGF-A, VEGF-B and to the placenta growth factor (P1GF) to form a stable 
inert complex; this latter prevents them from binding to their appropriate receptors 
(Weidle et al., 2012; Syed and McKeage, 2015). 
Another molecular target for new therapeutic strategies is constituted by the 
apoptosis pathway. Apoptosis is one of the major mechanisms of cell death in 
response to cancer therapies. Modifications in susceptibility to apoptosis by tumor 
cells not only contribute to neoplastic development, but also can enhance resistance 
to conventional anticancer therapies (Kang and Reynolds, 2009). The first agent 
targeting the B-Cell CLL/Lymphoma 2 (BCL2) that entered in clinical trials was a 
BCL2 antisense oligonucleotide (oblimersen sodium), which has shown chemo-
sensitizing effects when combined with conventional chemotherapy in chronic 
lymphocytic leukemia (CLL) patients, thereby improving survival (Kang and 
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Reynolds, 2009). More recent advances include the discovery of small molecule 
inhibitors of the B-cell lymphoma 2 (Bcl-2) family proteins, and three of them have 
entered clinical trials (gossypol, ABT-737, GX 15-070; Kang and Reynolds, 2009; 
Fulda, 2015). They are designed to bind the hydrophobic groove of anti-apoptotic 
Bcl-2 proteins in place of BH3-only proteins (i.e., BH3-mimetics). They can bind 
Bax or Bak, which can subsequently depolarize mitochondrial membrane potential, 
favor the cytochrome c release, begin caspase cascade and, consequently, activate 
apoptosis.  
The Figure 1 reassume the most common examples of targeted therapies. 
 
Figure 1. Mechanisms of targeted therapy. Some drugs (e.g., sorafenib 
[Nexavar], sunitinib [Sutent], imatinib [Gleevec], dasatinib [Sprycel]) have 
multiple targets, most of which are not indicated (CD=cluster of 
differentiation; BCR-ABL= breakpoint cluster region-Abelson; EGFR = 
epithelial growth factor receptor; VEGFR = vascular endothelial growth 
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factor receptor; VEGF = vascular endothelial growth factor). Modified 
from: Gerber, 2008. 
 
1.2 RECEPTOR TYROSINE KINASE 
Tyrosine kinases catalyze the transfer of the γ phosphate group from adenosine 
triphosphate (ATP) to target proteins. They can be classified either as receptor 
tyrosine kinases (RTKs) or non-receptor protein kinases (Arora and Scholar, 2005). 
RTKs are transmembrane receptors for extracellular signaling molecules, 
including growth factors and hormones. The typical RTK structure consists of an 
extracellular ligand-binding domain, a regulatory transmembrane region, and a 
cytoplasmic kinase domain (KD) that becomes phosphorylated on tyrosine residues 
upon dimerization or oligomerization (Lemmon and Schlessinger 2010). Once 
phosphorylated, RTKs recruit adaptor proteins to cause a cascade of protein 
interactions among intracellular effectors that eventually result in altered gene 
expression and protein functions. Some examples of these downstream effectors 
include small GTP kinases (RAS proteins), members of the mitogen activated protein 
kinase (MAPK) family, phosphoinositide 3-kinases (PI3K) and Janus kinase/signal 
transducers and activators of transcription (JAK/STAT) proteins. Overall, these 
proteins regulate critical cellular processes such as cell metabolism, survival, 
proliferation, differentiation as well as cell–cell communication. Since these 
processes are essential for cell maintenance and division, it is not surprising that 
dysregulation of RTKs, or their down-stream effectors, is considered a “driver event” 
in a wide range of cancers (Sun and Bernards, 2014). 
There are approximately 60 receptor tyrosine kinases identified so far, and 
these ones are divided into around 20 subfamilies defined by the receptor and/or their 
ligand (Arora and Scholar, 2005). Some examples of RTKs are represented by c-KIT 
or the platelet-derived growth factor receptor alpha (PDGFRα) and beta (PDGFRβ). 
 
1.3 TYROSINE KINASE INHIBITORS 
Small molecule tyrosine kinase inhibitors (TKIs) actually represent a major 
class of cancer targeted therapeutics.  
Their small size (usually <500 Da) allows them to translocate through the 
plasma membrane and interact with the cytoplasmic domain of cell-surface receptors, 
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competing with adenosine triphosphate (ATP) for the binding site and, thereby, 
inhibiting the kinase activity.  
In 2000, imatinib mesylate (IM, STI-571 or Gleevec) was introduced for the 
treatment of chronic myelogenous leukemia (CML; Arora and Scholar, 2005). In over 
90% of human patients with CML, and approximately 15-30% of adult patients with 
acute lymphoblastic leukemia (ALL), the t(9;22) translocation or Philadelphia 
chromosome (Ph) is a characteristic cytogenetic abnormality. This defect results in 
the formation of the BCR-ABL oncogene by fusing the breakpoint cluster region 
(BCR) on chromosome 22 with the tyrosine kinase Abelson murine leukemia viral 
oncogene homolog 1 (ABL) located on chromosome 9 (An et al., 2010). The fusion 
protein interacts with multiple downstream signaling pathways mediating the 
development and maintenance of CML, resulting in altered cellular adhesion, 
activation of mitogenic signaling, inhibition of apoptosis, and defective DNA repair. 
Imatinib is the first BCR-ABL tyrosine kinase inhibitor (An et al., 2010) and its 
mechanism of action is showed in Figure 2 (Deininger and Druker, 2003). 
 
Figure 2. Imatinib binding on 
BCR-ABL. ADP= adenosine 
diphosphate; ATP= adenosine 
triphosphate; P= phosphate. 
Modified from 
http://kohnpharmaceuticals.weebly.
com/biochemical-pathways.html. 
Besides BCR-ABL, imatinib also inhibits c-kit and pdgfr tyrosine kinases in 
gastrointestinal stromal tumor (GIST; Hirota et al., 1998). Most GIST carry c-KIT 
mutations associated with constitutive activation and receptor phosphorylation. 
Several clinical trials have shown a significant response to imatinib in more than half 
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the patients with advanced GISTs; those with mutations in the exon 11 of c-KIT had 
the best response, whereas the few patients without either c-KIT or PDGFRα 
mutations were not responsive. Imatinib is now approved for the treatment of patients 
with c-KIT-positive unresectable and/or malignant GISTs (Krause and Van Etten, 
2005; Antonescu, 2011).  
Other FDA (US Food and Drugs Administration) approved TKIs and their 
cellular targets are reported in Table 1. 
Inhibitor Trade Name Target Cancer Type 
Imatinib masylate Gleevec ABL, c-KIT, PDGFR Ph+ CML, GISTs, ALL 
Dasatinib Sprycel SFK, ABL CML, ALL 
Nilotinib Tasigna ABL CML 
Bosutinib Bosulif SFK, ABL CML 
Gefitinib Iressa EGFR NSCLC 
Erlotinib Tarceva EGFR Lung 
Lapatinib Tykerb EGFR, ERBB2 Breast, others 
Vandetanib Caprelsa EGFR, VEGFR, RET Medullary tryroid 
Crizotinib Xalkori EML4-ALK NSCLC 
Sunitinib Sutent VEGFR, PDGFR, c-KIT, FLT3 GIST, renal 
Sorafenib Nexavar B-Raf, VEGFR, PDGFR Renal, hepatocellular, 
prostate 
Pazopanib Votrient VEGFR, c-KIT, PDGFR Renal: soft tissue sarcoma 
Regorafenib Stivarga VEGFR, TIE2, PDGFR, RET, c-
KIT, RAF 
Colorectal 
Cabozantinib Cometriq VEGFR, RET, MET, TRKB, TIE2 Medullary thyroid 
Table 1: FDA approved tyrosine kinase inhibitors used for treatment of cancer. SFK= Src 
family kinase; EGFR= human epidermal growth factor receptor; ERBB2= Erb-B2 Receptor 
Tyrosine Kinase 2; RET= Ret proto-oncogene; EML4-ALK= echinoderm microtubule 
associated protein like 4 – anaplastic lymphoma kinase; FLT3= Fms-related tyrosine kinase 
3; BRAF= B-Raf Proto-Oncogene, Serine/Threonine Kinase; TIE2= TEK tyrosine kinase, 
endothelial; RAF= Raf Proto-Oncogene, Serine/Threonine Kinase; MET = MET Proto-
Oncogene, Receptor Tyrosine Kinase; TRKB = Neurotrophic Tyrosine Kinase, Receptor, 
Type 2. From Miller et al., 2013. 
Gefinitib and erlotinib are other TKIs acting as anti-epithelial growth factor 
receptor (EGFR) drugs in non-small cell lung carcinomas (NSCLC) and head and 
neck squamous cell carcinomas (HNSCC).  
1.3.1 LIMITS AND SECOND GENERATION TKIs 
Targeted cancer therapies are less toxic than conventional chemotherapy 
because they are specific for tumor cells. However, some toxic effects of TK-targeted 
therapies may be related to inhibition of tyrosine kinase in normal tissues. Defects in 
cell-mediated immunity have been reported in patients with imatinib-treated CML 
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and may be a consequence of blockade of c-ABL signaling in T-lymphocytes (Krause 
et al., 2005). 
Other clinical and in vitro evidences showed that cells treated with TKIs tend to 
acquire genetic modifications resulting in resistance to these agents. Up to now, more 
than 100 mutations have been described affecting more than 70 amino acids and 
causing resistance by heterogeneous molecular mechanisms. The most common and 
prevalent mechanism leading to resistance to TKIs therapy is the occurrence of point 
mutations within the KD, which decrease the affinity of the TKI to the receptor 
binding domain. Other mutations may affect the binding site, resulting in extensive 
conformational changes, which impede TKIs bond through steric hindrance.  
Around 30% of patients with CML interrupt Imatinib therapy due to intolerance 
and resistance. Only the T315I mutation (resulting in the substitution of Ile with Thr 
at the position 315) is responsible for 14% of reported cases. In CML, there are 
several second-generation ABL kinase inhibitors (i.e. nilotinib and dasatinib) 
showing increased potency and effectiveness against most of imatinib-resistant BCR-
ABL mutants (Weisberg et al., 2007). 
Secondary mutations in exon 14 of c-KIT and in its exon 17 (activation loop: 
D816V/H, D820Y, N822Y/K, Y823D), as well as in exon 14 of PDGFRα (D842V, 
ATP binding site: T670I) confer imatinib and sunitinib-resistance in GIST (Chen and 
Fu, 2011). Sunitinib is a new TKI that exerts its effects on various TKs such as 
VEGFR, c-KIT, and PDGFR and shows a broad-spectrum antitumor activity by 
inhibiting both tumor proliferation and angiogenesis. 
Although the precise mechanisms behind the incoming of these new alterations 
are not very clear, one evidence for these phenomena is that specific TKI treatments 
help tumor to select a preexisting cell population, which has a selective advantage in 
a sort of striking analogy to a bacterial culture treated with an antibiotic. In addition, 
TKIs increase patients’ genetic instability that promotes the acquisition of new 
mutations (Chen and Fu, 2011). 
Other well-defined mechanisms of resistance in patients are represented by the 
overexpression of genes, increments in protein level and activation of alternative 
survival pathways (Deininger and Druker, 2003). About this latter mechanism, MET 
amplification in EGFR-mutants NSCLC represents the strongest evidence that cells 
treated with TKIs tend to undertake new strategies to overcome the inhibition. The 
activation of MET, a transmembrane RTK acting as an hepatocytes growth factor 
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(HGF) receptor, leads to sustained activation of the PI3K/AKT signaling pathway, 
bypassing the inhibition of EGFR conferred by TKIs (Stewart et al., 2015). 
For the antiangiogenic agents (e.g., semaxinib, etc.), there may be additional 
explanations for the poor responses obtained against cancers up to date. VEGF is 
thought to be the most potent direct-acting stimulatory regulator of angiogenesis, and 
its expression is excessive in human cancers; however, there are a myriad of 
stimulatory and inhibitory factors involved in angiogenesis; some of these are 
produced by tumor cells, whilst others are produced by host cells. In addition, for 
each angiogenic factor, multiple regulatory factors and signaling pathways exist. 
With all this redundancy, inhibiting one factor or one pathway is often not sufficient 
to inhibit tumor growth. Furthermore, some factors such as VEGF, exist in multiple 
isoforms, contributing to the difficulty of inhibiting the angiogenic process (Arora 
and Scholar, 2005). 
Finally, in tumor cell lines, multidrug resistance (MDR) is often associated with 
an ATP-dependent decrease in cellular drug accumulation, which is usually attributed 
to the overexpression of certain ATP-binding cassette (ABC) transporter proteins. 
Among ABC-transporters, the overexpression of P-glycoprotein (MDR1/P-
gp/ABCB1) and the breast cancer resistance protein (BCRP/ABCG2) confer 
resistance to imatinib in CML or gefitinib in NSCLN. Further investigations 
indicated that imatinib, gefitinib, tandutinib, dasatinib, sunitinib and sorafenib are 
high-affinity substrates of MDR1 and ABCG2 (Ozvegy-Laczka et al., 2005). 
Collectively, the chemo-immune system seems to recognize targeted TKIs as 
xenobiotics at the membrane barriers and, in case of active extrusion, protects 
intracellular targets from the action of the TKIs (Chen and Fu, 2011). These findings 
suggest that overexpression of ABC-transporters protects tumor cells from TKIs 
inhibition activity contributing to their pharmacokinetics and pharmacodynamics. 
 
1.4 c-KIT 
The v-kit oncogene was identified in 1986 in the Hardy-Zuckerman 4 feline 
sarcoma virus (Besmer et al., 1986), and its human homolog c-KIT in 1987 (Yarden 
et al., 1987). It is located on chromosome segment 4q11 of the human’s genome and 
in the chromosome 13 of dog’s genome (Reimann-Berg et al., 2012). In both species, 
it consists of 21 exons spanning more than 34 kb of DNA. The first exon encodes the 
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translational initiation codon and the signal peptide. The RTK encoded by the KIT 
gene is a transmembrane protein where exons 2-9 code for the extracellular domain, 
the transmembrane region is encoded by exon 10, while the remaining exons encode 
for the intracellular part of the receptor. 
The promoter region of murine and human c-KIT has been thoroughly 
investigated (Yamamoto et al., 1993; Maeda et al., 2010). It includes binding sites for 
AP-2, basic helix-loop-helix proteins, Sp1, Ets, and Myb. Park et al. in 1998, 
demonstrated the importance of Sp1 for maximal activity of the c-KIT promoter, 
while loss of AP-2 expression caused loss of c-kit expression in malignant 
melanocytes (Huang et al., 1998). Finally, the basic helix-loop-helix microphthalmia 
associated transcription factor (MITF) binds to a CACCTG motif and regulates c-KIT 
expression in mast cells (MC) and melanocytes (Huang et al., 1998). 
The c-kit ligand is constituted by the stem cell factor (SCF, also called Steel 
factor or Kit ligand), a growth factor expressed by fibroblasts and endothelial cells; 
this ligand promotes proliferation, migration, survival, and differentiation of 
hematopoietic progenitors, melanocytes, and germ cells. It maps to chromosome 12 
and 15 in humans and dog genomes, respectively. Both membrane-bound and soluble 
SCF binds to c-kit and activate its intrinsic tyrosine kinase activity. 
The c-kit protein is a member of the class III of RTKs and it consists of 976 
amino acids, representing the core protein (110 kDa). Heterogeneous N-linked 
glycosylation results in a mature protein of between 145 and 160 kDa. It is formed by 
an extracellular part composed of five immunoglobulin-like domains, followed by a 
single spanning transmembrane region. The intracellular part of c-kit starts with the 
juxtamembrane domain (JM), a region of great importance for the regulation of c-kit 
kinase activity and the KD (Lennartsson and Rönnstrand, 2012). 
The c-kit activation process mediated by SCF is summarized in Figure 3. In cell 
membrane, c-kit is diffused as monomer. Each SCF molecule can bind to one c-kit 
molecule through contacts with the first three Ig-like domains (D1-D2-D3) of the 
receptor’s extracellular region, which have a complementary shape and charge to 
allow tight binding of SCF (Lemmon and Schlessinger, 2010; Lennartsson and 
Rönnstrand, 2012). When association with the SCF takes place in two c-kit 
monomers, their D1-D2-D3 regions are kept structurally unaltered but the two 
receptors are drawn closer to each other to form a dimer, leading to a reorientation on 
D4 and D5 (Lemmon and Schlessinger, 2010). Through homotypic interactions 
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between D4 and D5 across the dimer interface, the transmembrane regions and the 
intracellular tyrosine KDs get closer to each other, enabling their activation and 
transphosphorylation along the receptor. These mechanisms leads to initiation of 
downstream signal transduction.  
 
Figure 3. Representation of SCF-mediated c-KIT 
activation. (1) The stem cell factor (SCF) interact, at 
cell membrane level, with c-KIT Ig-like domains 1-3 of 
two monomers. (2) The SCF binding drive the two 
monomers close to each other and favored their 
interactions between Ig-domains 4 and 5. (3) c-kit 
homodimer allows for efficient trans-phosphorylation 
in the juxtamembrane region (Tyr568 and 570), kinase 
insert region (Tyr703, 721, 730, and 747), kinase 
domain (Tyr823 and 900) (by Src kinases), and 
COOH-terminal tail (Tyr936). Modified from 
Lennartsson and Rönnstrand, 2012. 
 
The expression pattern of c-KIT and SCF during mouse embryogenesis 
suggested that they are involved in migration of cells of the hematopoietic, germ cell, 
and melanoblast lineages as well as in the differentiation and proliferation of these 
cells. c-KIT expression is down-regulated upon differentiation of hematopoietic 
progenitors into mature cells of all lineages, except MC, which retain high levels of 
cell surface c-kit expression (Maeda et al., 2010).  
 
1.5 HUMAN c-KIT MUTATIONS AND RELATED DISEASES 
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The oncogenic c-KIT mutations found in neoplasms are gain-of-function 
mutations resulting in ligand-independent tyrosine kinase activity and consequent 
ligand-independent proliferation, differentiation and survival of the affected cells.  
Dysregulation of c-KIT activity plays a central role in the pathogenesis of those 
malignancies originated from cells dependent on SCF for differentiation/survival, 
such as MC and Cajal interstitial cells. These include MC proliferative disorders, 
GIST, melanoma, and acute myeloid leukemia (AML). Increased expression of 
normal c-KIT may also contribute to tumorigenesis in solid lung cancers from small 
lung cells that constitutively do not express c-KIT but are exposed to environments 
rich in SCF (Cruse et al., 2014).  
Gastrointestinal stromal tumors derive from Cajal interstitial cells and multiple 
activating mutations, involving c-KIT exons 8, 11, 13 or 17, have been reported in up 
to 80% of cases (Corless et al., 2011).  
Likewise, approximately 90% of adults with diseases characterized by an 
abnormal MC proliferation (mastocytosis) have, at least, a point mutation consisting 
of a substitution of Aspartic acid to Valine in the catalytic domain of c-KIT (D816V) 
rendering it constitutively active (Arock et al., 2015). The reasons behind the 
prevalence of exon 17 mutations in hematological malignancies compared to those in 
exon 11 in GISTs are still unknown. Activating mutations in JM alter the suppressive 
control effect of this region on the activity of the receptor, while those in the KD are 
catalytic in nature. Mutations occurring on other exons, such as 8, 9 and 10, coding 
either for the extracellular domain (8 and 9) than for the RTK transmembrane domain 
(10), have been described in AML (Malaise et al., 2009), GISTs (Corless et al., 2011) 
and in childhood patients with mastocytosis, albeit their incidence result much lower 
(Cruse et al, 2014). 
 
1.5.1 MASTOCYTOSIS 
Mastocytosis results from a clonal, neoplastic proliferation of morphologically 
and immunophenotypically abnormal MC that accumulate in one or more organ 
systems. It was considered one of eight subcategories of myeloproliferative 
neoplasms (MPN) in World Health Organization (WHO) classification of tumors of 
hematopoietic and lymphoid tissues (WHO, 2008). 
The clinical presentation of mastocytosis is quite heterogeneous; a skin-limited 
disease, peculiar in pediatric patients, in which it occurs within the first 2 years of 
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life, and that commonly results in a spontaneous regression of skin lesions (cutaneous 
mastocytosis, CM); alternatively, a more aggressive variant with extra-cutaneous 
involvement, generally seen in adult patients, that may be associated with multi-organ 
dysfunction/failure and shortened survival (systemic mastocytosis, SM; Arock et al., 
2015). 
The gold standard for diagnosis, according to WHO criteria, is the presence of 
multifocal clusters of morphologically abnormal MC in the bone marrow. Minor 
diagnostic criteria include elevated serum tryptase level, abnormal MC expression of 
CD25 and/or CD2, and presence of KIT D816V mutation. In 2008, the WHO 
recognized seven mastocytosis categories, listed in Table 2. 
 
Variant Subvariant 
Cutaneous mastocytosis (CM) Urticaria pigmentosa (UP), 
maculopapular CM (MPCM), diffuse 
CM (DCM), mastocytoma of skin 
Indolent systemic mastocytosis (ISM) Smoldering SM, isolated bone marrow 
mastocytosis 
Systemic mastocytosis with an associated clonal 
hematologic non-mast cell lineage (SM-AHNMD) 
SM–acute myeloid leukemia (SM-
AML), SM-myelodysplastic syndrome 
(SM-MDS), SM- myeloproliferative 
disorders (SM-MPD), SM- Chronic 
Myelomonocytic Leukemia (SM-
CMML), SM- Non-Hodgkin's 
Lymphoma (SM-NHL). 
Aggressive systemic mastocytosis (ASM)  
Mast cell leukemia (MCL) Aleukemic MCL 
Mast cell sarcoma  
Extracutaneous mastocytoma  
 Table 2. WHO systemic mastocytosis variants. From Metcalfe et al., 2008. 
 
Current therapy in WHO-defined SM is largely palliative and directed against 
MC degranulation symptoms (e.g. urticarial, angioedema, nausea, vomiting, diarrhea, 
abdominal pain), symptomatic skin disease (e.g. urticaria pigmentosa) and/or organ 
dysfunction resulting from MC tissue infiltration (e.g. hypersplenism; Pardanani, 
2015). 
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Among other types of treatments for SM there are cytoreductive agents as 
interferon-α (IFNα) and 2 chlorodeoxyadenosine (2-Cda). The IFNα acts against all 
SM subcategories, and improve dermatological, hematological, gastrointestinal, and 
systemic symptoms associated with histamine release. Imatinib mesylate 
demonstrates in vitro efficacy against wild-type c-KIT and certain transmembrane 
(F522C) and juxta-membrane (V560G) mutations, but not on D816V mutants. New 
TKIs are currently under investigation for SM treatment and are represented by 
dasatinib and midostaurin (PKC412). However, treatment of advanced SM remains 
one of the most challenging areas in clinical hematology; in fact, whereas mediator-
related symptoms can be controlled in most cases, MC expansion is usually resistant 
to most conventional antineoplastic drugs (Valent et al., 2010; Pardanani, 2015). 
 
1.6 CANINE c-KIT MUTATIONS AND RELATED DISEASES 
In dog MCTs, several c-KIT mutations, leading to uncontrolled signaling, have 
been identified (Bavcar & Argyle, 2012). These mutations are similar to those found 
in human GIST (Marech et al., 2014).  
Approximately 10-30% of canine MCTs present KIT mutations, more 
frequently localized in the JM (exon 11), and mostly consisting of internal tandem 
duplications (ITDs: Marech et al., 2014; Bonkobara, 2015). Mutations in the 
extracellular domain, namely in D5 (exons 8 and 9) are less frequent than those found 
in exon 11 (Letard et al., 2008; Takeuchi et al., 2013). Finally, mutations in other 
exons 2, 6, 7, 15 and 17 are quite infrequent (<3%: Bonkobara, 2015). 
Increased c-KIT mRNA levels and gene mutations occurring in exons 11 and 17 
were also observed in canine AMLs (Usher et al., 2009). In addition, also canine 
GIST evidenced c-KIT mutations occurring in the JM (Frost et al., 2003). 
 
1.6.1 CANINE MCT 
MCT is one of the most common tumor occurring in dogs. It is characterized by 
an abnormal MC accumulation in tissues, and mostly it appears as a solitary non-
painful cutaneous mass with preferred localization in the head/neck and in the arts. 
Systemic symptoms, such as anorexia, erythema, abdominal discomfort, edema, 
gastrointestinal ulceration, vomiting, and melena, are less common; these ones are 
frequently associated with visceral forms of MCT with a poorer prognosis and/or 
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with paraneoplastic disease due to the release of bioactive constituents from MC 
granules (Welle et al., 2008; Blackwood et al., 2012). 
The MCT clinical presentation varies according to the tumor grade: well-
differentiated cutaneous MCTs consist of slow growing, hairless and solitary lesions, 
while poorly differentiated cutaneous MCTs are characterized by rapid growing, 
ulcerated and pruritic lesions, sometimes surrounded by small “satellite lesions” 
(Blackwood et al., 2012). 
Upon the suspicion of a MCT, the definitive diagnosis can be achieved through 
cytology examination, for the most part using fine needle aspirate (FNA). 
Histological examination is also an important tool for MCTs grading and prognosis 
(Sabattini et al., 2015). Various histological grading systems have been proposed, but 
the mostly used one is the classification proposed by Patnaik et al. (1984), which 
divides MCTs into three grades: grade I MCTs (well-differentiated), which are 
mostly benign and slowly developed; grade III MCTs (poorly differentiated) that 
exhibit aggressive growth with local invasion. They are also more prone to 
metastasize and show a high recurrence potential. Finally, grade II (intermediately 
differentiated) MCTs; these latter are more difficult to predict, thereby accounting for 
more subjective and inconsistent classifications (Blackwood et al., 2012; Sabattini et 
al., 2015). The Patnaik grading scheme has inherent weaknesses characterized by 
subjective criteria and inter-observer variability. In particular, this traditional and 
widely accepted grading system has failed to reliably differentiate between aggressive 
and nonaggressive grade II MCTs (Giantin et al., 2014). There is another grading 
system, proposed by Kiupel and co-authors (2011), which divided tumors into high or 
low grade MCTs. Such a classification has improved prediction of metastasis and/or 
new tumor development, tumor mortality and survival (Takeuchi et al., 2013; 
Sabattini et al., 2015).  
Since histological grading alone is not suitable to predict the MCT biological 
behavior and treatment response, some supplementary prognostic markers have been 
investigated. Amon these ones, c-KIT mutational status has been identified as a useful 
prognostic and therapeutic marker. Furthermore, the expression of c-kit protein can 
be immunohistochemically characterized, and has been correlated with 
histopathological grading and prognosis in some studies, albeit not consistently 
(Takeuchi et al., 2013; Sailasuta et al., 2014; Patruno et al., 2014; Costa Casagrande 
et al., 2015). Other prognostic markers have been investigated, such as cellular 
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proliferation markers (e.g. mitotic index, the argyrophilic nucleolar organizer region 
AgNOR, the immunohistochemical markers Ki-67 and proliferating cell nuclear 
antigen, PCNA), angiogenesis markers and DNA ploidy analysis (Blackwood et al., 
2012; Fonseca-Alves, 2015; Gil da Costa, 2015; Sabattini et al., 2015).  
Complementary to histological grading, clinical staging is recommended to 
define the nature and extent of MCT, especially after diagnosis of a poorly 
differentiated tumor or when an expensive treatment is planned; this should include, 
at least, FNAs of draining lymph nodes and abdominal ultrasound. In cases of nodal 
metastasis presence, full staging is required with abdominal ultrasound (along with 
spleen and liver biopsies aspiration) and, if the case, bone marrow aspiration and lung 
radiographs (Blackwood et al., 2012). A clinical staging system was proposed by 
WHO: stage 0 is usually assigned to single tumors incompletely excised from the 
dermis without regional lymph node involvement; stages I and II comprise single 
tumors confined to the dermis without or with regional lymph node involvement, 
respectively; in stage III are included multiple dermal tumors, or large infiltrating 
tumors with or without regional lymph node involvement; stage IV includes any 
tumor with distant metastasis or recurrence with metastasis (Rogers, 2010). However, 
stage and prognosis do not directly correlate in all clinical situations (Blackwood et 
al., 2012). 
The prognostic indicators outlined above serve to aid in the therapeutic 
approach of MCT. Surgery is the treatment of choice in localized, non-metastatic 
canine MCTs. Most of dogs with low to intermediate grade MCTs experience longer 
survival times with complete surgical excision alone if compared with high grade 
MCTs. During surgery, safety margins should be included all around the mass. In 
cases in which a surgical excision with adequate margins is not feasible and/or poor 
prognostic factors such as histologic intermediate to high grade MCTs are 
encountered, radiation therapy and/or systemic chemotherapy is indicated. Due to the 
risk of radiation-induced MC granulation and consequent systemic effects, 
radiotherapy is generally avoided as a sole therapy. It is preferentially used as a 
postoperative adjunctive therapy after incomplete excision. Best results are achieved 
where radiation is planned prior to surgery, rather than afterthought following by an 
inadequate surgery (Blackwood et al., 2012). 
The most commonly used cytotoxic agents for the treatment of canine MCT 
include vinblastine (VBL) and lomustine (CCNU); in addition, systemic 
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corticosteroids have been shown to have some clinical efficacy. Indeed, the response 
rate to prednisone has been shown to be 20%, with remission times comprised 
between 10 and 20 weeks (London and Seguin, 2003). The use of an adjuvant 
systemic protocol (corticosteroids, CCNU and VBL), following surgical excision of 
intermediate grade MCT with evidence of local-regional lymph node metastasis, 
showed a median survival time of 1359 days (Lejeune et al., 2013).  
Recently, two TKIs have been approved by the European Medicines Agency 
(EMA) for the therapy of canine MCTs: 
(1) Toceranib phosphate (Palladia®, Pfizer Animal Health), approved for the use in 
recurrent, non-resectable grade II/III MCTs. Dogs with mutated c-KIT showed the 
highest response rate (69% against 37%: London et al., 2009). 
(2) Masitinib (Masivet ®, AB Science), approved for non-resectable grade II/III 
MCTs, particularly those with a c-KIT mutation. 
 
1.7 G-QUADRUPLEX (G4) 
G4, discovered by Gellert and collaborators in 1962, are stable DNA secondary 
structures alternative to the double helix of Watson and Crick. The basic elements 
that formed a G4 are showed in Figure 4. 
 
 
Figure 4. The dominant G4 conformation in the B-cell 
lymphoma 2 (BCL-2) promoter as an example of G4 
structure. Modified from Balasubramanian et al., 
2011. 
 
G4 originate in guanine-rich nucleic acids sequences when four guanine form a 
square planar platform called G-tetrad through cyclic Hoogsteen hydrogen bonding, 
in which each of the four bases is the donor and the acceptor of two hydrogen bonds 
(Bryan and Baumann, 2011). Stacked G-quartets form a G4 structure, and the 
interpose sequences are extruded as single-strand loops (although tetra-molecular G4 
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structures may also lack loops). The sequence and size of the loop regions varies but 
are usually small (1–7 nucleotides nucleotides), and smaller loops result in more 
stable G4 structures, as do longer G-tracts. Spaces between the loops, termed 
grooves, are bounded by charged phosphodiester backbones. 
This structure is stabilized by monovalent cations (mostly K
+
 and Na
+
) that 
occupy the central cavities and neutralize the electrostatic repulsion of inwardly 
pointing guanine oxygens (Bochman et al., 2012).  
Oligonucleotides containing G-stretches can form monomeric, dimeric or 
tetrameric G4 by folding/assembling one, two or four separate strands (Phan, 2009). 
DNA strands may be oriented in anti-parallel, parallel, or hybrid configuration. G4 
conformation is influenced by both the DNA sequence and the conditions used in the 
folding reaction, such as the nature of the stabilizing cation. Thus it is difficult to 
predict the propensity of a sequence to fold into a particular structure, and each 
sequence needs to be characterized under different folding conditions.  
Also the stability of G4 varies; it depends on the identity of the stabilizing 
cation, the DNA length and sequence, the length of intervening loops and, finally, the 
strand stoichiometry and alignment. In this respect, there have been some recent 
progresses in developing computational methods for predicting G4 stability. 
Many proteins have been shown to interact with G4 structures; these proteins 
may bind and stabilize G4 or unwind and destabilize them.  
One of the most important G4 structures are telomeres and telomerases. Human 
telomeres comprise tandem repeats of the DNA motif (TTAGGG) for ~5–10 kb, 
together with associated telomeric proteins. The shortening of telomeres to a critical 
length is a signal for cellular senescence. This phenomena is counteracted by 
telomerase, the telomere-specific reverse transcriptase that contains the RNA 
template to direct the addition of telomeric DNA by the catalytic telomerase reverse 
transcriptase (TERT) component. Telomerase is upregulated in ≥85% of tumors, 
providing a telomere maintenance mechanism that contributes to cellular 
immortalization and tumor progression. Telomeric DNA can fold into compact G4 
structures inhibiting the activity of telomerase. There are a large number of small-
molecule ligands showing a high binding affinity for G4, and most of them cause 
telomere dysfunction in vivo and inhibit telomerase activity in vitro (Moye et al., 
2015). 
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1.7.1 G-QUADRUPLEX IN PROMOTER REGIONS 
The potential for G4 formation in promoter regions is largely concentrated in 
genes associated with cell growth and proliferation. These oncogene promoters are 
typically TATA-less with G-rich regions in their proximal promoters; among these 
ones, there are the v-myc avian myelocytomatosis viral oncogene homolog (MYC), 
VEGF, BCL-2, PDGFR, the Kirsten rat sarcoma viral oncogene homolog (KRAS), 
as well as c-KIT (Onel et al., 2014). Furthermore, these structures seem to be 
underrepresented in tumor suppressor genes (Bochman et al., 2012). These evidences 
suggest that G4s may play a functional role in gene regulation (Bryan and Baumann, 
2011). 
MYC is an oncogene most commonly found to be altered in cancer, and its 
promoter is the one most extensively studied in terms of G4 formation (Chen and 
Yang, 2012). It encodes for a transcription factor that regulates the expression of 
several genes (Bidzinska et al., 2013). The G4-forming region within the MYC 
promoter is a sequence of 27-nucleotides , e.g. a Nuclease Hypersensitive Element 
(NHE) III1, which regulates most of the gene’s transcriptional activity (Chen and 
Yang, 2012; Onel et al., 2014). This sequence contains five consecutive runs of 
guanine (“G-runs”), and may fold into several G4s and loop isomers with different 
stabilities; the major G4 formed in K+ solution involves four consecutive 3G-runs 
that adopt a parallel folding (Myc2345), with the major loop isomer being 1:2:1 
(Chen and Yang, 2012; Onel et al., 2014).  
In MYC, the G4 structure is a negative regulator of the expression because a 
single base mutation, which destabilizes the chair form, increases MYC expression up 
to three-fold. Furthermore, compounds that stabilize this G4 structure (i.e., the 
cationic porphyrin TMPyP4) decrease c-MYC expression (Siddiqui-Jain et al., 2002; 
Tian et al., 2010).  
Two G-rich sequences capable of forming G4s have been identified in the 
promotorial region of human proto-oncogene c-KIT: KIT1 and KIT2, respectively 
located -12 /-34, and -64 / -84 base pairs upstream the transcription start site (TSS: 
McLuckie et al., 2011). They are located within a nuclease hypersensitive region, and 
are separated by 31 bp which contain an active SP1 site. Both sequences form G4s 
under physiological conditions, as proved by NMR and X-ray crystallography (Bryan 
and Baumann, 2011). A large number of G4 ligands have been reported in the 
literature, and TMPyP4 is the ligand most extensively studied to date. It inhibits both 
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telomerase (half maximal inhibitory concentration, IC50  0.7–10 µM) and Taq DNA 
polymerase (IC50  2 µM). It exhibits some promising anticancer activities in vivo, 
but it has very poor DNA specificity, causes anaphase bridges in sea urchin embryos, 
and is highly toxic in vivo. When administered at 0.1 mM (a dose near its MTD in 
cell cultures), TMPyP4 elicits a dramatic effect on gene expression, and it down-
regulates the transcription of both c-MYC and the catalytic subunit of telomerase. 
Moreover, it binds to duplex, triplex, G4, single stranded and bulk genomic DNA 
with similar affinities (Kd ≅ 200 nM); therefore, it cannot be considered a structure-
selective ligand. 
Telomestatin (SOT-095), a natural product isolated from Streptomyces anulatus 
3533-SV4, is one of the strongest and most specific inhibitors of telomerase reported 
to date (IC50 ≅ 1 μM).Telomestatin has molecular dimensions similar to those of G-
tetrad DNA, and can bind to various G4 with modest affinity (Kd ≅ 30 nM). 
Telomestatin exhibits good selectivity for intramolecular versus intermolecular G4 
structures, and it has a 70-fold lower affinity for duplex DNA. Telomestatin induces 
telomere shortening in treated cells more rapidly than through a single mechanism 
involving telomerase inhibition. Recent studies have shown that telomere uncapping 
and the loss of telomeric DNA is related to the competition between telomestatin and 
POT1, a shelterin protein that binds to the 3’ single-stranded overhang (Gomez et al., 
2006; Luedtke, 2009). While it is unknown if this type of activity might be cancer-
selective, telomestatin induces senescence and apoptosis in a number of different 
tumor cell types and exhibits less toxicity towards normal progenitor cells (Luedtke, 
2009). 
 
1.7.2 G-QUADRUPLEX IN CANINE c-KIT PROMOTER 
In 2014, part of this PhD study aimed to characterize the canine KIT proximal 
promoter. Similarly to the human KIT proto-oncogene, two putative quadruplex 
sequences were identified and reported in Figure 5: canine KIT1 (“d_kit1”, -117 to 
138 bp upstream the ATG), and KIT2 (“d_kit2”, -154 to -174 bp upstream the ATG). 
Both positions were not referred to TSS, because the 5’UTR of canine KIT gene has 
not yet been fully characterized. Da Ros and co-authors published these results in the 
same year (Da Ros et al., 2014). Canine KIT1 showed a high degree of sequence 
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homology with its human counterpart and shared a common overall parallel G4 
folding in a K+ containing solution (Da Ros et al., 2014).  
On the other hand, human and canine KIT2 sequences largely differ to each 
other. Two isoforms of canine KIT2 were identified; although a defined structure has 
not yet been attributed, it is conceivable that the multiplicity of folded structures that 
human KIT2 can form in solution may also occur in the canine species (Da Ros et al., 
2014).  
Overall, the potential functional role of the aforementioned G4 motifs may be 
of important relevance, not only for the canine, but also as a comparative model for 
human disease (Da Ros et al., 2014).  
 
 
 
 
Figure 5. Sequences involved in the formation of the two G4s 
present in the promoter regions of human and canine KIT 
(Rankin et al., 2005; Da Ros et al., 2014). 
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2. AIMS OF THE THESIS 
 
 
In human and canine cancer, c-KIT represents one of the best examples of 
therapeutic target, and its inhibition allows oncologists to treat tumors whose 
malignancy is partly or completely dependent on its activity. 
The present thesis groups together four scientific contributions related to c-KIT 
expression in human and canine tumors; overall, it attempted the exploration of new 
strategies for anticancer chemotherapy targeting c-KIT in multiple in vitro models. In 
particular, the specific aim of the first part of the thesis (chapters 3 and 4) consisted in 
the identification of candidate c-KIT G4 ligands that could stabilize G4 DNA 
secondary structures in the c-KIT promoter region and, hence, block its transcription 
in human and canine established cell lines. These studies were conducted in 
collaboration with the research group of Claudia Sissi, a Full Professor affiliated to 
the Department of Pharmacological Sciences of the University of Padua; she 
performed the compounds library screening. 
The other two publications (chapters 5 and 6) aimed to cover some scientific 
gaps in canine and comparative oncology. Precisely, in chapter 5 the characterization 
of c-KIT mutational profile in primary canine MCT and its own metastases was 
undertaken, to make a more careful recommendation about the use of c-KIT 
mutational analysis (and, consequently, decision therapy) in the clinical setting; in 
chapter 6, the occurrence of mutations in genes already known to be involved in 
pathogenesis of human SM (TET2, SF3B1, SRSF2, KRAS, NRAS, IDH1, IDH2) 
was investigated in canine MCT, to find out analogies between the two neoplastic 
diseases. Part of chapter 3 and the whole work discussed in chapter 6 were carried 
out, during my eight-months foreign internship, at the Centre de Recherche en 
Cancérologie de Marseille and under the supervision and support of Dr. Patrice 
Dubreuil and his research group. 
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3. Screening of candidate G-quadruplex ligands for the 
human c-KIT promotorial region and their effects in 
multiple in-vitro models 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Zorzan E., Da Ros S., Musetti C., Zorro Shahidian L., Ramos 
Coelho N.F., Bonsembiante F., Létard S., Gelain M. E., Palumbo M., Dubreuil 
P., Giantin M., Sissi C., and Dacasto M., 2015. Screening of candidate G-
quadruplex ligands for the human c-KIT promotorial region and their effects in 
multiple in-vitro models. Oncotarget, under revision. 
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3.1 ABSTRACT 
The V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog (c-
KIT) encodes for a tyrosine kinase receptor (RTK) and it is implicated in the 
pathogenesis of gastrointestinal stromal tumors, melanoma and acute leukemia. Two 
guanine-rich strands within c-KIT promoter can fold into G-quadruplex structures 
(G4). In this study, an “in house” library of compounds was screened for the 
recognition of the two G4 regions, hypothesizing a possible down-regulation of gene 
expression and the consequent discovery of potentially selective anticancer drugs. 
The cytotoxicity of the three most promising G4 ligands was measured in 
MCF7 and HGC27 cell lines, and transcriptional effects on c-KIT as well as on other 
oncogenes known to possess G4 structures in their promoters were investigated at 
different concentrations and times of culture. An anthraquinone derivative (AQ1) was 
the most effective inhibitor of c-KIT mRNA and protein amounts in both cell lines.  
Confirmatory experiments were executed in other in vitro models which strictly 
depend on c-KIT for survival (α155, HMC1.2 and ROSA cell lines), and an 
encouraging block of cell proliferation was noticed, also in cell lines having c-KIT 
mutations.  
In conclusion, AQ1 represent a promising compound for the treatment of c-
KIT-dependent tumors, worth of further and more in depth molecular investigations. 
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3.2 INTRODUCTION 
The c-KIT proto-oncogene (c-KIT) codes for a tyrosine kinase receptor (c-kit) 
that, when activated by stem cell factor (SCF) in mast cells, melanocytes, and Cajal 
interstitial cells, is involved in a broad range of physiological processes, including 
cell proliferation, migration, maturation and survival (Metcalfe, 2008; Gregory-
Bryson et al., 2010). 
c-KIT is dysregulated in many diseases, including cancer (Lennartsson and 
Rönnstrand, 2012); in neoplastic diseases, its increased expression and auto-
phosphorylation allows tumor cells to develop independently from growth and 
survival signals (Hanahan and Weinberg 2000; Pittoni et al., 2011). Furthermore, 
several mutations, potentially leading to c-kit activation in the absence of SCF 
binding, have been reported (Liang et al., 2013). Gain of function mutations can be 
found in gastrointestinal stromal tumor (GIST, >90%), mast cell tumors (>70%), 
nasal T-cell lymphomas (>17%), seminoma/dysgerminoma (>9%) and some acute 
myeloid leukemia (>68%; Ashman and Griffith, 2013). 
Less than fifteen years ago, tyrosine kinase inhibitors (TKIs) were approved for 
the treatment of human cancers overexpressing c-kit. The immediate results obtained 
by using TKIs were promising; nevertheless, drug-resistance phenomena have been 
observed for some TKIs such as imatinib (Rosenzweig, 2012). It has been 
hypothesized that several cellular mechanisms contribute to drug resistance; 
moreover, the same drug may show differential clinical responses depending on the 
presence of a wild type or a mutated c-KIT genotype (Ustun et al., 2011). To 
overcome this limit, the promoter region of c-KIT has been considered attractive as a 
molecular target (Rankin et al., 2005; Fernando et al., 2006). G-rich sequences are 
known to fold into non-canonical structures named G4. They are formed by stacked 
G-tetrads, each constituted by four guanines connected by a Hoogsteen-hydrogen 
bonds network to provide a square planar platform (Bryan and Baumann, 2011). 
Clusters of guanines are typically present at telomere level, however, they are also 
frequently found in the promoter regions of proto-oncogenes including c-KIT, where 
G4 structures have been assumed to act as regulatory elements for gene expression 
(Balasubramanian et al., 2011; Bryan and Baumann, 2011). Within the human c-KIT 
promoter, two guanine-rich (G-rich) sequences have been identified: KIT1 and KIT2, 
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occurring respectively between positions -12 and -34 bp and positions -64 and -84 bp 
upstream the transcription starting site (McLuckie et al., 2011). 
Therefore, the idea of applying G4 targeting ligands that can induce/stabilize 
these non-canonical tetrahelices, is considered a novel approach in cancer treatment 
(Balasubramanian et al., 2011) and the goal is the identification of compounds 
capable of repressing target gene transcription through the stabilization of G4 
structures. 
Up-to-date, several small molecules that efficiently bind the G4 form of c-KIT 
have been identified. For some of them a drug-mediated inhibition of c-KIT 
expression has been confirmed: these include trisubstituted isoalloxazines, 
naphthalene diimide derivatives, substituted indenoisoquinolines and 
benzo[a]phenoxazines (Bejugam et al., 2007; Gunaratnam et al., 2009; Bejugam et 
al., 2010; McLuckie et al., 2011). 
To further optimize the promising outcome of these derivatives, here we set up a 
library of “in house” available compounds and composed of derivatives which can be 
clustered into six different families according to their main scaffold: anthraquinone 
(AQ; Zagotto et al., 2011), anthracene (AN; Folini et al., 2010), phenantroline (Phen; 
Musetti et al., 2009; Bianco et al., 2010; Bianco et al., 2013), naphthalene diimide 
(NDI; Milelli et al., 2012) and heterocyclic diamidines (HAD; Nanjunda et al., 2012). 
Within each family of compounds, structural variations concern mostly the side 
chains in terms of composition or relative localization on the pharmacophore. This 
represents a precise choice. Indeed, upon stacking of the planar core, the side chains 
are available to achieve selective recognition of the G4 loops and grooves which are 
the structural domains that mainly define the unique conformational signature of G4s. 
According to this model, compounds able to drive the preferential recognition of 
nucleic acid structures which are structurally divergent in these portions, might be 
expected to modulate the affinity/selectivity towards different G4 arrangements.  
Giving the purpose of the present study, the whole library has been screened 
against both the G-rich c-KIT sequences to select the most promising candidates (G4-
ligands) for the suppression of c-KIT expression by efficient stabilization of KIT1 
and/or KIT2 G4 structures. From the binding studies, three positive hits were selected 
and subsequently tested for cytotoxicity. Finally, their effects on c-KIT mRNA levels 
and protein expression were evaluated in different human cancer cell lines including 
some well-known in vitro models of c-KIT-dependent tumors. 
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3.3 MATERIALS AND METHODS 
3.3.1 Ligands 
AQ and AN derivatives were synthesized by Prof. G. Zagotto (University of 
Padua, Italy); NDI were synthesized by Prof. V. Tumiatti and A. Milelli (University 
of Bologna, Italy), HAD by Prof. D. W. Boykin (Georgia State University, USA) and 
Phen analogues by Prof. A. P. Krapcko (University of Vermount, USA). Stock 
solutions (1 mM) of each library member were prepared in dimethyl sulfoxide 
(DMSO, Sigma-Aldrich Co., St. Louis, USA) and stored at -20°C. For positive hits 
(AQ1, AQ7 and AN6), 10 mM stock solutions were prepared in DMSO and freshly 
diluted in culture medium the day of the experiment. 
  
3.3.2 Fluorescence melting assay 
Fluorescence melting analyses were performed with a Roche Light Cycler® 
480 II (Roche Applied Science, Indianapolis, USA), using an excitation source at 488 
nm and recording the fluorescence emission at 520 nm. Samples (20 µl final volume) 
containing 0.25 M DNA were loaded on a 96-well plate in 10 mM LiOH pH 7.5 
with H3PO4, containing 50 mM KCl and increasing concentrations of ligands. 
Samples were first heated to 95°C at a rate of 0.1°C/s, maintained at 95°C for 5 min 
and then annealed by cooling to 30°C at a rate of 0.1°C/s. Then samples were 
maintained at 30°C for 5 min before being slowly heated to 95°C (1°C/min) and 
annealed at a rate of 1°C/min. For the analyses with double strand oligonucleotides, 
the two complementary strands were annealed before ligand addition and melting 
acquisition. Each curve was repeated at least three times and errors were ± 0.4°C. 
Melting temperatures were determined from the first derivatives of the melting 
profiles using the Roche Light Cycler software (Roche Diagnostics, Mannheim, 
Germany). 
 
3.3.3 Fluorescent Intercalator Displacement (FID) assay 
FID screening assay was performed in a 96-well plate reader Victor3TM 1420 
Multilabel Counter Perkin Elmer (Perkin Elmer, Waltham, USA) set at 25°C. An 
excitation λ of 485 nm and emission λ of 535 nm were used. Before data acquisition 
the 96-well plate was shaken for 2 s. In each well, 80 µl of reaction mixture 
containing oligonucleotide (1 M), Thiazole Orange (TO, Sigma-Aldrich Co., St. 
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Louis, USA) (2 µM) and increasing concentrations of each compound (1-2-8 µM) in 
10 mM Tris, 50 mM KCl, pH 7.5 were loaded. Fluorescence titrations were 
performed in a Perkin Elmer LS55 Luminescence spectrometer (Perkin Elmer, 
Waltham, USA) equipped with a cell holder termostated at 25°C and using an 
excitation wavelength of 501 nm. For FID, a solution containing 0.62 μM of target 
DNA and 1.24 μM of TO was added of increasing concentrations of tested 
compounds in 10 mM Tris, 50 mM KCl, pH 7.5. The percentage of TO displacement 
was calculated as TO displacement = 100 - [(F/F0) × 100], where F0 is the 
fluorescence in the absence of ligand and F the fluorescence recorded at each point of 
titration. TO displacement was plotted as a function of compound concentration. 
From these plots the EC50 (half maximal effective concentration) was calculated. 
Each titration was repeated at least in triplicate. 
 
3.3.4 Surface Plasmon Resonance (SPR) 
Surface Plasmon Resonance measurements were performed on a Biacore X100 
(GE Healthcare Life Sciences, Little Chalfont, United Kingdom) set up with a 
streptavidine-coated sensor chips prepared for use by conditioning with injections of 
1 M NaCl, 50 mM NaOH in 50% isopropanol for 1 min and finally extensively 
washed with a 0.22 µm filtered buffer (10 mM Tris pH7.5, 50 mM KCl, 0.025% 
P20). Previously annealed, 5’-biotinylated oligonucleotides were then immobilized 
on one cell of the chip surface by flowing a 50 nM DNA solution at a 1 µl/min flow 
rate until the level of 400 response unit (RU) was obtained. A second cell was left 
blank as control. Sensorgrams were acquired using serial dilution of tested ligands in 
the same buffer. To avoid interference by DMSO, its concentration was kept constant 
and added to the running buffer too (1.7%). Compounds solutions were injected at a 
25 µl/min flow rate until a constant steady-state was reached (60-200 s). After each 
run, a 30 s regeneration step was performed with 10 mM glycine pH 2.5 followed by 
a 60 s stabilization period in the running buffer. The experimental RU values were 
recorded at the steady state. Data were fitted according to a binding site model. 
 
3.3.5 Polymerase stop assay 
A 20 nM equimolar mixture of 
32
P 5’-labeled primer and the human telomeric 
template sequence HT4-temp 
d[TC2A2CTATGTATAC(T2AG3)4ACATATCGATGA3T2GCTATAGTGAGTCGTA
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T2A] was annealed in the required polymerase buffer and subsequently added of 
increasing tested ligand concentrations. After incubation (30 min at room 
temperature), 2.5 U of Taq polymerase (Thermo Scientific, Waltham, USA) and 100 
µM dNTPs mixture were added to each sample and the resulting solutions were kept 
for 30 min at 55°C. Reaction products were resolved by gel electrophoresis (12% 
polyacrylamide gel with 7 M urea) in 1X TBE (89 mM Tris base, 89 mM boric acid, 
2 mM Na2EDTA). Gels were dried and resolved bands were visualized on a 
PhosphorImager (GE Healthcare, Little Chalfont, United Kingdom). 
 
3.3.6 Cell cultures 
The breast adenocarcinoma human cell line MCF7 (Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cultures) and the human gastric 
carcinoma cell line HGC27 (European Collection of Cell Cultures) were maintained 
in 25 or 75 cm
2
 flasks under a humidified 5% CO2 atmosphere, at 37°C. Cells were 
grown in Eagle’s Minimal Essential Medium (EMEM, Gibco® Life Technologies, 
Carlsbad, USA) supplemented with 10% fetal bovine serum (Gibco
®
 Life 
Technologies, Carlsbad, USA), 2 mM L-glutamine (Euroclone, Milan, Italy), 1% 
non-essential amino acids (Euroclone, Milan, Italy) and 1% penicillin/streptomycin 
(Euroclone, Milan, Italy). MCF7 were cultured in presence of 10 µg/ ml of human 
insulin (Elli Lilly & Co., Indianapolis, USA). 
The human mast cell leukemia HMC1.2, containing both juxtamembrane and 
catalytic c-KIT domain mutations (V560G and D816V), was kindly provided by Dr. 
Joseph Butterfield (Mayo Clinic, Rochester, MN, USA). This cell line, as well as the 
human mast cell leukemia α155 (possessing only the V560G mutation), the human 
prostate cancer cell line PC3, the human lymphoma cell line KARPAS 299 and 
ROSA mast cell lines (WT and transfected with KITD816V; Saleh et al., 2014) were 
cultured in RPMI medium (Gibco
®
 Life Technologies, Carlsbad, USA) supplemented 
with 10% FBS, 2 mM L-glutamine and 1% penicillin/streptomycin. 
Cell number and viability were checked by using Trypan Blue dye exclusion 
test (Sigma-Aldrich Co., St. Louis, USA). For all the experiments, cells were used 
from passage 5 to passage 25 maximum. 
Cell cultures were checked for Mycoplasma contamination both before and at 
the end of experiments through PCR Mycoplasma Test Kit (PromoKine, Heidelberg, 
Germany). 
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3.3.7 G4-ligands cytotoxicity 
MCF7 and HCG27 cells were seeded at concentrations comprised between 
0.3x10
4
 and 0.5x10
4
 cells/well in a 96-well flat bottom plate (Sarstedt Italia, Verona, 
Italy). After 24 hours, AQ1 or AN6 were added at concentrations from 0.01 µM up to 
10 µM for 72 hours. Additional wells exposed to the vehicle (DMSO, 0.1% final 
concentration) and medium alone were prepared, too. At the end of the experiment, 
20 µl of CellTiter-Blue
®
 Cell Viability Assay (Alamar Blue, Promega, Madison, 
USA) were added to each well and the fluorescence was measured at 560 nm as 
excitation wavelength and 590 nm as emission wavelength, by using a VICTOR
™
X4 
Multilabel Plate Reader (Perkin Elmer, Waltham, USA). Three separate experiments 
were executed and each concentration was tested in sestuplicate. For AQ7, the 
sulforhodamine B (Sigma-Aldrich Co., St. Louis, USA) assay was used as 
proliferation test instead of Alamar Blue. Both cell lines were exposed to a range of 
concentrations up to 10 µM for 0, 24, 48, 72, and 96 hours. Three separate 
experiments were executed, and each concentration was tested in sestuplicate. 
 
3.3.8 Target genes constitutive expression 
Since no information about the constitutive expression of c-KIT were available 
in literature, a first set of experiments were undertaken to define the best 
experimental settings for measuring G4-ligands efficacy. 
Cells were seeded onto 6-well plates at concentration of 5x10
5
 and 4x10
5
 
cells/well (for MCF7 and HGC27, respectively) and collected after 6, 24, 48, 72 and 
96 hours. Monolayers were washed with 1 ml of fresh PBS, scraped off and 
centrifuged at 100g for 5 min. Cell pellets were resuspended in 0.5 ml of 
TRIzol
®
reagent (Invitrogen
™
, Life Technologies, Carlsbad, USA), and total RNA 
was extracted according to manufacturer’s instructions. Nucleic acids yield and purity 
(260/280 and 260/230 nm absorbance ratios) were measured by using the Nanodrop 
ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, UK), whilst 
their quality was checked by 1% agarose gel electrophoresis. Total RNA (1 μg) was 
reverse transcribed by using the High Capacity cDNA Reverse Transcription Kit 
(Life Technologies, Foster City, USA) and following the manufacturer instructions.  
The full list of primers used in the present study for qPCR analysis is reported 
in Table 1. 
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Gene UPL probe Primers (5’- 3’) Source 
MYC  #67 
F : TGGTGCTCCATGAGGAGACA 
R : GTGGCACCTCTTGAGGACCA 
Gunaratnam et al., 2009 
PDGFA 
 
#77 
F: ACACGAGCAGTGTCAAGTGC 
R: CCTGCAGTATTCCACCTTGG 
Iqbal et al., 2012 
PDGFRB #14 
R: TGCTCATCTGTGAAGGCAAG 
F: TGGCATTGTAGAACTGCTCG 
Chanakira et al., 2012 
BCL2 
 
#75 
F: ATGTGTGTGGAGAGCGTCAA 
R: GCCGTACAGTTCCACAAAGG 
Brassesco et al., 2010 
B2M 
 
#42 
F: AGGCTATCCAGCGTACTCCA 
R: TGTCGGATGGATGAAACCCA 
designed ex novo 
GAPDH  #60 
F: CTCTGCTCCTCCTGTTCGAC 
R: ACGACCAAATCCGTTGACTC 
designed ex novo 
HPRT1 
 
#22 
F: TGATAGATCCATTCCTATGACTGTAGA 
R: CAAGACATTCTTTCCAGTTAAAGTTG 
designed ex novo 
KIT  #29 
F: GGCACGGTTGAATGTAAGGC 
R: CAGGGTGTGGGGATGGATTT 
designed ex novo 
KRAS
 
#62 
F: GGAGCTGGTGGCGTAGGCAAG 
R: GCCCTCCCCAGTCCTCATGT 
designed ex novo 
hTERT
 
#68 
F: GGAGAACAAGCTGTTTGCGG 
R: AGCCATACTCAGGGACACCT 
designed ex novo 
Table 1. Primers and probes used for the qPCR analysis either obtained from previous 
publications or specifically designed for this study. UPL=Universal Probe Library; F= 
forward; R= reverse 
 
Despite c-KIT, which is the main target of this study, we also analyzed other 6 
genes known to contain putative G4 structures in their promoter region: such as the 
V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC), the Kirsten rat 
sarcoma viral oncogene homolog (KRAS), the beta-type platelet-derived growth 
factor receptor (PDGFRβ), the B-cell lymphoma 2 (BCL2), the Platelet-Derived 
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Growth Factor Alpha Polypeptide (PDGFA) and the Telomerase Reverse 
Transcriptase (hTERT). Gene-specific primers for MYC, PDGFA, BCL2 and 
PDGFRß were selected from previously published studies (Gunaratnam et al., 2009; 
Brassesco et al., 2010; Chanakira et al., 2012; Iqbal et al., 2012), and the most 
appropriate Universal Probe Library (UPL) probe was later determined by using the 
UPL Assay Design Centre web service (Roche Diagnostics, Mannheim, Germany). 
For the remaining genes, primers were designed ex novo by using the Primer3 
software (http://primer3.ut.ee/). Assay specificity was evaluated either in silico, by 
using the BLAST tool, than experimentally by Power SYBR Green I (Life 
Technologies, Carlsbad, CA) amplification and melting curve analysis. 
Quantitative real-time RT-PCR (qPCR) reactions (10 µl final volume) consisted 
of 1X LightCycler 480 Probe Master (Roche Applied Science, Indianapolis, USA), 
300 or 600 nM forward and reverse primers (Eurofins MWG Operon, Ebersberg, 
Germany) derived from the assay set-up, 200 nM human UPL probe (Roche Applied 
Science, Indianapolis, USA) and 2.5 µl of 1:7.5 diluted cDNA. The analysis was 
performed in a LightCycler 480 Instrument (Roche Applied Science, Indianapolis, 
IN) using standard PCR conditions (95°C for 10 min; 45 cycles at 95°C for 10 s and 
at 60°C for 30 s; 40°C for 30 s). Calibration curves, using 3-fold and 4-fold serial 
dilutions of a cDNA pool, were performed, and corresponding values of slope, 
efficiency (E) and dynamic range, for each cell line, are reported in Table 2. 
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Table 2. qPCR assay standard curve values for MCF7 and HGC27. 
 
 Only qPCR assays with E (%) comprised between 90% and 110% were 
considered acceptable. qPCR data were analyzed with the LightCycler480 software 
release 1.5.0 (Roche Applied Science, Indianapolis, USA), by using the second 
derivative method. mRNA relative quantification was performed by using the ΔΔCt 
method (Livak et al., 2001). Three internal control genes (ICGs), e.g. Hypoxanthine 
Phosphoribosyltransferase 1 (HPRT1), Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) and Beta-2-Microglobulin (ß2M) were amplified in all samples, but only 
ICGs genes whose expression was not statistically varied during experimental 
conditions were considered for the relative quantification (RQ). A cDNA pool was 
used as calibrator.  
Experiments were performed in triplicate and, for each experiment, two biological 
replicates were included.  
 
3.3.9 Determination of G4-ligands efficacy by qPCR 
To measure the transcriptional effects of each candidate G4-ligand, cells (24 
hours after seeding) were incubated with vehicle (DMSO, 0.1% final concentration) 
or two sub-cytotoxic doses of G4-ligands (1/3 and 2/3 of IC50 value, respectively). 
Based on constitutive c-KIT expression during time culture, cells were collected as 
Gene MCF7 HGC27 
 Slope Efficiency (%) Dynamic range (Ct) Slope Efficiency (%) Dynamic range (Ct) 
B2M -3,192 105,7 18,78 - 32,06 -3,34 99,1 18,74 - 30,85 
BCL2 -3,41 96,5 25,82 - 34,13 -3,27 102,2 24,90 - 33,43 
GAPDH -3,48 93,7 15,81 - 30,59 -3,28 102 16,20 - 30,64 
HPRT1 -3,324 99,9 20,23 - 32,63 -3,3 101 20,96 - 33,18 
KIT -3,137 108,3 29,01 - 35,78 -3,531 92 29,58 - 39,58 
KRAS -3,34 99 21,50 - 32,28 3,352 98,8 21,30 - 32,41 
MYC -3.3 100.7 26.85 - 33.06 -3,502 93 22,47 - 30,89 
PDGFA -3,169 106,8 22,97 - 31,68 -3,18 106,3 23,87 - 33,02 
PDGFRB Not expressed -3,36 98,4 24,84 - 32,28 
hTERT -3,11 109,2 33,24 - 38,82 -3,34 99,2 29,38 - 35,78 
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described above after 6, 12 and 24 hours of incubation. Methods used for RNA 
extraction, reverse transcription and qPCR were the same described in the previous 
paragraph. ICGs expression was checked within every experimental condition. The 
choice of the most suitable ICGs to be used for normalization was cell line- and 
ligand-dependent. 
 
3.3.10 Determination of G4-ligands efficacy by flow cytometry 
Cells (5x10
5
/well
 
and 4x10
5
/well
 
for MCF-7 and HGC-27 cell lines, 
respectively) were seeded in 6-well plates; after 24 hours, the vehicle (DMSO, 0.1% 
final concentration) or AQ1 or AN6 (1 µM, final concentration) were added to the 
medium. Forty-eight hours post-exposure, monolayers were washed twice with PBS 
1X 0.02% EDTA, detached and centrifuged at 100g for 4 min. Cells were 
resuspended in RPMI medium (Gibco
®
 Life Technologies, Carlsbad, USA) 
supplemented with 3,3% FBS (Gibco
®
 Life Technologies, Carlsbad, USA). Fifty µl 
of the cell suspension were incubated for 15 min at 4°C with 50 µl of a rat anti-mouse 
monoclonal antibody raised against cell surface c-KIT (CD117PE: clone ACK 45, BD 
Pharmingen, California, USA), concentrated 1:25; then, a wash step with 500 µl of 
PBS and a centrifugation step at 100g at 4°C for 10 min, were performed. After 
removing the supernatant, 900 µl of PBS 1X were added to the cells. For BCL2 
detection, 100 µl of the cell suspension were fixed and permeabilized with the 
IntraStain kit (DAKO Italia SRL, Milano, Italy) and then incubated with an anti-
BCL2 antibody FITC conjugated (clone 124, DAKO Italia SRL, Milano, Italy). For 
acquisitions, the CyFlow® Space (Partec® GmbH, Münster, Germany) was used. 
Cells not incubated with the anti-CD117PE and anti-BCL2FITC were considered as 
negative controls. For each sample, c-kit expression was evaluated either in terms of 
events that stained for CD117 and in terms of mean fluorescent intensity (MFI), 
calculated as the ratio of the MFI in neoplastic cells by the MFI of unstained cells. 
Samples were analyzed by using FlowMax® software (Quantum Analysis GmbH, 
Münster, Germany), version 2.82. 
 
3.3.11 Confirmatory experiments with other cellular models 
Confirmatory proliferation studies were executed on α155, HMC1.2, PC3, 
ROSA
WT
 and ROSA
KITD816V
 cell lines, by using methods and conditions mentioned 
above (IC50 determination). Cells were treated with AQ1 or AN6 at concentrations 
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from 0.2 µM up to 3 µM and for 72 hours. To check for the resistance or sensitivity 
of the used cellular models, an imatinib control (1 µM final concentration) was 
included in the experimental setting. 
As regards qPCR, three independent confirmatory experiments were executed 
in α155 and HMC1.2 cell lines to confirm the transcriptional effects of AQ1 on c-KIT 
mRNA. About 9x10
5
/well cells
 
were seeded onto 6-well plates, and DMSO or AQ1 
were added at final concentrations of 0.1% and 1 µM, respectively. Cells were 
incubated for 6 and 12 hours and centrifuged at 100g for 5 min; pellets were then 
washed once with 1 ml PBS and, finally, submitted to the same methodological 
procedure reported above (determination of G4-ligands efficacy by qPCR). For each 
cell line, values of slope, efficiency and dynamic range of qPCR assays are reported 
in Table 3. 
 
Gene α155 HMC1.2 
 Slope Efficiency 
(%) 
Dynamic range 
(Ct) 
Slope Efficiency 
(%) 
Dynamic range 
(Ct) 
B2M -3.33 99.6 17.18-31.68 -3.38 97.7 17.46-31.25 
GAPDH -3.37 98 16.43-30.91 -3.40 96.7 17.34-31.36 
HPRT1 -3.39 97.1 21.75-35.65 -3.38 97.5 22.14-37.67 
KIT -3.32 99.7 18.00-32.32 -3.30 101 19.08-32.90 
Table 3: qPCR assay standard curve values for α155 and HMC1.2. 
 
For confirmatory flow cytometry investigations, HMC1.2, α155 and KARPAS 
299 cells were seeded in P6-well plates (3x10
5
 cells/well); then, DMSO or AQ1 were 
added at final concentrations of 0.1%, and 1 or 2 µM, respectively. After 48 hours, 
3x10
5
 cells were collected. HMC1.2 and α155 cells were labeled, at 4°C for 30 min, 
with mouse monoclonal anti-CD117 SC 13508 (Santa Cruz Biotech, Texas, USA), 
diluted 1:100. The secondary antibody used was an anti-mouse PE conjugated 
(diluted 1:50). The high affinity IgE receptor (FcεRI), present on mast cell 
membrane, was saturated by incubation with human serum for 10 min at room 
temperature. The human leukocyte antigens (HLA) were used as reference proteins 
and α155, HMC1.2 and KARPAS 299 cell lines were labeled with monoclonal anti-
human leukocyte antigen (HLA) PeCy5 conjugated (W6-32 eBioscience, California, 
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USA). Unstained cells with the proper isotype control were used to check for non-
specific fluorescence signals. 
The cytofluorimetric analysis was made in a BD LSRFortessa™ (Becton 
Dickinson, New Jersey, USA) and data were analyzed by using DIVA
TM
 (BD 
Pharmingen, California, USA) software. The c-kit expression was evaluated, for each 
sample, in terms of median fluorescent intensity (mFI), calculated as the ratio of the 
mFI in neoplastic cells by the mFI of unstained cells. Final results consisted in the 
mean of three different experiments. 
 
3.3.12 Statistical analysis 
 The statistical analysis of data was performed by using GraphPad Prism 
version 5.00 for Windows (GraphPad Software, San Diego, USA). Dose-response 
curves and IC50
 
values were determined by nonlinear regression analysis, fitting a 
sigmoid dose-response curve.  
Data on the time-dependent constitutive expression of target genes were 
expressed as -fold change (%) of the respective T6 value, and analyzed with one-way 
analysis of variance (ANOVA) followed by Bonferroni post-test.  
The statistically significant differences in mRNA levels in cells treated with 
G4-ligands were checked by the two-way ANOVA followed by Bonferroni post-test 
to identify if any difference in terms of transcriptional response was dependent either 
from the dose and/or time of treatment. Each RQ value of treated cells was 
normalized to the average RQ of the respective time-control samples.  
In cell proliferation experiments, the viability data obtained with the different 
cell lines were analyzed with the Student t-test. 
Data from cytofluorimetric analysis were expressed as n–fold changes against 
control cells; either the Student t-test nor the one-way ANOVA were used to unveil 
statistically significant differences between cells treated with vehicle only and AQ1. 
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3.4 RESULTS 
 
3.4.1 Ligands selection 
As anticipated, all members of the library were previously tested for their 
ability to stabilize the G4 structure of the human telomeric sequence as well as a 
random DNA double helix and a general preference for G4 vs dsDNA was previously 
reported for most compounds of the library (Musetti et al., 2009; Bianco et al., 2010; 
Folini et al., 2010; Zagotto et al., 2011; Milelli et al., 2012; Nanjunda et al., 2012; 
Bianco et al., 2013). Consistently, as a first preliminary screening tool, we analyzed 
all the members of our library by fluorescence melting measurements. The induced 
thermal stabilization on the G4s assumed by the target sequences in the same 
experimental conditions are reported in Figure 1A and Table 4.  
 
Figure 1. (A) Increments of the melting temperature of the G4 arrangements of tested c-KIT 
sequences induced by 1 µM concentrations of tested ligands. Data were acquired in LiP 
buffer with 50 mM or 1 mM KCl for KIT1 or KIT2, respectively. (B) Percentage of TO 
displacement from KIT1 or KIT2 induced by a 4-fold excess of AQ, AN and HAD derivatives.  
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Compound Ref      KIT1      KIT2      HTS dsDNA 
HAD1 DB832
a
 12.5 13.3 10.9 2.4 
HAD2 DB1450
 a
 21.8 11.3 12.8 12.1 
HAD3 DB2037
 a
 19.6 17.5 16.8 7.8 
HAD4 DB1463
 a
 10.1 1.2 7.3 2.0 
HAD5 DB1438
 a
 3.5 11.0 13.3 1.2 
HAD6 DB1972
 a
 14.0 13.1 9.9 4.2 
HAD7 DB1949
 a
 15.7 13.4 12.6 2.6 
HAD8 DB934
 a
 7.4 5.8 5.0 2.9 
HAD9 DB1693
 a
 12.1 9.5 9.4 2.2 
HAD10 DB1694
 a
 10.6 13.9 5.6 1.1 
HAD11 DB1093
 a
 12.9 13.4 11.7 11.5 
HAD12 DB1999
 a
 8.1 13.1 4.9 2.4 
NDI1 2
b
 1.5 8.3 10.3 3.0 
NDI2 1
 b
 0.6 0.7 9.2 2.8 
NDI3 20
 b
 2.0 3.3 13.5 4.4 
NDI4 22
 b
 0.4 0.7 7.0 1.9 
NDI5 8
 b
 0.2 0.5 10.1 5.0 
Phen1 K34
c
 0.0 0.0 0.1 0.0 
Phen1_Ni(II) (K34)2Ni(II)
 c
 1.9 0.0 3.1 0.0 
Phen2 P120
d
 0.0 0.0 0.1 0.0 
Phen2_Ni(II) (P120)2Ni(II)
d
 1.8 0.0 10.0 0.0 
Phen3 P115
e
 2.5 5.2 0.1 0.0 
Phen3_Ni(II) (P115)Ni(II)
e
 30.9 30.6 23.6 0.3 
AQ1 D-13
f
 13.1 15.3 18.0 4.6 
AQ2 E-13
 f
 6.7 8.4 18.9 4.5 
AQ3 B-13
 f
 9.9 12.9 14.2 2.5 
AQ4 C-13
 f
 5.2 5.1 9.9 1.4 
AQ5 D-15
 f
 10.2 6.0 18.2 1.2 
AQ6 E-15
 f
 13.0 1.7 4.5 0.1 
AQ7 B-15
 f
 9.5 11.1 7.0 0.3 
AQ8 C-15
 f
 4.0 6.4 4.3 0.1 
AN1 Ant1
g
 0.0 2.4 1.0 1.2 
AN2 Ant2
 g
 0.0 0.1 0.3 0.6 
AN3 Ant9
 g
 0.0 0.2 1.0 1.6 
AN4 Ant9,10
 g
 5.0 6.5 1.7 0.9 
AN5 Ant1,5
 g
 2.0 6.7 13.6 0.5 
AN6 Ant1,8
 g
 5.2 8.0 3.0 0.8 
AN7 Ant2,6
 g
 4.4 7.2 4.7 0.1 
AN8 Ant2,7
 g
 1.2 3.6 2.0 0.1 
Table 4. Library of tested compounds and variation of the melting 
temperature they induced at 1 µM concentration of each tested DNA 
sequence. Errors were ± 0.4 °C. The previously used compound name and 
the corresponding reference are reported in the ref column. 
a
 Nanjunda
 
et 
al., 2012, 
b
 Milelli et al., 2012, 
c
 Musetti et al., 2009, 
d
 Bianco et al., 2013, 
e 
Bianco et al., 2010, 
f 
Zagotto et al., 2011, 
g 
Folini et al., 2010. 
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Interestingly, some behaviors were conserved among derivatives belonging to 
the same scaffold. As an example, all tested polyamine derivatives recognized G4 
irrespectively of DNA sequence (telomere, KIT1 or KIT2). As regards the NDI 
derivatives, all of them showed a preferential stabilization of the telomeric G4. Thus, 
none of these compounds were selected for further investigations. About Phen-
derivatives, only their Ni(II) complexes involving two Phen moieties were confirmed 
to be active, as previously shown on the telomeric sequence; thus, we considered 
them as not appropriate for in cells studies, since in the living environment the 
distribution among complexes with different stoichiometry can be hardly monitored. 
On average, anthraquinone derivatives (AQ) showed higher thermal 
stabilization in comparison to the tested anthracenes (AN). Moreover, for both 
families of compounds, some variations in terms of efficiency and selectivity were 
highlighted according to the nature and relative position of the side chains. This led 
us to consider them as promising candidates. In order to further reduce the number of 
hits we added a second screening protocol, a G4 fluorescent intercalator displacement 
(G4-FID). This assay is based on competitive displacement of TO form DNA by our 
putative ligands. In agreement with literature data, we confirmed that, in our 
experimental conditions, TO showed comparable binding constant for KIT1 and 
KIT2 (Largy et al., 2011). Consequently, this assay provides a direct indication of the 
affinity ranking order by tested competitors. For comparison, in this assay we 
included some HAD derivatives which are suggested to bind G4 into the grooves. 
Accordingly, they were not able to displace the end-stacking agent TO. The results of 
FID are summarized in Figure 1B. 
FID and thermal stabilization data are in good agreement. On average, AQ 
derivatives were the best TO competitors. This result prompted us to perform full 
titrations with some derivatives. We focused on the comparison between 1,5 and 2,6 
regioisomers within the AQ family (AQ1 and AQ5 vs AQ3 and AQ7, respectively) 
since they appear to be the best performing compounds (Table 5).  
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Table 5. DC50 (50% displacement concentration;M) derived from TO
 
displaces (FID) by 
selected ligands (AQ and AN derivatives) with KIT sequences.  
 
Within the 1,5 series, the aminoacidic composition of the side chain (βAla-Lys 
in AQ1 vs βAla-Phe-Lys in AQ5) did not cause significant variations in TO 
displacement. Conversely, the insertion of a phenylalanine moiety seemed to 
positively affect it within the 2,6 series (βAla-Lys in AQ3 vs βAla-Phe-Lys in AQ7). 
As far as AN derivatives are concerned, they were confirmed to be remarkably less 
efficient than AQs. Among them, AN6 was the best performing on both the tested 
KIT sequences. Noteworthy differences were never observed between KIT1 or KIT2 
sequences. 
Hence, by merging FID and thermal stabilization results, anthracene derivative 
AN6 and anthracenedione derivatives AQ1 and AQ7 were selected for further 
investigations.  
 
3.4.2 Binding affinity and functional interaction of selected ligands 
To better characterize the interaction between the selected ligands and the G4 
folded form of KIT1 and KIT2, we performed SPR. For this experiment, 
oligonucleotides labeled at 5’with Biotin-TEG (tetra-ethyleneglycol) were folded in 
KCl and subsequently immobilized on a gold chip functionalized with streptavidine. 
Sensorgrams were acquired and the data at the steady state were used to evaluate the 
binding constants of the selected binders towards the c-KIT sequences (Figure 2, 
Table 6). 
 
 AQ1 AQ5 AQ3 AQ7 AN6 
KIT1 0.32 ± 0.05 0.27 ± 0.02 0.50 ± 0.04 0.24 ± 0.04 4.11 ± 0.7 
KIT2 0.35 ± 0.05 0.41 ± 0.03 0.62 ± 0.05 0.25 ± 0.02 3.63 ± 1.00 
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Figure 2. Representative examples of SPR analysis. (A) Sensorgrams derived from the 
analysis of AQ1 with KIT2. (B) Plots of the RU at the steady state plotted vs the 
concentration of injected ligand on chip functionalized with KIT1.  
 
 KIT1 KIT2 
AQ1 1.99 ± 0.15 1.01 ± 0.15 
AQ7 3.04 ± 0.43 2.29 ± 0.28 
AN6 71.5 ± 20.1 25.5 ± 4.01 
Table 6. Dissociation constants, (Kd, M) of selected ligands (AQ and AN derivatives) with 
KIT sequences determined by SPR
 
in 10 mM Tris, 50 mM KCl, pH 7.5, 0.025% surfactant 
P20. 
 
All experimental equilibrium data well fitted with a single binding model. 
Interestingly, all tested ligands showed a preferential, albeit modest, interaction with 
KIT2. However, in line with the above presented results, the binding constant of AN6 
was confirmed to be at least one order of magnitude lower than those provided by AQ 
derivatives. 
Before moving toward the cell system, we assessed if the binding of our ligands 
to the c-KIT sequences can actually impairs the processing of the c-KIT promoter. 
Thus, we performed polymerase stop assay: KIT1 and KIT2 sequences were inserted 
into a template strand and the elongation of a complementary primer by Taq 
polymerase was monitored. As shown in Figure 3, increasing concentrations of each 
ligand in the reaction mixture resulted in a progressive reduction of the full length 
product. In parallel, a predominant arrest product, which corresponds to the primer 
elongation up to the G-rich region, appeared. According to the above reported 
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binding affinity ranking order, this effect occurred at lower ligand concentration 
when the AQ derivatives were used and with a slight more pronounced efficiency on 
KIT2 sequence. This reinforces a model in which the G4-ligand complex prevents the 
oligonucleotide replication by Taq polymerase. 
 
Figure 3. Polymerase stop assay with 0-15 µM of tested ligands. P, A and F correspond 
respectively to primer, arrest product and full length product. 
 
3.4.3 G4-ligands cytotoxicity 
In short-term cultures (72 hours) AQ1 and AN6 showed dose-dependent 
cytotoxic effects in both MCF7 and HGC27 cell lines. Dose-response curves, the 
relative IC50 values and the corresponding linear regression coefficients (R
2
) for each 
G4-ligand are reported in Figure 4. AQ7 was comparatively less cytotoxic, and the 
IC50 value could not be determined even using concentrations up to 10 µM (Figure 
4E and 4F). 
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Figure 4. Dose-response curves and proliferation curves of HGC27 and MCF7 after 
treatment with the G4-ligands. (A) HGC27 and (B) MCF7 dose-response curves from Alamar 
Blue experiments to determine IC50 values and R
2
 following the incubation with AQ1. (C) 
HGC27 and (D) MCF7 dose-response curves from Alamar Blue experiments to determine 
IC50 values and R
2
 after the exposure to AN6. (E) HGC27 and (F) MCF7 proliferation curves 
from sulforhodamine B experiments following the incubation with AQ7. Data are expressed 
as mean values ± standard deviation of three independent experiments, each one performed 
in different passages. 
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3.4.4 Target genes constitutive expression 
To define the best protocol of exposure to G4-ligands, we measured the time-
dependent (from T6 and up to T96) changes in the constitutive expression of c-KIT, as 
well as of 6 other genes known to contain G4 forming sequences in their promoter 
region, e.g., MYC, BCL2, PDGFA, PDGFRβ, KRAS and hTERT. Results are shown in 
Figure 5. 
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Figure 5. Effects of culturing time on gene expression. (A) Total RNA was isolated from 
HGC27 monolayers and mRNA levels of c-KIT, MYC, PDGFA, hTERT, KRAS, BCL2 and 
PDGFRβ were measured by using a qPCR approach. (B) Total RNA was isolated from 
MCF7 monolayers and mRNA levels of c-KIT, MYC, PDGFA, hTERT, KRAS and BCL2 were 
measured by using a qPCR approach. Data (arithmetic means ± S.D.) are expressed as n-
fold change (a.u.) normalized to the RQ mean value of cells stopped at T6, to which an 
arbitrary value of 100 was assigned.
a, aa, aaa
: P<0.05; P<0.01; P<0.001 T6 vs T24; 
b, bbb
: 
P<0.05; P<0.001 T6 vs T48; 
c, cc, ccc
: P<0.05; P<0.01; P<0.001 T6 vs T72; 
ddd
: P<0.001 T6 vs 
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T96; 
e, eee
: P<0.05; P<0.001 T24 vs T48; 
f, ff, fff
: P<0.05; P<0.01; P<0.001 T24 vs T72; 
g, gg, ggg
: 
P<0.05; P<0.01; P<0.001 T24 vs T96; 
hhh
: P<0.001 T48 vs T72; 
ii, iii
: P<0.01; P<0.001 T48 vs 
T96; 
jjj
: P<0.001 T72 vs T96. 
 
Overall, c-KIT seemed to be the most variable gene, with a differential pattern 
of expression between the two cell lines. In the HGC27 cell line, it reached a peak of 
expression at T24, then it significantly decreased day by day; however, in MCF7 cell 
line, c-KIT expression increased slowly and reached a top at T96. As regards the other 
genes, no evident time-dependent differences in gene expression were ever noticed, 
except for BCL2 in MCF7 and PDGFRβ in HGC27 whose mRNA levels significantly 
increased with time; however, in MCF7 cell line both MYC and PDGFA mRNAs 
decreased after T6. Worth mentioning, PDGFRβ gene expression was not detectable 
in MCF7 cell line. Taking into consideration the present results and since the 
objective of the treatment was to block the promoter activity, the transcriptional 
effects of candidate G4-ligands on c-KIT gene were investigated in cells incubated for 
6, 12 and 24 hours. 
Table 7 summarized qPCR and flow cytometry experimental settings chosen for each 
cell line and ligand. 
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Cell line Ligand IC50 qPCR 
Concentration 
Tested 
qPCR 
Time 
Tested 
Flow 
cytometry 
Concentration 
Tested 
Flow  
cytometry 
Time tested 
HGC27 AQ1 1.65 0.5 µM - 1 µM T6, T12, T24 1 µM - 2 µM
a
 T48 
 AQ7 >10 µM 10 µM
 b
 T6, T12, T24
b
 / / 
 AN6 2.04 0.5 µM - 1 µM T6, T12, T24 1 µM T48 
MCF7 AQ1  3.00 1 µM -2 µM T6, T12, T24 1 µM - 2 µM
a
 T48 
 AQ7 >10 µM 10 µM
 b
 T6, T12, T24
 b
 / / 
 AN6 2.70 1 µM -2 µM T6, T12, T24 1 µM T48 
α155 AQ1 / 1 µM T6, T12 1 µM - 2 µM T48 
HMC1.2 AQ1 / 1 µM T6, T12 1 µM - 2 µM T48 
Table 7. qPCR and flow cytometry experimental settings chosen for each cell line and ligand 
tested in the study. 
a
 2 µM concentration was used only in BCL2 detection experiment,
 b 
data 
not shown in the manuscript. 
 
3.4.5 Evaluation of G4-ligands efficacy 
The incubation with AQ1 led to an inhibition of c-KIT expression (range 2-10-
fold) in HGC27 cells (Figure 6A), while in MCF7 cell line the gene was almost 
completely suppressed after 24 hours (37-fold; Figure 6B). In both cell lines, the 
down-regulation by treatment was always statistically significant (P<0.0001). 
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Figure 6. Effect of AQ1 on c-KIT mRNA and protein expression in HGC27 and MCF7 cell 
lines. The c-KIT mRNA level (A) and (B) was measured by using qPCR approach, and data 
(arithmetic means ± S.D.) are expressed as n-fold change normalized to the RQ of control 
cells at each time (T6, T12, T24) to which an arbitrary value of 1 (a.u.) was assigned. Two-way 
ANOVA followed by Bonferroni post-test were used to assess statistical differences between 
doses and time of treatment. The c-kit protein amount (C) and (D) was measured by flow 
cytometry and data are expressed as n-fold change (a. u.) to the mean fluorescence intensity 
(MFI) of not treated cells. Student t-test was used to assess statistical differences between 
cell treated with AQ1 and those treated with the vehicle (DMSO).
 *,**, ***
: P<0.05; P<0.01; 
P<0.001. 
 
 
c-KIT transcriptional results were confirmed, although to a lower magnitude, at 
the protein level by flow cytometry analysis. A significant decrease of c-KIT (2-fold) 
was observed in HGC27, and a similar trend was also noticed in MCF7 cell line 
(Figure 6C and 6D, respectively). An example of flow cytometry dot plots, with 
population gate and histograms showing the fluorescence of CD117, is reported in 
Figure 7. 
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Figure 7. Evaluation of CD117 expression in HCG27 cells after 24h of incubation: 
Control sample: (A) morphological scatter (forward scatter, FSC; side scatter, SSC); (B) 
isotype control, histogram; (C) CD117 expression, histogram;  
HCG27 cells incubated with DMSO (D) morphological scatter (forward scatter, FSC; side 
scatter, SSC); (E) isotype control, histogram; (F) CD117 expression, histogram. 
HCG27 cells incubated with AQ1 1 µM: (G) morphological scatter (forward scatter, FSC; 
side scatter, SSC); (H) isotype control, histogram (I) CD117 expression, histogram. 
 
 
Besides c-KIT, AQ1 caused a marked and significant inhibition (P<0.0001) of 
BCL2 gene expression in both cell lines (Figure 8).  
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Figure 8. Effect of treatment with AQ1 on BCL2 mRNA and protein in HGC27 and MCF7 
cell lines. The BCL2 mRNA level (A) and (B) was measured by using a qPCR approach, and 
data (arithmetic means ± S.D.) are expressed as n-fold change normalized to the RQ of 
control cells at each time (T6, T12, T24) to which an arbitrary value of 1 (a.u.) was assigned. 
Two-way ANOVA followed by Bonferroni post-test was used to assess statistical differences 
between doses and time of treatment. 
***
: P<0.001. The bcl2 protein amount (C) and (D) was 
measured by flow cytometry, and data are expressed as n-fold change (a.u.) of the mean 
fluorescence intensity (MFI) measured in untreated cells. One-way ANOVA followed by 
Bonferroni post-test was used to assess statistical differences between cell treated with AQ1 
and those treated with the vehicle (DMSO).
 *,**
: P<0.05; P<0.01. 
 
 
The magnitude of such inhibition accounted for 2.5-5 and 4-6 -fold for HGC27 
and MCF7, respectively. No post-transcriptional effects were noticed in HGC27 
under the present experimental conditions (Figure 8C); however, a significant 
decrease (P<0.01) of bcl2 protein amount was observed, at 48 hours, only in MCF7 
cells with AQ1 treatment at 2 µM (Figure 8D). 
Concerning the other oncogenes, known to possess G4 structures in their 
promoter region, a significant, although of minor importance, down-regulation was 
observed for PDGFRβ in HGC27 (P=0.0003; Figure 9), and for MYC and hTERT in 
MCF7 with P<0.0001 (Figure 10). 
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Figure 9. Effect of AQ1 on mRNA of other oncogenes possessing G4 structures in HGC27. 
(A) MYC, (B) hTERT, (C) KRAS, (D) PDGFA and (E) PDGFRβ mRNA level were measured 
using qPCR, and data (arithmetic means ± S.D.) are expressed as n-fold change (a.u.) 
normalized to the RQ of control cells at each time (T6, T12, T24) to which an arbitrary value of 
1 was assigned. Two-way ANOVA and Bonferroni post-test were used to assess statistical 
differences between doses and time of treatment. 
*, **, ***
: P<0.05; P<0.01; P <0.001. 
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Figure 10: Effect of AQ1 on mRNA of other oncogenes possessing G4 structures in MCF7. 
(A) MYC, (B) hTERT, (C) KRAS and (D) PDGFA mRNA level were measured using qPCR, 
and data (arithmetic means ± S.D.) are expressed as n-fold change (a.u.) normalized to the 
RQ of control cells at each time (T6, T12, T24) to which an arbitrary value of 1 was assigned. 
Two-way ANOVA and Bonferroni post-test were used to assess statistical differences between 
doses and time of treatment. 
*, **, ***
: p<0.05; p<0.01; p<0.001. 
 
As regards AN6, it did not affect c-KIT mRNA in HGC27 cell line, whereas a 
decrease, only at T12 hours and at the highest ligand concentration, was observed in 
MCF7 cell line (P<0.05; Figure 11A and 11B). The amount of c-kit protein was 
significantly decreased, after 48 hours of incubation in both cell lines (P<0.01 and 
P<0.05 in HCG27 and MCF7, respectively; see Figure 11C and 11D). On the 
contrary, contrasting results were obtained for the other oncogenes under 
investigation.  
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Figure 11: Effect of AN6 on c-KIT mRNA and protein expression in HGC27 and MCF7 cell 
lines. The c-KIT mRNA levels (A and B) were measured by using a qPCR approach; data 
(arithmetic means ± S.D.) are expressed as n-fold change normalized to the RQ of control 
cells at each time (T6, T12, T24), to which an arbitrary value of 1 (arbitrary units, a.u.) was 
assigned. Two-way ANOVA, followed by Bonferroni post-test, were used to assess statistical 
differences between doses and time of treatment. 
**
: P<0.01. The c-kit protein amounts (C 
and D) were measured by flow cytometry, and data are expressed as n-fold change (a.u.) 
with respect to the mean fluorescence intensity (MFI) of untreated cells. Student t-test was 
used to assess statistical differences between cell treated with AN6 and those treated with the 
vehicle (DMSO).
 *,**
: P<0.05; P<0.01. 
 
 
The PDGFA mRNA levels increased after AN6 treatment in both cell lines 
(Figure 12D and 13D), while KRAS and PDGFRβ were up-regulated in HGC27 cell 
line only (Figure 12C and 12E).  
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Figure 12: Effect of treatment with AN6 on mRNA of oncogenes possessing G4 structures in 
HGC27. (A) MYC, (B) hTERT, (C) KRAS, (D) PDGFA, (E) PDGFRβ, and (F) BCL2 mRNA 
levels were measured by using qPCR, and data (arithmetic means ± S.D.) are expressed as n-
fold change (a.u.) normalized to the RQ of control cells at each time (T6, T12, T24) to which an 
arbitrary value of 1 was assigned. Two-way ANOVA and Bonferroni post-test were used to 
assess statistical differences between doses and time of treatment. 
*, **, ***
: p<0.05; p<0.01; 
p<0.001. 
 
On contrary, in MCF7 cell line a significant blocking effect was noticed for 
MYC and hTERT only at the highest tested concentration (P<0.01 and P<0.05; Figure 
13A and 13B, respectively).  
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Figure 13: Effect of exposure with AN6 on mRNA of oncogenes possessing G4 structures in 
MCF7. (A) MYC, (B) hTERT, (C) KRAS, (D) PDGFA and (E) BCL2 mRNA level were 
measured by using a qPCR approach, and data (arithmetic means ± S.D.) are expressed as 
n-fold change (a.u.) normalized to the RQ of control cells at each time (T6, T12, T24) to which 
an arbitrary value of 1 was assigned. Two-way ANOVA followed by Bonferroni post-test was 
used to assess statistical differences between doses and time of treatment. 
*, **, ***
: p<0.05; 
p<0.01; p<0.001. 
 
Finally, the exposure to AQ7 at 10 µM did not lead to a significant up- or 
down- regulation of c-KIT and the whole set of alternative genes considered in the 
present study (data not shown). 
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3.4.6 Confirmatory results with other cellular models 
To confirm that the effective molecular target of AQ1 is located in c-KIT 
promoter, a proliferation study was undertaken in a new mast cell line, e.g. the SCF 
dependent ROSA cell line and, particularly, the WT cell line (ROSA
WT
) as well as its 
SCF independent sub-clone ROSA
KITD816V
, engineered by lentiviral transfection 
(Saleh et al., 2014) and consequently regulated by a different promoter. In Figure 
14A the viability results obtained treating cells with imatinib at 1 µM as control of 
stable transfection were reported. As expected, ROSA
WT
 were much more sensitive 
to the treatment then the sub-clone transfected with the imatinib resistant mutation 
KITD816V. As reported in Figure 14B, AQ1 significantly inhibited proliferation to a 
greater extent in ROSA
WT
 than in ROSA
KITD816V
. The absence of G4 in the promoter 
region of ROSA
KITD816V
 favor the survival of cells under the treatment with AQ1. 
The anti-proliferative effects of AQ1 were then tested in other three cell lines: 
the α155 and the HMC1.2 in which the growth strictly depends on c-KIT, and PC3 
where c-KIT is not constitutively expressed (Simak et al., 2000). As shown in Figure 
14C, an overall inhibition of cell proliferation was observed, with a different order of 
magnitude and significantly less relevant for the non-expressing c-KIT PC3 cell line. 
The same experiment was also repeated on other cell lines where c-KIT is not 
responsible for growth namely TOV112 ovarian cancer cells and KARPAS299 
lymphoma cell line. Data obtained corroborated those described with PC3 cell line 
(data not shown). Interestingly, no differences in term of viability among AQ1 
concentrations were noticed between α155 and HMC1.2 cell lines, while a 
differential response was visible after treatment with imatinib between imatinib-
sensitive (α155) and imatinib-resistant (HMC1.2 and PC3) cell lines (Figure 14D). 
These results suggest that AQ1 and imatinib exert their actions at different molecular 
levels, because the former compound was not influenced by the mutation as the 
second. 
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Figure 14. Effect of exposure (72 hours) to imatinib, AQ1, and AN6 on proliferation of ROSA
WT
, ROSA
KITD816V, α155, HMC1.2 and PC3 cell lines. Data are 
expressed as percentage of viability ± S.D. against cells treated only with the vehicle (DMSO). (A) Effect of imatinib 1 µM on ROSA cell lines. Student t-test. 
***
: P<0.001. (B) Effect of AQ1 on ROSA cell lines. Student t-test. 
*,
 
***
: P<0.05; P<0.001. (C) Effect of AQ1 on α155, HMC1.2 and PC3. Student t-test. aaa: 
P<0.001 α155 vs PC3; bbb: P<0.001 HMC1.2 vs PC3. (D) Effect of imatinib 1 µM on α155, HMC1.2 and PC3 cell lines. One-way ANOVA followed by 
Bonferroni post-test. 
aaa
: P<0.001 α155 vs HMC1.2; bbb: P<0.001 α155 vs PC3; ccc: P<0.001 HMC1.2 vs PC3. (E) Effect of AN6 on ROSA cell lines. Student 
t-test. 
***
: P<0.001. (F) Effect of AN6 on α155, HMC1.2 and PC3. Student t-test. aa, aaa: P<0.01; P<0.001 α155 vs PC3; b, bb, bbb: P<0.05; P<0.01; P<0.001 
HMC1.2 vs PC3. 
- 62 - 
 
As far as AN6 is concerned, it seemed to bind specifically to the c-KIT 
promoter (Figure 14E). Indeed, a different pattern of inhibition between ROSA
WT 
and 
ROSA
KITD816V
 cells proliferation was noticed. Nevertheless, no antiproliferative 
effects were ever observed in PC3, α155 and HMC1.2 cell lines (Figure 14F). This 
would suggest a non-selective action of AN6 towards other G4 sequences, 
particularly when c-KIT is expressed to a lower extent or is undetectable. 
Consequently, and taking into account also the reduced inhibitory effect on c-KIT 
mRNA, we focused our attention on AQ1. 
 
Figure 15. Effect of AQ1 on c-KIT mRNA and protein in α155 and HMC1.2 cell lines. The c-
KIT mRNA levels (A and B) were measured by qPCR, and data (arithmetic means ± S.D.) are 
expressed as n-fold change normalized to the RQ of control cells at each time (T6, T12) to 
which an arbitrary value of 1 (a.u.) was assigned. Two-way ANOVA, followed by Bonferroni 
post-test, was used to assess statistical differences between doses and time of treatment. 
***
: 
P<0.001. The c-kit protein amounts (C and D) were measured by flow cytometry and data 
are expressed as n-fold change (a.u.) to the mFI of not treated cells. One-way ANOVA, 
followed by Bonferroni post-test, was used to assess statistical differences between cell 
treated with AQ1 and those treated with the vehicle (DMSO).
 a, aa
: P<0.05; P<0.01 DMSO vs 
1 µM AQ1; 
bb
: P<0.01 DMSO vs 2 µM AQ1. 
 
Following the treatment of α155 and HMC1.2 cell lines with 1 µM AQ1 (final 
concentration), we measured c-KIT mRNA and protein levels by qPCR and FACS, 
respectively. A significant transcriptional down-regulation was noticed, in both cell 
lines, after 6 and 12 hours of exposure (Figure 15A and 15B). This result was 
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confirmed at the post-translational level after 48 hours of exposure (Figure 15C and 
15D).  
An example of scatter plots and histograms obtained with α155 cell line is 
reported in Figure 
16. Following the 
treatment with 
AQ1, the side-
scatter of cell 
population 
change; this 
phenomenon 
might be 
attributed to a 
ligand-dependent 
morphological 
effect. 
 
 
Figure 16: Flow 
cytometry analysis 
of CD117 in α155 
cell line. 
Morphological 
scatter plot with 
forward scatter 
(FSC) vs side 
scatter (SSC) and 
c-kit histogram plot 
of fluorescence 
intensity (FI) of 
different samples: 
(A) and (B) 
irrelevant antibody 
IgG; (C) and (D) 
control cells; (E) 
and (F) DMSO 
treated cells FI; 
(G) and (H) AQ1 1 
µM treated cells; 
(I) and (J) AQ1 2 
µM treated cells. 
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To demonstrate that the inhibition of c-KIT protein was not due to a toxic 
effect, we performed the same experiment labeling the HLA complex, a protein 
supposed to be not influenced by the treatment. Data obtained with α155, HMC1.2 
and KARPAS299 cell lines (the last one survives independently from c-KIT) showed 
that HLA complex expression was never influenced by AQ1 exposure (see Figure 
17). 
 
Figure 17: Effect of treatment with AQ1 on HLA proteins of α155 (A), HMC1.2 (B) and 
KARPAS299 (C). HLA protein level was measured by flow cytometry and data are expressed 
as n-fold change (a. u.) to the mFI of not treated cells. One-way ANOVA with Bonferroni 
post-test were used to assess statistical differences between cell treated with AQ1 and those 
treated with the vehicle (DMSO).
 
 
 
An example of scatter plots and histograms obtained with α155 cell line is 
reported in Figure 18. This would confirm that the occurring morphological changes 
were not due to a high non selective toxicity of our candidate G4-ligand.  
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Figure 18: Flow 
cytometry analysis of 
HLA in α155 cell 
line. Morphological 
scatter plot with 
forward scatter 
(FSC) vs side scatter 
(SSC) and HLA 
histogram plot of 
fluorescence intensity 
(FI) of different 
samples: (A) and (B) 
irrelevant antibody 
IgG; (C) and (D) 
control cells; (E) and 
(F) DMSO treated 
cells FI; (G) and (H) 
AQ1 1 µM treated 
cells; (I) and (J) AQ1 
2 µM treated cells. 
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3.5 DISCUSSION 
The silencing of c-KIT is currently a promising therapeutic strategy to treat 
several types of cancers. Among the different tools, which can be applied to reach 
this goal, an interesting method is represented by G4-ligands. The advantages rest in 
the structural knowledge of the target (NMR and X-ray data of the G-rich promoter 
region of c-KIT are currently available) and on the small size of the potential ligands 
for these targets (thus allowing affordable subsequent optimization steps). To set the 
basis for a rational design of novel compounds working according to this mechanism, 
we started with a screening program of a library of compounds to clarify the 
molecular features required by a G4-ligand in order (a) to bind the selected KIT1 and 
KIT2 sequences and, (b) to consequently cause the downregulation of c-KIT 
expression in cancer cells.  
As regards the target recognition step, the combination of two different binding 
assays (thermal stabilization of the G4 form of KIT1/KIT2 and the displacement of a 
G4-bound dye) allowed us to identify three potential candidates out of 39 tested 
derivatives. They belong to the AQ or AN series thus supporting that the tricyclic 
aromatic structure can properly recognize the desired targets. 
Most of publications focused on c-KIT and G4 topic, use MCF7 and HGC27 
cell lines as experimental in vitro models (Bejugam et al., 2007; Gunaratnam et al., 
2009; Waller et al., 2009; McLuckie et al, 2011). Thus, our choice to test candidate 
G4-ligands on these cells reflects the need to use in vitro models suitable for this type 
of studies. Through the Alamar Blue cytotoxicity test, both AQ1 and AN6 provided 
lower IC50 values in HGC27 cell line than in MCF7 cell line. We could attribute such 
evidence to the different doubling time of the two cell lines (17 for HCG27 and 38 
hours and MCF7). Indeed, the obtained IC50 values are usually and comparatively 
lower in cell lines with a shorter doubling time that, therefore, perform a higher 
number of cell cycles in an equal period of time (Baguley et al., 2002). The third 
ligand (AQ7) did not show any relevant antiproliferative effects even at the highest 
tested concentration (10 µM); moreover, no transcriptional effects were noticed on c-
KIT expression; consequently, we decided to exclude it for the ensuing experiments. 
Nevertheless, this result is important because the affinity of AQ1 and AQ7 for the 
target sequence was comparable.  
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Overall, the most interesting results have been obtained with AQ1, followed by 
AN6. 
The exposure to AQ1 resulted in a significant inhibition of c-KIT mRNA levels 
in both cell lines. Moreover, this transcriptional effect was confirmed at the protein 
level by flow cytometry. This inhibitory effect was more pronounced in MCF7 than 
in HGC27 cells, probably due to the different constitutive expression of the gene in 
the two cell lines. An analogous behavior has already been observed by Bejugam et 
al. (2007), in a similar study with a different G4-ligand. Once characterized the 
inhibitory effect of AQ1 on c-KIT expression, a set of confirmatory studies were 
undertaken by using cellular models commonly recruited to study the effects of TKIs 
on c-KIT expression (Gabillot-Carré et al., 2006; Saleh et al., 2014). Firstly, the 
experiment with ROSA cells clearly demonstrated that the observed inhibition of 
proliferation was effectively due to the binding of AQ1 to c-KIT promoter. Moreover, 
the α155 and HMC1.2 cell lines showed a high sensitivity to AQ1, while the prostate 
cancer cell line PC3 did not. This further result supports that AQ1 binds specifically 
the oncogene c-KIT affecting mostly the proliferation of α155 and HMC1.2 cell lines 
which growth strictly depends on c-KIT. In the PC3 cell line, that do not express the 
proto-oncogene, the proliferation is less inhibited and this could demonstrate the 
absence of functional binding with other potential G4 structures in the genome 
(Simak et al., 2000). Worth mentioning, in the present study we also demonstrated 
that HMC1.2, a cell line naturally possessing the mutation D816V in the c-KIT 
protein and therefore resistant to imatinib, was highly responsive to AQ1. It is well 
known that some c-KIT mutations could represent a limitation in the use of the TKIs; 
for example, mutations involving exon 17 such as D816V and occurring in around 
80% of adult mastocytosis and some mutations of exon 9 in GIST (Liegl et al., 2008; 
Ustun et al., 2011). Present results are therefore very encouraging and unveil the 
potentialities of this compound also against tumor harboring c-KIT mutations in the 
coding region. The decrease of c-KIT mRNA and protein amounts, noticed in MCF7 
and HGC27, were also confirmed on α155 and HMC1.2 cell lines. To the best of our 
knowledge this is the first screening of candidate G4-ligands undertaken in a panel of 
designed target-specific cell lines and ever published so far. 
An important aspect that needs to be considered about G4-ligands is their 
affinity towards several different G4 structures that could be bound by the same 
molecule along the genome. However, it has been hypothesized that ligands capable 
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of binding several G4 structures might present an increased inhibitory effect due to 
interference on multiple cellular pathways (Chen et al., 2012). Boddupally et al., in 
2012, when studied the effects of G4-ligands on MYC’s G4, demonstrated how two 
G4-ligands, previously proved to have high affinity toward MYC’s G4 in cell-free 
models, inhibited cell growth by modulating, at the same time, the expression of 
several genes. For this reason we decided to check for possible ligand interactions 
with other oncogenes that contain, in the promoter, one or more putative G4 
sequences. In particular, we evidenced an inhibition of AQ1 against BCL2 in both 
MCF7 and HGC27 (confirmed also in α155 and HMC1.2 cell lines; data not shown). 
Huang et al. (2004) clarified that the anthraquinones decreased BCL2 expression and 
favored apoptosis. Present results confirmed this finding, despite the slighter 
inhibition noticed at the protein level, which has already been reported in other 
similar studies with other G4-ligands (Shen et al., 2013). At the same time, it is well 
documented that SCF, the endogenous c-KIT ligand, maintains the survival of human 
mast cells by repressing apoptosis through the expression of BCL2 (Mekori et al., 
2001); therefore, it is actually impossible to attribute the observed mRNA inhibition 
to a direct interaction of AQ1 with the G-rich region of BCL2 or to an indirect 
repression due to the decrease of c-KIT mRNA.  
In line with in solution data, the experiments in which we tested AN6 in c-KIT-
dependent cell lines showed that this ligand effectively binds the G4 sequence of c-
KIT, as demonstrated by the anti-proliferative effect measured in ROSA
KITD816V
 cells, 
where c-KIT expression is regulated by another promoter. At the same time, the 
proliferation studies conducted in the panel of cell lines showed a common and 
similar inhibition of cell replication irrespectively of their dependence upon c-KIT 
expression. This result might be justified with (a) a possible non-specific effect of 
AN6 on different cellular pathways or, (b) a lower affinity of AN6 for the G4 within 
c-KIT promoter, which might allow for a clearer detection of AN6-mediated effects 
on different cellular pathways. The AN6 exposure in MCF7 and HGC27 cell lines 
showed minor effect on c-KIT mRNA; however, c-kit protein was markedly 
inhibited. These contradictory results could derive from post-transcriptional 
modifications and/or the involvement of other pathways in c-kit mechanisms of 
regulation. To support such a hypothesis, we observed a decrease in MYC and hTERT 
and even an increase in KRAS, PDGFA and PDGFRβ gene expression. Noteworthy, 
the possible up-regulation of some target genes following the exposure to candidate 
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G4-ligands has already been described previously (Halder et al., 2012); therefore, 
more detailed studies are required to further decipher the exact mechanism 
underlying G4-mediated changes in oncogene transcription. Overall, taking into 
account that c-KIT was the gene target of the present study as well as that no 
differences in proliferation were noticed among the different cell lines, we cannot 
consider AN6 as a good candidate and worthy of further investigations. 
In conclusion, this work exhaustively demonstrated the capability of a putative 
G4-ligand, that is AQ1, to decrease c-KIT mRNA and protein amounts and, 
consequently, block proliferation in different but target-designed cellular models. 
Present results constitute a solid starting point for further studies about this promising 
molecule(s). Future studies will be addressed to demonstrate the specific binding of 
AQ1 to c-KIT promoter and elucidate the exact molecular mechanism of cell damage 
induced by the treatment of AQ1 and resulting in the blockage of cell proliferation. 
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4. Targeting Canine c-KIT Promoter by Candidate DNA 
G-quadruplex Ligands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Zorzan E., Da Ros S., Zorro Shahidian L., Palumbo M., Giantin 
M., Sissi C., and Dacasto M., 2015. Targeting Canine c-KIT Promoter by 
Candidate DNA G-quadruplex Ligands. Manuscript in preparation. 
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4.1 ABSTRACT 
G-quadruplexes (G4) are DNA secondary structures formed by stacked G-
tetrads frequently located in telomeres and promoter regions of proto-oncogenes. 
Recently, two G-rich sequences, canine KIT1 (d_kit1) and KIT2 (d_kit2), folding 
into G4, have been identified in canine c-KIT promoter. In this study, three 
compounds known to stabilize specifically KIT1 and KIT2 G4 structures are tested in 
a canine cell line, in order to identify a promising G4 ligand able to decrease c-KIT 
expression in dog. 
The 50% inhibitory concentration (IC50) of each ligand was determined by 
using the Alamar Blue cytotoxicity test in the canine mast cell tumor (MCT) cell line 
C2. The constitutive gene expression of c-KIT and other proto-oncogenes (BCL2, 
VEGFα, VEGFR2, KRAS, TERT) mRNA was measured by quantitative RT-PCR 
(qPCR). Therefore, ligand time- and dose-dependent effects upon c-KIT and other 
target genes were evaluated by using qPCR. 
In canine cells, target genes were shown to be constitutively expressed and 
measurable up to 96 hours of culture. Two compounds named AQ1 and AN6 
significantly inhibited c-KIT mRNA and protein expression independently from times 
and ligand concentrations used. 
From these preliminary data, both ligands could represent promising candidate 
for targeting canine KIT-dependent tumors such as MCT. However, such an 
assumption needs to be confirmed with further molecular studies. 
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4.2 INTRODUCTION 
The G4 structure is formed in guanine-rich DNA sequences and consists in a 
stable, four-stranded structure alternative to the double helix conformation. Four 
guanine residues connected through Hoogsteen hydrogen bonds constitute a G-
quartets and three or more quartets stacked one upon the other formed a G4 (Zhao et 
al., 2007). Bioinformatics analysis revealed that around 400,000 putative G4 forming 
sequences are present in the human genome. They are mainly located within the 
telomeres and in the promoter region of oncogenes, suggesting that these particular 
conformations may be involved in multiple cellular processes as telomerase 
maintenance, RNA transcription and translation (Bidzinska et al, 2013). Such 
hypothesis is supported by promising results, in terms of antiproliferative effects and 
gene regulation, obtained targeting G4 with small molecules that stabilize these 
structures. The first evidence of the role of G4 structures in the regulation of gene 
transcription derived from studies carried out on the v-myc avian myelocytomatosis 
viral oncogene homolog (MYC, Siddiqui-Jain et al., 2002). Recently, other studies 
demonstrated that two G4 sequences are located in the proximal promoter of the v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (c-KIT) proto-oncogene 
(Rankin et al., 2005; Fernando et al., 2006). It codes for a tyrosine kinase receptor 
implicated in cell survival, proliferation and differentiation; furthermore, the 
occurrence of activating mutations and/or overexpression of this gene can result in 
aberrant functions and oncogenic cellular transformation in mast cells, interstitial 
cells of Cajal and myeloid cells (Balasubramanian et al., 2011). Recent encouraging 
results were published about the human c-KIT stabilization by different classes of G4 
ligands: trisubstituted isoalloxazines, bis-indole carboxamides, 
benzo[a]phenoxazines, anthraquinone and bisanthrene derivatives (Bejugam et al., 
2007; Dash et al., 2008; McLuckie et al., 2011; Zorzan et al., chapter 3 of the present 
thesis).  
In the canine species, the constitutive activation of c-kit and mutations 
occurring in its DNA sequence are considered relevant pathogenic events in the 
development of cutaneous mast cell tumor (MCT), the most common skin tumor of 
dogs (Marconato et al., 2014). 
The advent of target therapy, and in particular the use of a new class of drugs 
called tyrosine kinase inhibitors, brought some benefits in the treatment of canine 
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MCT; however, potential resistance effects and a different selectivity of the drug 
depending by the mutational status of the gene sequence could occur (London et al., 
2009; Bonkobara, 2015). 
The presence of G4 sequence in genomes other than the human one has already 
been investigated, particularly in prokaryotes (Rawal et al., 2006), chicken (Du et al., 
2007) and warm-blooded animals such as rat, mouse, dog and zebrafish (Zhao et al., 
2007; Verma et al., 2008). Also in animals, the maximum frequency of G4 DNA 
motifs occur in the gene transcriptional regulatory region, comprised among the -500 
and +499 base pairs, in particular in the 100 bp preceding the transcription starting 
site. 
The recent discovery that canine c-KIT promoter presents, alike the human one, 
two putative G4 sequences surrounding a predicted Sp1 binding site, addressed us to 
test, in a canine MCT cell line, three candidate human G4 ligands previously 
investigated in two human established cell lines (Zorzan, chapter 3 of the present 
thesis). The conclusions published in Da Ros and co-authors in 2014 remarked that 
KIT1 G4 was very similar among the two species, human and dog, while KIT2 
sequence presented more differences that could vary the molecule binding. The aim 
of the present work was to establish the possibility to find a promising G4 ligand able 
to decrease c-KIT expression in dog and prevent malignant cell proliferation. 
 
4.3 MATERIALS AND METHODS 
4.3.1 Ligands 
Information and characteristic of ligands tested in the present study (named 
AQ1, AQ7 and AN6) are reported in chapter 3 of the present thesis. 
 
4.3.2 Cell cultures 
The canine MCT cell line C2, expressing mutated c-KIT (48 bp internal tandem 
duplication in the juxtamembrane domain) was kindly provided by Dr. Patrice 
Dubreuil (Centre de Recherche en Cancérologie de Marseille, France). Cells were 
cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 1 
mM sodium pyruvate and 1% penicillin/streptomycin (Gibco, Thermo Scientific, 
Waltham, USA). 
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Cell number and viability were checked by using Trypan Blue dye exclusion 
test (Sigma-Aldrich Co., St. Louis, USA). Cell cultures were checked for 
Mycoplasma contamination through PCR Mycoplasma Test Kit (PromoKine, 
Heidelberg, Germany). For all the experiments, cells were used from passage 5 to 
passage 15 maximum. 
 
4.3.3 Characterization of the G4 sequence 
The canine c-KIT proximal promoter region was amplified through PCR and 
cloned into TOPO TA vector as previously reported (Da Ros et al., 2014). Around 8 
different colonies and plasmids were sequenced for the obtainment of the exact c-KIT 
G4 sequence present in C2 cell line. 
 
4.3.4 G4-ligands cytotoxicity 
Cells were seeded in microplates at a concentration of 2 x 10
4
 cells per well; 
then, they were treated with AQ1, AQ7 and AN6 at concentrations ranging from 0.01 
µM up to 10 µM. Additional wells exposed to the vehicle (DMSO, 0.1% final 
concentration) and medium alone were included in each experiment, too. After an 
exposure of 72 hours, proliferation and cytoxicity were checked by adding 20 µl of 
CellTiter-Blue
®
 Cell Viability Assay (Alamar Blue, Promega, Madison, USA) to 
each well and the fluorescence was measured at 560 nm (excitation wavelength) and 
590 nm (emission wavelength), by using a VICTOR
™
X4 Multilabel Plate Reader 
(Perkin Elmer, Waltham, USA). Three separate experiments were executed and each 
concentration was tested in sestuplicate. 
 
4.3.5 Time-dependent constitutive expression of target genes  
mRNA levels of seven genes known to contain putative G4 structures in their 
promoter were measured in cultured cells during 96 hours without treatment. Cells 
were seeded onto 6-well plates at a final concentration of 6 x 10
5
 cells/well and 
collected after 6, 24, 48, 72 and 96 hours. Cell pellets were washed once with PBS 
1X 0.02% EDTA and, finally, resuspended in 0.5 ml of TRIzol
® 
reagent. The 
procedure of total RNA extraction, its quality and quantity evaluation and 
retrotranscription into cDNA are reported in chapter 3 of the present thesis. 
The full list of primers used in the present study for qPCR analysis is reported 
in Table 1. 
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Gene Sequence Source UPL 
probe 
c-KIT F: CCTTGGAAGTAGTAGATAAAGGATTCA designed ex novo #60 
R: CAGATCCACATTCTGTCCATCA 
BCL2 F: ACAACGGAGGCTGGGAATG designed ex novo #110 
R: CCTTCAGAGACAGCCAGGAGAA 
MYC F: GCTGCACGAGGAGACACC designed ex novo #77 
R: TCAATTTCTTCTTCGTCCTCTTG 
TERT F: TGACGTGGAAGATGAAGGTG designed ex novo #128 
R: CTCTCTCCGACGGTGTTC 
KRAS F: TGTGGTAGTTGGAGCTGGTG designed ex novo #62 
R: TCCCTCATTGCACTGTACTCCT 
VEGFA F: CGT GCC CAC TGA GGA GTT Giantin et al., 
2012 
#9 
R: GCC TTG ATG AGG TTT GAT CC 
VEGFR2 F: GGAACCCAATCAGAGACCCA designed ex novo #31 
R: GTCTTTGCCATCCTGCTGAG 
ATP5β F: TCTGAAGGAGACCATCAAAGG Giantin et al., 
2014 
#120 
R: AGAAGGCCTGTTCTGGAAGAT 
GOLGA1 F: GGTGGCTCAGGAAGTTCAGA Aresu et al., 2011 #149 
R: TATACGGCTGCTCTCCTGGT 
CGI-119 F: TCTACAATCTAAGAGAGATTTCAGCAA Aresu et al., 2011 #15 
R: TTCCTGACAAGCACAAAATCC 
CCZ1 F: TGAAGCACTGCATTTAATTGTTTAT Giantin, submitted 
manuscript 
#148 
R: CTTCGGCAAAAATCCAATGT 
Table 1: Primers and probes used for the qPCR analysis either obtained from previous 
publications or specifically designed for this study. UPL=Universal Probe Library; 
VEGFR= vascular endothelial growth factor receptor; ATP5β= ATP synthase, H+ 
transporting, mitochondrial F1 complex, beta polypeptide; GOLGA1= the Golgin A1; CGI-
119= the transmembrane BAX inhibitor motif containing 4; CCZ1= CCZ1 vacuolar protein 
trafficking and biogenesis associated homolog. 
 
Candidate genes included were c-KIT, c-MYC, VEGF, VEGFR2, KRAS, BCL2 
and Telomerase Reverse Transcriptase (TERT). To design genes primers, the Primer3 
software (http://primer3.ut.ee/) was used. Assay specificity was evaluated either in 
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silico, by using the BLAST tool, than experimentally by Power SYBR Green I (Life 
Technologies, Carlsbad, CA) amplification and melting curve analysis. 
Quantitative real-time RT-PCR (qPCR) reactions (10 µl final volume) were 
performed as previously reported (Zorzan et al., chapter 3 of the present thesis) with 
2.5 µl of 1:150 diluted cDNA. The analysis was performed in a LightCycler 480 
Instrument (Roche Applied Science, Indianapolis, IN) using standard PCR conditions 
(95°C for 10 min; 45 cycles at 95°C for 10 s and at 60°C for 30 s; 40°C for 30 s). 
Calibration curves, using 3-fold serial dilutions of a cDNA pool, were performed, and 
corresponding values of slope, efficiency (E) and dynamic range are reported in 
Table 2. The qPCR assays with E (%) comprised between 90% and 110% were 
considered as acceptable. 
 
 
Name Slope Efficiency (%) Dinamic range Error 
c-KIT -3.32 99.9 17.67-28.85 0.00544 
BCL2 -3.42 95.9 26.36-36.46 0.0232 
VEGFA -3.29 101.4 22.04-31.05 0.00528 
CGI-119 -3.43 95.7 23.23-31.64 0.00665 
GOLGA1 -3.28 101.8 25.60-36.74 0.00866 
ATP5β -3.26 102.7 19.17-30.39 0.00585 
CTBP1 -3.37 98.2 23.63-34.85 0.0104 
CCZ1 -3.34 99.2 25.30-33.35 0.0116 
KRAS -3.33 99.7 20.97-32.11 0.00849 
MYC -3.34 99.4 22.40-33.06 0.0109 
TERT -3.21 105.1 27.12-37.92 0.0162 
VEGFR2 -3.33 99.6 24.87-36.25 0.0393 
Table 2: qPCR assay standard curve values for C2 cell line. 
The obtained qPCR data were analyzed using the LightCycler480 software 
release 1.5.0 (Roche Applied Science, Indianapolis, USA) and the second derivative 
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method; the mRNA relative quantification (RQ) was performed by using the ΔΔCt 
method (Livak et al., 2001). Four internal control genes (ICGs), e.g. ATP synthase, 
H
+
 transporting, mitochondrial F1 complex, beta polypeptide (ATP5β), the Golgin A1 
(GOLGA1), the transmembrane BAX inhibitor motif containing 4 (CGI-119) and 
CCZ1 vacuolar protein trafficking and biogenesis associated homolog (CCZ1). These 
genes were amplified in all samples, but only ICGs genes whose expression was not 
statistically modulated during experimental conditions were used for the relative 
quantification. A cDNA pool was used as calibrator.  
Experiments were performed in triplicate and, for each experiment, two 
biological replicates were included.  
 
4.3.6 Transcriptional effects of G4-ligands on target genes 
Cells were incubated with vehicle (DMSO, 0.1% final concentration) or two 
sub-cytotoxic doses of G4-ligands. After 6, 12 and 24 hours of incubation, cell pellets 
were collected as described above. Methods used for RNA extraction, reverse 
transcription and qPCR were the same described above. The ICGs expression was 
checked within every experimental condition and the choice of the most suitable 
ICGs to be used for normalization was cell line- and ligand-dependent. A cDNA pool 
was used as calibrator. Experiments were performed in triplicate and, for each 
experiment, three biological replicates were included.  
 
4.3.7 Confirmatory post-translational effects of G4-ligands  
The first day of experiment, 5.4 x 10
6
 cells/well were seeded in Petri dishes and 
treated with AQ1 (final concentration 1.5 µM) or just with the vehicle (DMSO, 0.1% 
final concentration) for 24 hours. Cell pellets were washed with PBS 1X 0.02% 
EDTA, resuspended in RIPA buffer (50 mM Tris-HCl pH 7.4, 1% Triton X-100, 
0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 0.2 mM Sodium 
Orthovanadate, 1% protein inhibitor cocktail), incubate 30 min on ice and centrifuged 
for 10 min at high speed. Proteins were separated in 4-12% NuPAGE
® 
Novex
®
 Bis-
Tris Gels by using the XCell SureLock™ Mini-Cell electrophoresis system (Thermo 
Scientific, Waltham, USA), and then transferred onto nitrocellulose filters through 
the iBlot™ Dry Blotting System (Thermo Scientific, Waltham, USA). On each gel, 
one prestained molecular marker (Thermo Scientific PageRuler Plus Prestained 
Protein Ladder, Thermo Scientific, Waltham, USA), one unstained molecular marker 
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(MagicMark
TM
 XP Western Protein Standard, Thermo Scientific, Waltham, USA), 
and a c-KIT positive control (TF1 cells stable transfected with KITD816V and kindly 
provided by Drs. Patrice Dubreuil and Paulo De Sepulveda CRCM, Marseille, 
France) were loaded. 
Membranes were incubated with goat anti-human c-KIT (C-14, Santa Cruz 
Biotechnology, Dallas, Texas, USA), and goat anti-human GAPDH (V-18, Santa 
Cruz Biotechnology, Dallas, Texas, USA) primary antibodies, both diluted 1:1000. 
The secondary antibody was a peroxidase conjugated anti-goat IgGs (Merck Spa, 
Milano, Italy). The peroxide signal was detected with the Super Signal West Pico 
Chemioluminescent Substrate Kit (Thermo Scientific, Waltham, USA). 
Images were captured by Canon MG 5150 and the integrate optimal density of 
each band was measured with the program ImageJ. Data were normalized with 
GAPDH values, and the TF1 KITD816V was used as reference. 
 
4.3.8 Statistical analysis 
Data statistical analysis was performed by using GraphPad Prism version 5.00 
for Windows (GraphPad Software, San Diego, USA). Any details about statistical 
analysis used in the proliferation experiment and in the qPCR expression analysis are 
reported in chapter 3 of the present thesis. 
Immunoblotting data were expressed as a percentage of control integrated 
density, where control is represented by normal cells in culture. Variations between 
DMSO control cells and AQ1-treated cells were statistically evaluated by using the 
Student t-test. 
 
4.4 RESULTS 
4.4.1 Sequencing of the C2 c-KIT proximal promoter 
Before testing the effects of the putative G4 ligands on canine cells, we 
confirmed that C2 cells possessed the exact KIT1 and KIT2 sequences already 
characterized by Da Ros et al. (2014); in particular, we focused our attention on 
nucleotide -159, owing to the polymorphism previously detected in dog samples (-
159 G>A). The exact sequences of KIT1 and KIT2 are the following: KIT1: 
AGGGAGGGCGCCGGGAGGAGGG; KIT2: AGGAGGGGCGCGGGGAAGGGG. 
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4.4.2 Cytotoxicity tests and qPCR results 
To identify a potential ligand for canine KIT1 and KIT2 G4 structures, three 
compounds were tested in canine C2 MCT cell line. By using the Alamar Blue 
cytotoxity test, the dose-response curve of each ligand was determined and the 
corresponding IC50 value identified. The IC50 values for AQ1, AN6 and AQ7 were 
1,27 µM (R
2
: 0.9813), 5,87 µM (R
2
: 0.9721) and IC50>10 µM, respectively. In Figure 
1, dose-response curves for AQ1 and AN6 are reported.  
 
 
Figure 1: Dose-response curves of AQ1 and AN6 tested in canine C2 MCT cell line. Data 
are expressed as mean values ± standard deviation of three independent experiments, each 
one performed in different passages. 
 
The constitutive expression analysis was indicative of a variable expression for 
almost all the genes taken into account in the present study (see Figure 2). The c-KIT 
and KRAS expressions were not affected by time of culture, while a significant 
decrease, after 24 or 48 hours, was noticed for BCL2, MYC and hTERT expressions. 
The unique gene showing increased (up to 96 hours) mRNA level depending on time 
was VEGFA. 
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Figure 2. Effects of culturing time on gene expression. Total 
RNA was isolated from C2 cells and c-KIT, BCL2, VEGFA, 
KRAS, MYC and hTERT mRNA levels were measured by using 
a qPCR approach. Data (arithmetic means ± S.D.) are 
expressed as n-fold change (a.u.) normalized to the RQ mean 
value of cells stopped at T6, to which an arbitrary value of 100 
was assigned. *: P<0.05; ***: P<0.001. 
 
Taking into consideration these results, we decided to treat cells with the three 
putative ligands at two sub-cytotoxic doses and three different time points: T6, T12 
and T24 hours. 
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With regard to AQ7, as already seen in human cell lines, no significant effects 
on mRNA levels of target genes were ever detected for the genes included in the 
study (data not shown). 
Concerning AQ1, Figure 3 shows a significant decrease in c-KIT mRNA at T12 
and T24 with both concentrations. No differences between the two concentration were 
noticed. Transcriptional results were confirmed at the protein level, as shown in 
Figure 3. The densitometric analysis revealed a 2-fold significant inhibition of c-kit 
protein level following the exposure to 1.5 µM AQ1. 
 
Figure 3: Effect of AQ1 on c-KIT mRNA and protein amounts. (A) mRNA was measured 
using qPCR, and data (arithmetic means ± S.D.) are expressed as n-fold change (a.u.) 
normalized to the RQ of control cells at each time (T6, T12, T24) to which an arbitrary value of 
1 was assigned. Two-way ANOVA and Bonferroni post-test were used to find out statistical 
differences between doses and time of treatment. The c-KIT protein amount (B and C) was 
measured by immunoblotting, and data are expressed as n-fold change (a.u.) with respect to 
the densitometry untreated cells. Student t-test was used to assess statistical differences 
between cell treated with AQ1 and those treated with the vehicle only (DMSO).
 *,**
: P<0.05; 
P<0.01. 
 
Concerning the other target genes investigated, no significant effects were ever 
detected except for BCL2, for which a moderate inhibition at T12 with the highest 
dose was noticed (see Figure 4). 
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Figure 4: Effect of AQ1 on MYC (A), BCL2 (B), KRAS (C), TERT (D), VEGFR2 (E), VEGFα 
(F) mRNA. mRNA levels were measured using qPCR, and data (arithmetic means ± S.D.) are 
expressed as n-fold change (a.u.) normalized to the RQ value of corresponding control cells 
(T6, T12, T24) to whom an arbitrary value of 1 was assigned. Two-way ANOVA and Bonferroni 
post-test were used to check for statistical differences between doses and time of treatment.  
 
About AN6 (Figure 5), the two-way ANOVA showed an overall significant 
decrease of c-KIT mRNA at the highest ligand concentration (4 µM), and a moderate 
down-regulation at T12 with the AN6 lowest dose (2 µM). Confirmatory post-
transcriptional investigations (immunoblotting) showed a 2-fold decrease of c-kit 
protein, after 24 hours of exposure, with 4 µM AN6. 
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Figure 5: Effect of AN6 on c-KIT mRNA and protein amounts. (A) mRNA was measured 
using qPCR, and data (arithmetic means ± S.D.) are expressed as n-fold change (a.u.) 
normalized to the RQ of control cells at each time (T6, T12, T24) to which an arbitrary value of 
1 was assigned. Two-way ANOVA and Bonferroni post-test were used to find out statistical 
differences between doses and time of treatment. The c-KIT protein amount (B and C) was 
measured by immunoblotting, and data are expressed as n-fold change (a. u.) with respect to 
the densitometry of untreated cells. Student t-test was used to assess statistical differences 
between cell treated with AN6 and those treated with the vehicle only (DMSO).
 *,**
: P<0.05; 
P<0.01. 
 
Other target gene mRNA levels did not show time- or treatment-dependent 
significant variations, with the exception of VEGFR2, for which a significant 
increase after 12 hours (T12) of exposure was noticed at the highest ligand 
concentration (Figure 6). 
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Figure 6: Effect of AQ1 on MYC (A), BCL2 (B), KRAS (C), TERT (D), VEGFR2 (E), VEGFα 
(F) mRNA. mRNA levels were measured using qPCR, and data (arithmetic means ± S.D.) are 
expressed as n-fold change (a.u.) normalized to the RQ value of corresponding control cells 
(T6, T12, T24) to whom an arbitrary value of 1 was assigned. Two-way ANOVA and Bonferroni 
post-test were used to check for statistical differences between doses and time of treatment.  
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4.5 DISCUSSION 
The discovery of G4 structures in specific, biologically important regions of the 
genome known to be essential for cancer cells to proliferate, made them a significant 
drug target; therefore, several compounds targeting these structures have been 
discovered and shown a promising anticancer activity. A number of molecules, 
showing good potentialities in term of G4 stabilization have been proposed as 
candidate anticancer drugs. However, the compounds discovered so far are either 
moving very slowly to clinical trials or have not yet fully passed pre-clinical 
investigations (Shalaby et al., 2013). In this sense, the discovery of two c-KIT G4 
sequences in dog similar to human ones could be of help either to better understand 
the G4 biological functions in vivo, than to develop new G4-ligand candidates with 
realistic drug-like structures, higher selectivity and decreased side effects. Worth 
mentioning, even the domestic dog suffers of c-KIT-related tumors and indirectly 
could benefit from these novel strategies. 
In the present study, three candidate G4 ligands, previously evaluated in human in 
vitro models, were tested in the canine C2 MCT cell line, which has been shown to be 
successfully used in TKIs validation studies (Dubreuil et al., 2009; Halsey et al., 
2014). In term of cytotoxicity, AQ1 was proved to be as the most cytotoxic ligand, 
while AQ7 showed a value of IC50 > 10 µM, likewise to human cells. Considering the 
qPCR results, AQ7 did not elicit appreciable effects on c-KIT transcription, 
corroborating human data. Based on these results, it should be hypothesized that AQ7 
might be unable to enter within the cell or, rather, it may possess a lower efficacy 
compared to other ligands.  
Independently from the incubation times and concentrations used, AQ1 
significantly down-regulated c-KIT mRNA. Nevertheless, if compared with human 
data, such an inhibition is less pronounced (2-fold decrease) than in human mast cell 
leukemia cells HMC1.2 (5-fold decrease). The inhibitory effect on c-KIT expression 
was confirmed also at the protein level in cells treated with the highest dose (1.5 µM). 
Among the other tested oncogenes, only BCL2 disclosed an inhibitory trend 
under treatment with AQ1, and such a down-regulation was significant at 12 hours in 
cells exposed to the highest G4-ligand concentration. This result was not unexpected; 
as a matter of fact, AQ1 caused a marked inhibition of BCL2 mRNA also in human 
cells as reported in chapter 3 of the present thesis. This is partly confirmed by the 
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evidence, that anthraquinones compounds decrease BCL2 levels and increase 
apoptosis (Huang et al., 2006).  
By contrast, the bisantrene derivative AN6, let to a significant inhibition of c-
KIT expression in canine cells while in humans such an effect was never observed. 
Even in this case, post-translational investigations confirmed the inhibition of gene 
transcription. Comparing results obtained in human and canine cells treated with this 
ligand, we should suppose that the different behavior observed between the two 
species could depend on differences between KIT1 and KIT2 G4. Multiple 
mutagenesis studies in human have already confirmed the direct correspondence 
between G-rich sequence composition, G4 conformation and ligand interaction; so, 
any modification in G4 sequences could influence the effectiveness of the ligand 
bond (Siddiqui-Jain et al., 2002; Patel et al., 2007; Tian et al., 2010). 
Besides this, approximately 30–40% of human promoters contain a putative G4 
motif, and actually there are no information about canine genome. Since many genes 
containing potential G4 structures are overexpressed in cancer tissues, striking 
importance assumes the development of highly selective G4 ligands avoiding an 
overall gene transcription inhibition, that could potentially result in non-specific 
toxicity. As regard AQ1, results are encouraging for both species. However, for AN6 
some species specific differences seem to be present, and further investigations are 
needed to clarify in depth the affinity of this candidate compound against c-KIT. 
To the best of our knowledge this work represent the first attempt to explore the 
capability of putative G4 ligands to inhibit c-KIT transcription in dog cancer, and 
particularly in a canine tumor cell line derived from MCTs. These preliminary results 
demonstrate that these ligands may decrease the c-KIT expression in cancer cells and 
seem encouraging particularly for canine c-KIT-dependent tumors such as MCTs. 
Further studies are needed to demonstrate the specific action of these ligands 
against c-KIT G4. In this sense, chromatin immunoprecipitation and/or gene reporter 
assays might demonstrate whether AQ1 and AN6 really bind KIT1 and KIT2. 
Furthermore, other in vitro models could be useful for an in depth characterization of 
molecular phenomena regulating gene inhibition and subsequent effects on kinase 
cascade and related pathways. 
- 88 - 
 
  
- 89 - 
 
5. Concordance of c-KIT Mutational Status in Matched 
Primary and Metastatic Cutaneous Canine Mast Cell 
Tumors at Baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted with the permission of Wiley from: Marconato L.,* Zorzan E.,* Giantin M., Di 
Palma S., Cancedda S., and Dacasto M., 2014. Concordance of c-kit Mutational 
Status in Matched Primary and Metastatic Cutaneous Canine Mast Cell Tumors at 
Baseline: Implications for Clinical Practice. Journal of Veterinary Internal Medicine, 
28: 547-553. Copyright © 2013 by the American College of Veterinary Internal Medicine 
* These authors contributed equally to this work.  
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5.1 ABSTRACT 
Background: Mutation analysis of c-KIT is advisable before starting treatment 
with tyrosine kinase inhibitors in dogs with mast cell tumor (MCT), including 
those with metastatic disease. Testing is usually performed on primary tumors, 
assuming that c-KIT mutation status does not change in metastasis. 
Hypothesis/Objectives: To give an insight into the mutational processes and to 
make a recommendation on the use of c-KIT mutational analysis in the clinical 
setting. 
Animals: Twenty-one client-owned dogs with metastatic MCT. 
Methods: Dogs undergoing resection or biopsy for both primary and matched 
metastatic MCT were prospectively enrolled. Total RNA or DNA was extracted 
from primary MCT and corresponding metastases. Exons 8, 9 and 11 were 
amplified by PCR and sequenced. Genetic features between primary MCT and 
metastases were compared. Their correlation with clinicopathological features was 
investigated. 
Results: Concordance (mutated or wild type, WT) of mutational status, evaluable 
in 21 primary and matched metastatic (20 nodal and 1 splenic) MCTs, was 100%. 
Three new c-KIT mutations were identified. No significant correlation was noticed 
between c-KIT mutation and clinicopathological features.  
Conclusions and Clinical Importance: c-KIT mutational status is conserved 
between any primary and its matched secondary tumor, suggesting that both can 
be used for c-KIT mutational testing. Targeted therapies might be also used to treat 
metastatic disease. 
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5.2 INTRODUCTION 
The proto-oncogene c-KIT (c-KIT), which encodes for the transmembrane 
receptor c-kit, is known to play a critical role in mast cell development and tumors 
(Ma et al., 1999). In dogs, approximately 9 to 30% of mast cell tumors (MCTs) 
show c-KIT mutations, including internal tandem duplications (ITDs) in the 
juxtamembrane domain, resulting in constitutive activation of KIT in the absence 
of ligand binding (London et al., 1999; Ma et al., 1999), and activating point 
mutations in c-KIT extracellular domains (e.g., exons 8 and 9; Letard et al., 2008). 
In general, ITDs are associated with an increased risk of metastasis and local 
recurrence, higher tumor proliferation index, and aberrant KIT localization 
(London et al., 1999; Downing et al., 2002; Webster et al., 2006; Webster et al., 
2007).  
The importance of the mutational status has been elucidated by 2 clinical 
trials, which showed a lower objective response rate and a shorter survival time 
when tyrosine kinase inhibitors (TKIs) including toceranib and masitinib, 
respectively, were administered to dogs with wild-type (WT) tumors (Hahn et al., 
2008; London et al., 2009). Although TKI-based therapy is used in dogs with 
MCT to also treat metastatic disease in the lymph nodes (London et al., 2009), c-
KIT status is generally evaluated in the primary lesions because metastatic sites are 
rarely removed or biopsied before treatment. However, it is still unknown whether 
c-KIT status differs in metastases compared with primary tumors. The rationale for 
using small molecule inhibitors of oncogenic proteins as cancer therapies depends, 
at least in part, on the assumption that metastatic tumors are primarily clonal with 
respect to the mutant oncogene. If this is not the case, targeted therapies might 
only be partially efficacious. Therefore, it is of primary importance to verify the 
correlation between primaries and related metastases with regard to c-KIT status. 
In people, controversy exists regarding the stability of mutational status in 
various tumors throughout the course of the disease, leading to metastases with 
different mutational status from that of the primary tumor (Ganceberg et al., 2002; 
Scartozzi et al., 2004; Italiano et al., 2006). In veterinary medicine there are only 2 
studies comparing immunohistochemical phenotypes between primary mammary 
carcinomas and their related lymph node metastasis (Beha et al., 2012; Brunetti et 
al., 2013). In cats, concordance between primary mammary carcinoma and 
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matched metastasis was detected in 57.1% of cases (Brunetti et al., 2013),
 
whereas 
in dogs in 65% of cases (Beha et al., 2012). 
To the authors’ knowledge, very few studies have been conducted in dogs 
on the rate of concordance in terms of c-KIT mutations. One study showed c-KIT 
ITD heterogeneity in different sites of multiple MCTs in 2 dogs (Amagai et al., 
2013); in another study, c-KIT ITDs were used to provide evidence of tumor 
clonality in multiple MCTs developing over 1-2 years in 2 dogs (Zavodovskaja et 
al., 2004). 
In the current study, we prospectively analyzed matched primary and 
metastatic MCT specimens for c-KIT intra- and inter-tumor heterogeneity, (1) to 
give an insight into the mutational processes, and (2) to make a recommendation 
on the use of c-KIT mutational analysis in the clinical setting. Moreover, the 
treatment with TKIs is associated with potential toxicity and high costs; 
additionally, resistance to certain TKIs is often due to secondary mutations of c-
KIT (London et al., 2009; Gao et al., 2013), therefore it is important to critically 
review all aspects of the mutational testing to enhance upfront patient selection.  
We hypothesized a discordance of c-KIT mutational status between 
matched primary and metastatic MCT, thereby recommending the use of c-KIT 
mutational testing on all involved sites. 
 
5.3 MATERIALS AND METHODS 
 
5.3.1 Case selection - Inclusion Criteria 
Dogs with histologically confirmed MCT undergoing complete clinical 
staging and total or partial surgical excision of the primary tumor and 
corresponding metastasis were prospectively recruited. Treatment with 
neoadjuvant medical therapy (including steroids, chemotherapy, targeted therapy) 
was not permitted. 
Background information recorded for each dog included: signalment, body 
weight, and primary tumor description (location, dimension, presence of 
ulceration, grade according to Patnaik and Kiupel’s systems; Blackwood et al., 
2012). Initial staging included history and physical examination, complete blood 
cell count with differential, serum biochemistry, coagulation profile, cytological 
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evaluation of the cutaneous nodule and regional lymph node, thoracic radiographs 
(3 views), abdominal ultrasound, fine-needle aspirates of liver and spleen 
regardless of their sonographic appearance, and cytologic examination of bone 
marrow obtained from the iliac crest. Lymph nodes or viscera were considered 
metastatic, if mast cells appeared in clusters or sheets, in very large numbers or 
atypical on morphology, as previously documented (Stefanello et al., 2009).
 
Histologically, nodal metastatic spread was supported by the localization of mast 
cells in the subcapsular sinuses; special histochemical stains (Giemsa) were used 
to detect poorly granulated mast cells.  
Written informed consent was obtained from all owners. 
 
5.3.2 Tumor Specimens 
Tumor samples were obtained by partial or total surgical resection from 
each primary MCT and matched metastasis before starting any medical treatment. 
To formulate a histologic diagnosis, samples were fixed in 10% buffered formalin, 
processed, and embedded in paraffin by using a standardized protocol. Slides were 
reviewed by a single board-certified pathologist (SDP), and histopathological 
criteria for diagnosis were based on those previously published for canine MCT 
(Patnaik et al., 1984; Kiupel et al., 2011). 
With regards to c-KIT sequencing analysis, either one tissue core (2-mm 
diameter) or fine-needle aspirates (FNA) were obtained from each primary MCT 
sample and matched metastases. Specimens were submersed in a stabilization and 
storage solution
 
(RNAlater
®
 Solution, Life Technologies, Foster City, CA) and 
refrigerated at -20°C until use. Whenever the primary tumor was surgically 
excised by other veterinarians, 10 µm sections of the corresponding formalin-fixed 
and paraffin-embedded (FFPE) block were used for nucleic acid extraction. 
 
5.3.3 Nucleic Acid Extraction 
Total RNA was extracted from biopsies and FNA (Kobayashi et al., 2012) 
by using a nucleic acid isolation reagent (TRIzol
®
 Reagent, Applied Biosystems, 
Foster City, CA) and a commercial kit (High Pure RNA Isolation Kit, Roche 
Applied Science, Indianapolis, IN), respectively, according to the manufacturer’s 
instructions. Whenever nucleic acids were extracted from FFPE primary tumor 
sections, another commercial kit (AllPrep DNA/RNA FFPE kit, Qiagen, Milan, 
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Italy) was used. In this case, the genomic DNA was preferred to RNA because of 
the poor quality of the extracted RNA. 
Nucleic acids yield and purity (260/280 and 260/230 nm absorbance ratios) 
were measured by using a spectrophotometer Nanodrop ND-1000 
Spectrophotometer (Nanodrop Technologies, Wilmington, UK), whilst their 
quality was checked by 1% agarose gel electrophoresis. Two μg of total RNA 
were reverse transcribed by using a commercial kit
 
(High Capacity cDNA Reverse 
Transcription Kit, Life Technologies, Foster City, CA). Both cDNA and DNA 
were finally stored at -20°C until use. 
 
5.3.4 c-KIT Genotyping 
Exons 8, 9, and 11 considered the hotspot regions for activating protein 
mutations were screened by PCR and direct sequencing (Letard et al., 2008; 
Torres-Cabala et al., 2009). To amplify either c-KIT exons 8, 9, and 11 (starting 
from cDNA) or exon 11 (from DNA), previously published primers pairs and PCR 
conditions were used (Giantin et al., 2012). Conversely, exons 8 and 9 primers for 
genomic DNA amplification were designed ex novo (Primer3 software, 
http://primer3.ut.ee/) and forward and reverse primers as well as the expected 
amplicon sizes are reported in Table 1.  
 
exon primer sequence (5’-3’) expected amplicon size (bp) 
8 F: ACTCACTGGTTCCGATGCTC 408 
 R: CCCTTAAAAAGCCACATGGA  
9 F: CACCCTTGGTTGAAAAAGGA 458 
 R: ATATGGCAGGCAGAGCCTAA  
Table 1. Primers for genomic DNA amplification and sequencing of c-KIT exons 8 and 9 
 
Amplifications were carried out in a thermocycler (TPersonal, Biometra 
GmbH, Goettingen, Germany) by using a commercially available PCR kit 
(GoTaq
® 
Flexi DNA polymerase, Promega Corp., Madison, WI). Two μL of 5-
fold diluted DNA were used as template, while primers
 
(Eurofins MWG Operon, 
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Ebersberg, Germany) concentrations were 16.5 pmoles each. Amplicons were 
visualized in 1.5% agarose gel. 
Whenever the presence of additional bands of different length (roughly 30 bp) was 
noticed, these ones were at first individually excised from the agarose gel and, 
then, purified with a commercial kit (High Pure PCR Cleanup Micro Kit, Roche 
Applied Science, Indianapolis, IN), according to the manufacturer’s instructions. 
Hence, PCR products were sequenced, by using the same PCR primers, with either 
a capillary electrophoresis machine (ABI Prism 3100 Genetic Analyzer, Life 
Technologies, Foster City, CA) or an automatic sequencer (ABI 3730XL DNA 
Analyzer, Life Technologies, Foster City, CA). 
Sequences were analyzed with a commercially available software 
(FinchTV software, Geospiza Inc., Seattle WA). Alignments with the WT c-KIT 
mRNA sequence NM_001003181.1, to discover potential single nucleotide 
polymorphisms (SNPs), ITDs or deletions, were performed by using an open 
source software Multalin (http://multalin.toulouse.inra.fr/multalin/).  
 
5.3.5 Treatment and Response Criteria  
The type of treatment was at the investigator’s personal discretion, and 
included surgery, radiation therapy, chemotherapy, TKI or a combination of these. 
Response was determined by using RECIST criteria (Eisenhauer et al., 2009).
 
Briefly, disappearance of all lesions was defined as complete response (CR); a 
decrease of at least 30% in the diameter of a lesion was defined as partial response 
(PR); the appearance of new MCTs or at least a 20% increase of the diameter of a 
lesion was defined as progressive disease (PD); less than 30% reduction or 20% 
increase in the diameter of a lesion was defined as stable disease (SD). 
 
5.3.6 Statistical Analysis 
To evaluate the relationship between c-KIT mutations and 
clinicopathological factors, data were analyzed by Fisher’s exact test and Pearson 
χ2 test. To this purpose, the following clinicopathological features were taken into 
account: gender (male or female), reproductive status (intact or neutered), breed 
(purebred or crossbred; predisposition to biologically aggressive MCTs [meaning 
advanced grade or clinical stage], e.g. Shar-pei and Labrador retriever), age (< or 
≥ 10 years), weight (< or ≥ 10 kg), dimension of the primary lesion (< or ≥ 3 cm), 
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clinical stage (II or III or IV), substage (a or b), and histological grading (both 
Patnaik and Kiupel’s systems) (Kiupel et al., 2005; Murphy et al., 2006; White et 
al., 2011; Blackwood et al., 2012; Dobson, 2013). The anatomic site was 
categorized as benign or malignant, as some locations have been described as 
biologically aggressive (e.g. inguinal/perineal, head and neck, digit; Blackwood et 
al., 2012). Survival time was defined as the time interval between the initiation of 
treatment and death. Dogs dead from disease or MCT-related causes were 
classified as events; those dead for unrelated causes or lost to follow up at the time 
of the study closure were censored. 
Statistical calculations were performed using a commercial software 
package (GraphPad Prism 5, San Diego, California, USA). For all statistical 
analysis, significance was set at P < .05.  
 
 
5.4 RESULTS 
 
5.4.1 Dogs and MCT Demographics 
Between July 2011 and August 2013, 21 dogs met the inclusion criteria 
and were enrolled. There were 6 Labrador retrievers, 5 crossbred dogs, 3 Boxers, 
and one each of the following: Breton, Shih-Tzu, Shar-pei, Beagle, American 
Staffordshire terrier, German hound, and Dogue de Bordeaux. Twelve dogs were 
spayed females, 3 intact females, 4 intact males, and 2 castrated males. Median 
age was 8 years (range, 3 to 14 years), and median body weight was 26.7 kg 
(range, 7.4 to 50.2 kg). 
Eighteen (86%) dogs had single lesions, and 3 (14%) had concurrent 
multiple tumors. In these latter ones, the biggest MCT was sampled for both 
histopathological and mutational analysis. MCTs were in various locations, 
including 6 (29%) dogs with tumors on distal limbs; 4 (19%) dogs with their 
tumors on the head; 3 (14%) dogs with digital MCTs; 2 (10%) dogs with tumors 
on proximal limbs; 2 (10%) dogs with vulvar tumors; and 1 (5%) dog with a MCT 
on the abdominal wall. All dogs with multiple tumors had them in the same 
regional areas (axillary region, head, and abdominal wall).  
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Histopathology was available for all primary MCTs: 14 (66%) dogs had 
Patnaik’s grade 2 MCTs, 6 (29%) dogs had grade 3 MCTs, and 1 (5%) dog had a 
grade 1 MCT. Regarding the Kiupel’s grading system, 11 (52%) tumors were 
classified as low grade MCTs, and 10 (48%) as high grade MCTs. 
All dogs had metastatic disease: 20 (95%) dogs had regional lymph node 
involvement and, among these, 2 also had hepatic metastasis, 2 had splenic and 
hepatic metastasis, 1 had hepatic, splenic and marrow metastasis, 1 had splenic 
metastasis, and 1 had cutaneous metastasis. One (5%) dog had involvement of 
liver and spleen without regional lymph node metastasis. Lymph node metastases 
were confirmed in all 20 dogs by means of histopathology; the remaining dog 
without lymph node metastasis had only cytologic diagnosis of liver and spleen 
involvement. 
Overall, 11 (52%) dogs had stage II disease, 8 (38%) dogs had stage IV 
disease, and 2 (10%) dogs had stage III disease. Sixteen (76%) dogs were 
asymptomatic (substage a), and 5 (24%) dogs had signs of systemic effects of 
MCT (vomiting, diarrhea, pruritus, and regional edema). 
 
5.4.2 c-KIT Mutation Status 
All specimens of primary tumors and paired metastases were suitable for c-
KIT genotyping. Mutations of c-KIT sequence were detected in 3 (14%) MCTs: 1 
in exon 8 (Figure 1), and 2 in exon 11 (Figure 2). Two of them were noticed in 
dogs with grade 3 MCTs, and 1 in a dog with a grade 2 MCT. 
A new 28 amino acids (AAs) deletion affecting 10 AA codons, namely 
from Histidine-421 (H421) to Glutamine-430 (Q430), coupled with a 
contemporary insertion of 10 base pairs (bp) coding for four AAs (Leucine-
Threonine-Phenylalanine-Methionine, LTFM), was detected in exon 8 (Figure 1).  
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Figure 1. Direct sequencing of c-KIT exon 8 from canine MCTs. Both wild type (WT) and 
mutated nucleotide and protein alignments sequences are reported. In cDNA obtained 
from primary tumor and matched metastasis (the corresponding lymph node), a deletion 
of 10 AAs (HESLTNGMLQ), associated with an insertion of 4 AAs (LTFM), was detected. 
This new c-KIT mutation was termed 1262_1289delinsTGACTTTCAT, according to the 
nomenclature for human sequence variations (Den Dunnen and Antonarakis, 2001). 
 
This mutation was named 1262_1289delinsTGACTTTCAT, in agreement 
with the nomenclature for human sequence variations (Den Dunnen and 
Antonarakis, 2001). Moreover, 2 new ITDs were found in exon 11 (Figure 2): a 
first one, consisting in the insertion of 12 AAs at the residue 571 (ITD
571-582
), and 
a second one based on an addition of 14 AAs at the residue 574 (ITD
574-587
). 
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Figure 2. Direct sequencing of mutant c-KIT exon 11 from canine MCTs. Both wild type 
(WT) and mutated nucleotide and protein alignments sequences are reported. Two ITDs, 
namely ITD
571-582
 and ITD
574-587
, were detected in cDNA obtained from primary tumor and 
matched metastasis (the corresponding lymph node). 
 
Furthermore, 2 already known silent SNPs were detected in exon 8 
(1275G>A),
3
 and in exon 11 (1759C>T; Zemke et al., 2002). The relative 
frequencies were 33% (7/21) and 5% (1/21), respectively. 
Noteworthy, the comparison of c-KIT mutations and SNPs in primary 
tumors and corresponding metastases showed a concordance rate of 100%. 
Likewise, all dogs with a primary WT c-KIT genotype showed a WT c-KIT in 
their matched metastases. 
 
5.4.3 Treatment and Clinical Follow-up 
Eleven (52%) dogs (including the 3 dogs with c-KIT mutation) underwent 
surgical excision of their MCT. Four of these animals also received systemic 
chemotherapy (vinblastine and prednisone) as front-line treatment, 3 dogs received 
vinblastine and TKIs, 1 dog was treated with curative radiation therapy and TKIs, 
and 1 with curative radiation therapy and vinblastine. Two (10%) dogs received 
systemic chemotherapy (vinblastine and prednisone) as their only treatment. Six 
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(28%) dogs were treated with palliative radiation therapy; 4 out of these 6 also 
received vinblastine and prednisone, and 4 other ones TKI. Finally, 2 (10%) dogs 
were only treated with TKIs. 
Overall, 11 (52%) dogs achieved CR, 7 (33%) dogs PR, 2 (10%) dogs SD, 
whereas 1 (5%) dog did not respond to the treatment and experienced PD. At the 
end of the study, 10 (48%) dogs were still alive with a median follow-up of 205 
days (range, 41 to 473 days), and 11 (52%) dogs died or were euthanized because 
of progression of their MCT (n=10) or for tumor-unrelated causes (n=1). The 
overall median survival was 51 and 149 days for dogs harboring c-KIT mutations 
and with WT c-KIT gene, respectively. 
 
5.4.4 Relationship between c-KIT Mutational Status and Clinicopathological 
Features 
No significant correlation was found between primary c-KIT mutation and 
the considered clinicopathological characteristics (Table 2). 
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Variables 
 
c-KIT 
mutation 
 
 positive negative P value 
age (years)    
<10 2 9  1.000* 
>10 1 9  
sex    
male 2 4 0.184* 
female 1 14  
breed    
pure breed 3 13 0.549* 
crossbred 0 5  
breed predisposition to aggressive 
MCTs 
   
yes 2 5 0.247* 
no 1 13  
weight (kg)    
<10 1 1 0.271* 
>10 2 17  
primary lesion, anatomic site    
benign 0 11 0.090* 
malignant 3 7  
primary lesion, dimension (cm)    
<3 1 9 1.000* 
>3 2 9  
metastatic lymph node    
yes 3 17 1.000* 
no 0 1  
stage    
I-II 0 11 0.097** 
III 1 1  
IV 2 6  
substage    
a 1 15 0.128* 
b 2 3  
histological grade (Patnaik)    
I 0 1 0.283** 
II 1 13  
III 2 4  
histological grade (Kiupel)    
low 1 10 0.586* 
high 2 8  
Table 2. Relationship between c-KIT mutational status and clinicopathological features in 
21 primary MCTs. *: Fisher exact test; **: Pearson χ2 test. 
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5.5 DISCUSSION 
In the current study, we compared c-KIT mutational status of exons 8, 9 
and 11 between primary MCT and matched metastasis, and found a perfect 
(100%) concordance.  
Metastatic MCT represents a major health problem in the canine 
population, but the introduction of a novel class of targeted antineoplastic agents 
directed against KIT, TKI, has significantly changed the therapeutic options 
available for these dogs (Hahn et al., 2008; London et al., 2009). Indeed, the 
important role of targeted therapy against molecules contributing to tumor 
development, progression, and metastasis has attracted considerable attention 
(London, 2009).  
Because the identification of the mutational status of c-KIT could help to 
select dogs that have a high probability of benefiting from TKI (London et al., 
2009), it is of primary importance to verify the degree of correlation between 
primaries and related metastases with regard to c-KIT status. Indeed, mutations are 
mainly evaluated at the primary site and there is little data available regarding the 
possible concordance in mutational status between the primary tumor and the 
corresponding metastases (London et al., 2009; Hahn et al., 2008). However, the 
death of metastatic cells is the main goal of treatment in a metastatic setting. These 
cells might be biologically different from the primary tumor, which has 
implications for the clinical management of MCT.  
It is well known that the progression of cancer develops from a single 
mutated cell, followed by malignant clonal expansion secondary to additional 
genetic and genomic alterations. As a consequence, the ongoing acquisition of 
these alterations can result in the emergence of neoplastic subclones with varying 
genotypes and, consequently, phenotypes (Fidler and Kripke, 1977) leading to 
discordance between the primary tumor and its metastases. In people, several 
tumors including melanoma (Karatona et al., 2007), gastrointestinal stromal tumor 
(GIST; Liegl et al., 2008), and lung cancer (Taniguchi et al., 2008), show intra-
tumor and inter-tumor heterogeneity, indicating the presence of more than one 
clone of cancer cells within a given neoplastic mass, and the presence of different 
genetic alterations in different metastatic sites from a single patient, respectively. 
Therefore, determining if there is homogeneous mutational status between primary 
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tumor and its metastatic sites has important clinical implications, over all to select 
the appropriate treatment. 
To our knowledge, the question of mutational status in metastases versus 
primary MCT has not been addressed so far.  
Compared to previously published studies, the mutational status of our case 
series, including both primary and secondary metastatic tumors, showed a similar 
proportion of c-KIT mutations (Giantin et al., 2012). Two already known SNPs 
were found in exon 8 and 11 (Zemke et al., 2002; Letard et al., 2008); furthermore, 
3 novel mutations (1 in exon 8 and 2 in exon 11), with unknown clinical 
relevance, were found.  
The data presented in this study provide evidence that the WT or mutated 
c-KIT genotype is conserved in primary MCTs and their matched, concurrent 
metastases. Although a similar behavior has been reported in human melanomas 
(Torres-Cabala et al., 2009), this result is somewhat surprising, in the light of 
genomic instability and heterogeneity that characterize most malignant tumors. In 
fact, it is generally accepted as true that loss of primary mutation and/or gain of 
secondary mutation might occur in patients regardless of the use chemotherapy or 
targeted therapy; such a phenomenon can be explained by the fact that cells with 
different mutations coexist within the primary tumor, and clonal selection for 
mutations during tumor progression might lead to different c-KIT mutations status 
in metastatic sites from that of the primary tumors (Amagai et al., 2013; Dai et al., 
2013).  
In the present analysis, discordant cases were not observed, pointing out 
that in canine MCTs c-KIT status is maintained in all cases unchanged during the 
metastatic process. 
Another question, still matter of debate, is whether activating c-KIT 
mutations might be related to a poor prognosis in canine MCTs (Giantin et al., 
2012; Takeuchi et al., 2013). Based on our results, dogs with c-KIT mutations had 
a shorter survival time when compared with dogs with WT MCTs. However, due 
to the different treatments and the limited number of mutated cases, conclusions 
on the prognostic relevance of c-KIT mutations cannot be drawn. Also, a number 
of variables, including gender, reproductive status, breed, age, weight, dimension 
of the primary lesion, clinical stage, substage, and histological grading, were 
evaluated to determine whether they were correlated to c-KIT status. None of these 
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variables were found to be significantly associated with the presence of c-KIT 
mutations, although the small population might have led to an insufficient power 
to detect differences between subgroups. 
Although the current report is limited by the small sample size, our 
observations indicate that c-KIT mutation in the primary tumors might predict c-
KIT mutated metastases with a reasonably high probability, suggesting that c-KIT 
mutation represents a very early mutational step in MCT pathogenesis and plays a 
central role in tumor progression. The implication of these results for general 
oncology practice is that both tissues of primary tumor or metastasis can be used 
for c-KIT mutation testing. However, the low number of mutated cases analyzed at 
the present time does not allow drawing any definitive conclusions about the c-
KIT asset in synchronous and metachronous metastases, as well as their 
association with response to therapy. 
Clearly, further molecular studies, carried out on dogs with metastatic 
MCT and receiving chemotherapy and/or TKI, are needed to clarify whether c-KIT 
genotype might be somewhat affected by anticancer drugs.  
Finally, it must be stressed that the results of our study are valid for lymph 
node metastases and cannot be extrapolated to other metastatic locations, as only 
one dog with splenic involvement was evaluated here. The lymph node is the 
predominant site of metastases in the majority of dogs with metastatic MCT; 
therefore the results of our study of 20 lymph node metastases provide a reference 
for clinical decision-making as to TKI therapy. Nevertheless, as the molecular 
patterns might differ between metastatic sites (Stefanello et al., 2009; Amagai et 
al., 2013), and because c-KIT secondary mutations are likely to occur following 
TKIs administration (Wang et al., 2009; Ando et al., 2011; Gao et al., 2013), more 
results need to be obtained by testing additional metastatic sites, including spleen 
and liver, before and after targeted therapies. Also, the identification of new c-KIT 
ITDs underscores the need of further molecular investigations on their prognostic 
significance.  
In conclusion, the mutational status seems to be stable during MCT 
metastasis, which is encouraging for TKI use in the clinical setting. 
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6. Mutational Hotpots of TET2, IDH1, IDH2, SRSF2, 
SF3B1, KRAS, and NRAS from Human Systemic 
Mastocytosis Are Not Conserved in Canine Mast Cell 
Tumors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted with the permission of Plos One from: Zorzan E., Hanssens K., Giantin 
M., Dacasto M., Dubreuil P., 2015. Mutational hotspot of TET2, IDH1, IDH2, 
SRSF2, SF3B1, KRAS, and NRAS from human systemic mastocytosis are not 
conserved in canine mast cell tumors. Plos One 12; 10(11): e0142450. 
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6.1 ABSTRACT 
 
Introduction: Both canine cutaneous mast cell tumor (MCT) and human systemic 
mastocytosis (SM) are characterized by abnormal proliferation and accumulation of 
mast cells in tissues and, frequently, by the presence of activating mutations in the 
receptor tyrosine kinase V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene 
Homolog (c-KIT), albeit at different incidence (>80% in SM and 10-30% in MCT). In 
the last few years, it has been discovered that additional mutations in other genes 
belonging to the methylation system, the splicing machinery and cell signaling, 
contribute, with c-KIT, to SM pathogenesis and/or phenotype. In the present study, 
the mutational profile of the Tet methylcytosine dioxygenase 2 (TET2), the isocitrate 
dehydrogenases 1 and 2 (IDH1 and IDH2), the serine/arginine-rich splicing factor 2 
(SRSF2), the splicing factor 3b subunit 1 (SF3B1), the Kirsten rat sarcoma viral 
oncogene homolog (KRAS) and the neuroblastoma RAS viral oncogene homolog 
(NRAS), commonly mutated in human myeloid malignancies and mastocytosis, was 
investigated in canine MCTs. 
Methods: Using the Sanger sequencing method, a cohort of 75 DNA samples 
extracted from MCT biopsies already investigated for c-KIT mutations were screened 
for the “human-like” hot spot mutations of listed genes. 
Results: No mutations were ever identified except for TET2 even if with low 
frequency (2.7%). In contrast to what is observed in human TET2 no frame-shift 
mutations were found in MCT samples. 
Conclusion: Results obtained in this preliminary study are suggestive of a substantial 
difference between human SM and canine MCT if we consider some target genes 
known to be involved in the pathogenesis of human SM. 
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6.2 INTRODUCTION 
In dogs, cutaneous mast cell tumor (MCT) is the most common skin tumor, and 
it accounts for up to 10-30% of all cases. MCTs occur mostly in the dermis and 
subcutaneous tissue but some visceral forms can also be located in other sites e.g. 
gastrointestinal tract and spine bone marrow as well as liver, oral cavity, urethra, 
salivary gland, nasopharynx and spleen (Ohmori et al., 2008; Blackwood et al., 2012; 
Takeuchi et al., 2010). It is commonly identified as a solitary neoplastic mass in the 
skin and/or subcutaneous tissue of older dogs, with a mean age of onset of 
approximately 9 years of age. Some dog breeds, such as Boxers, Labrador Retrievers 
and Shar Pei, are more prone to develop MCTs (Webster et al., 2007; Warland and 
Dobson, 2012). 
Activating mutations of the tyrosine kinase receptor c-kit, which binds to stem 
cell factor (SCF), a known hematopoietic cytokine, have been described in canine 
MCTs. Mutations in c-KIT occur in 15-50% of MCTs, and have been associated with 
a more aggressive tumoral phenotype (Webster et al., 2006), possibly due to an 
increased proliferation and a resistance to apoptosis (Gleixner et al., 2007; Letard et 
al., 2008). The most common type of mutations identified in canine MCTs are 
internal tandem duplications (ITD) involving exon 11 (Zemke et al., 2002; Webster et 
al., 2006) but also deletions and point mutations in exons 8, 9 and 11 can occur 
(Ohmori et al., 2008; Takeuchi et al., 2013). 
Human mastocytosis is a rare and clonal hematopoietic disease described as the 
proliferation and the accumulation of abnormal mast cells in the bone marrow and 
organs (Hanssens et al., 2014). Mastocytosis is schematically divided into cutaneous 
mastocytosis (CM) and systemic mastocytosis (SM). Localized mast cell tumors as 
mastocytomas and mast cell sarcoma are very rare. CM is usually diagnosed at birth 
or in childhood and spontaneously regress over time. However, some types are 
locally invasive, clinically very severe and, consequently, hard to treat. In most adult 
patients, the disease is systemic, although also the skin is often affected.  
Most cases of SM are associated with the presence of activating mutations in 
the c-KIT proto-oncogene. The most frequent KIT genetic alteration is the 
substitution of aspartic acid to valine at position 816 (KIT D816V), that leads to the 
constitutive activation of the kinase domain of the receptor (Arock et al., 2015).  
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It has been recently discovered as further cooperating events may contribute to 
the phenotype and/or the pathogenesis of SM (Traina et al., 2012; De Vita et al., 
2014) e.g. mutations in tet methylcytosine dioxygenase 2 (TET2) which have been 
reported in 40% of KIT D816V-positive SM cases (Tefferi et al., 2009). The enzyme 
TET2 regulates gene methylation and expression, catalyzing the conversion of 5-
methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) (Ito et al., 2011). In 
SM, it has recently been reported a more aggressive disease and an overall worse 
prognosis when there is the coexistence of KIT D816V and TET2 mutations (Soucie 
et al., 2012). Other mutations were identified in isocitrate dehydrogenase 1 and 2 
(IDH1 and IDH2, respectively). They affect both histone modifications and DNA 
methylation, catalyzing the decarboxylation of isocitrate to alpha-ketoglutarate (or 2-
oxoglutarate, 2-OG). Hotspot mutation sites are represented by heterozygous 
substitution clusters in conserved arginines R132 of IDH1 and R140 and R172 of 
IDH2 (Itzykson et al., 2013). Further additional mutations were found in genes 
encoding for components of the splicing machinery involved in the intron splicing 
during pre-mRNA maturation, in particular the serine/arginine-rich splicing factor 2 
and the splicing factor 3b, subunit 1 (respectively SRSF2 and SF3B1). Overall, recent 
data are suggestive of a specific hierarchy, where TET2 gene alterations arise in early 
progenitor cells, while SRSF2 mutation can occur relatively later during the ontogeny 
but both prior to KIT mutation during the disease progression (Hanssens et al., 2014). 
Likewise, neuroblastoma RAS Viral (V-Ras) oncogene homolog (NRAS) mutations 
have also been reported in SM, having the potential to precede KITD816V in clonal 
development (Wilson et al., 2011). 
Besides SM, loss-of-function mutations in TET2 as well as alterations in other 
genes mentioned above have been also reported in a variety of hematological 
malignancies, including acute myeloid leukemias (AMLs), chronic myelomonocytic 
leukemia (CMML), myeloproliferative neoplasms (MPNs), myelodysplastic 
syndromes (MDS) and lymphoid malignancies (Delhommeau et al., 2009; 
Langemeijer et al., 2009; Tefferi et al., 2009; Li et al., 2011; Moran-Crusio et al., 
2011). To the best of our knowledge, no data on mutational status of these genes are 
available for canine MCTs.  
In the present study, hypothesizing analogies in molecular mechanisms and 
gene dysfunctions with human SM and hematopoietic diseases, the mutation profile 
of genes commonly mutated in myeloid malignancies has been evaluated in a cohort 
- 109 - 
 
of 75 MCTs, most of them previously screened for c-KIT mutations (Letard et al., 
2008). 
 
6.3 MATERIALS AND METHODS 
6.3.1 Samples and ethical statement 
All tissue biopsies and blood samples were not specifically taken for the 
purposes of this study; they were part of authors in-house collections and were 
already used in previous studies (Hahn et al., 2008; Letard et al., 2008; Da Ros et al., 
2014). 
Tissue biopsies were originally collected as part of routine treatment procedures 
from dogs affected by at least one histologically-confirmed MCT (Patnaik grade II or 
III) (Patnaik et al., 1984), recurrent after surgery (as standard of care) and/or 
nonresectable. Female and male dogs, regardless of breed, were previously recruited 
with owner consent from veterinary clinics in France and in United States.  
Blood samples were collected in Italy from 39 healthy random-source adult 
kennel dogs undergoing routine examination as described in details previously (Da 
Ros et al., 2014). An Institutional Animal Care and Use Committee approval number 
was not requested because of an agreement between the Faculty of Veterinary 
Medicine of University of Padua (Italy) and the kennel for the execution of routinary 
clinical checkups as described in details previously (Da Ros et al., 2014). Animal care 
was carried out in accordance with good veterinary practices.  
 
6.3.2 DNA extraction, PCR and sequence analysis 
Genomic DNA was extracted from 75 frozen canine MCT tissue samples using 
QIAamp DNA Mini Kit (Qiagen France, Paris, France), according to manufacturer’s 
protocol. In the 23% of the cohort samples, different c-KIT mutations were previously 
identified in exons 8, 9 and 11 (Letard et al., 2008). Among them, internal tandem 
duplications of exon 11 represented 36% of total mutations registered. 
In the present study, PCR amplifications of all TET2 coding exons and the hot-
spot regions of IDH1 (exon 2), IDH2 (exon 1), SF3B1 (exons 13, 14, 15, 16), SRSF2 
(exon 1), NRAS (exons 1, 2) and KRAS (exon 1) were executed. Primer 
oligonucleotide sequences were designed using the AmplifX software 
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(http://crn2m.univ-mrs.fr/AmplifX) and CanFam3.1 genome sequences available 
http://www.ncbi.nlm.nih.gov/. Primer sequences, are reported in Table 1. For every 
exon analyzed, the extreme parts of the flanking introns were also sequenced (around 
100 bp upstream the 5´-end and downstream its 3´-end) to check for the presence of 
alternative splicing sites. All the detected variations were analyzed by using the tool 
Berkeley Drosophila Genome Project (BDGP, http://www.fruitfly.org) that computed 
splice sites predictions. Genes were amplified using Taq Phire® Hot Start II DNA 
Polymerase (Thermo Fisher Scientific, Walthman, MA, USA). The reaction mix 
contained the following reagents: 1X Phire® Reaction Buffer, 200 µM dNTPs, 0.5 
µM of each primer and 0.15 µL of the enzyme (in a final volume of 22 µL). 
Approximately, 30 ng of genomic DNA were added to each PCR reaction and 
amplified through the following thermal protocol: an initial denaturation step at 98°C 
for 30 sec, an amplification step of 35-40 cycles (denaturation at 98°C for 5 sec, 
annealing at the primer-specific temperature for 5 sec and elongation at 72°C for 5-10 
sec depending on the length of the PCR product) and a final elongation step at 72°C 
for 1 min. PCR products were purified and sequenced in an ABI 3730 sequencer. 
Sequence PCR reactions were performed with both primer forward (F) and reverse 
(R) using the Big Dye Terminator V1.1. (Applied Biosystem, Life Technologies, 
Carlsbad, USA) and the mix included: 3.2 pmol of oligo F or R, 1µL of Big Dye 
Terminator V1.1, 1X reaction buffer and water (in a final volume of 10 µL). The 
thermal protocol consisted in: an initial denaturation (1 min at 96°C) followed by 25 
cycles of 10 sec at 96°C, 5 sec at 50°C and 2 min at 60°C. 
 
GENE AND PRIMER SEQUENCES (5´-3´) EXON TEMP. ANNEALING PRODUCT 
LENGHT 
KRAS    
F: CTCATCTGTGGTCAACTGAA 1 60°C 466 bp 
R: AGCCAATGGAACCCAAGTA    
IDH1    
F: TGGCACTGTCTTCAGGGAAGCTAT 2 70°C 163 bp 
R: TGGGCAACCAAGGACAGGAAAA    
IDH2    
F: CTCCATCTCTGTCCTCGTAGAGT 4 67°C 343 bp 
R: TTAGCACCGCTGCCATCCTTT    
NRAS    
F: TCTCTAGTTGTGGCTCGCCCATTA 1 65°C 223 bp 
R:CAAAAGCCAGAGGTAGGGTCAGT    
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F:GCTAGGAGCTTATCTAACCTTGGC 2 60°C 367 bp 
R: TGCGGTATCCTCATTTCCTGTTCC    
SF3B1    
F: ACTGGAGGATCAAGAGCGTCAT 13 67°C 1101 bp 
R: GCTGTCGTGTTACGGACATACT    
F: ATGCTAGAGTGGAAGGTCGAGA 14 67°C 855 bp 
R: TGTGTTGGCGGATACCCTT    
F: GACCATTAGCGCTTTGGCCATT 15-16 67°C 529 bp 
R: GTTCCACAACACTGCTTCACCA    
TET2    
F: AGCCTGATGGAACAGGATAGA 3 60°C 782 bp 
R: GCCTGACTGTTAATGGCA    
F:CAAGAAAGTAATCCAGGCAAAGGC 3 60°C 718 bp 
R: AATACCGTTCAGAGCTGCCA    
F: CCTGTCCCTTCCAGAAACCAGAAA 3 60°C 605 bp 
R: TGTTGGGTTATGCTTGAGGTGTTC    
F: CCCCAACCAAAGTAACACAGCTCT 3 60°C 702 bp 
R: GCTTTGGATGAAGGGTCTGTCTTG    
F: GGCATCACTGCGGTCAGTTCTT 3 60°C 715 bp 
R: ATTCTGTCCTTGCTCCAATCCCA    
F: TCCCAAGGCAACAATGATCAGC 3 60°C 760 bp 
R: GGGGTGGAATCTCTTGCTTAGTTG    
F: CTCCCCAGAAGGACATTCAAAAG 3 60°C 784 bp 
R: CTCTCTTGCACAGCACAAGCAT    
F: GGATAAGCTTTGTGGATGTAGCCT 4 60°C 371 bp 
R: GCTCGCAGACTATTAGTCCTGT    
F: TCCAGTTTGCTTGGCTTAGAC 5 60°C 380 bp 
R: GAGCAACGTTCATTTCAACTAGC    
F: AATGCCCTAGTTGTGACCCAG 6 60°C 421 bp 
R: AAATGTCGGTTCAACTCCCTTCCC    
F: CCAGAATCCAAGATTGGTAGCC 7 60°C 295 bp 
R: GACTGCTTACTTCATCTGTACTCA    
F: TCATTTGGATCTAGGCTGTAGGGG 8 65°C 336 bp 
R: AACAGAACACTGTGGCTTCACT    
F: CGAGAGTCTTTCTGACCTGTTC 9 60°C 398 bp 
R: AAGGTCACCTTTGCAACAGC    
F: AGGCATGTCACTAATCTGGTCCAA 10 60°C 638 bp 
R:GGGACTTCAGGGAAGATTCTGGTA    
F: GGGGTTCTCACATACATTTAAGCA 11 65°C 920 bp 
R: GAGCTGTTGAACATGCCTGG    
F: ACTTCATGGGAGCCACCTCTAGAT 11 60°C 853 bp 
R: AGACAGGTTGGTTGGTTGGTTGTG    
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Table 1. Forward (F) and reverse (R) primer sequences of canine genes included in the 
present study and used for polymerase chain reaction with the corresponding annealing 
temperature and product length. 
 
Blood samples of 39 healthy dogs were collected and DNA extraction was 
performed as previously reported (Da Ros et al., 2014). Around 30 ng of genomic 
DNA were used in PCR reaction to amplify TET2 exon 11 and the products obtained 
were subsequently sequenced as described above.  
Sequences were analyzed and aligned by using the SeqScape software v3.0 
(Life Technologies, Carlsbad, USA) and identity percentage between dog protein 
sequences and mouse, rat, dog and cat were assessed through BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast). 
 
6.3.3 Statistical analysis 
To evaluate the possible relationship between the presence of glutamine 
repetitions in canine TET2 exon 11 and c-KIT mutations or the tendency to develop 
MCT, a Pearson χ2 correlation test was performed by GraphPad Prism version 5.00 
for Windows (GraphPad Software, San Diego, USA). A value of P< 0.05 was 
considered significant. 
 
6.4 RESULTS 
6.4.1 Gene sequences homology among canine and human species 
In myeloproliferative disorders and particularly in SM, the majority of the 
genes considered in this study possess hot spot sites for mutations; therefore, in the 
first part of the study, a comparison between human and canine genomic sequences 
was performed to verify the potential conservation of the same mutations sites in dog 
and, subsequently, their localization. To give a general overview, the percentages of 
protein sequence identities in target genes between the canine and the other most 
commonly studied species (human, cat, mouse and rat) are reported in Table 2. In 
general, a high degree of conservation was noticed among them and, for our 
purposes, the CanFam3.1 genome sequence proved to be definitely complete and 
reliable.  
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Gene Human Cat Mouse Rat 
TET2 84% 91% 58% 60% 
IDH1 97% 99% 95% 96% 
IDH2 96% 99% 97% 96% 
NRAS 100% 100% 100% 100% 
KRAS 99% 97% 96% 96% 
SF3B1 100% 100% 100% 100% 
SRSF2 100% NA 100% 100% 
Table 2. List of target genes and percentage of protein sequence identity between dog and 
other reference species (Homo sapiens, Felis catus, Mus musculus, Rattus norvegicus). NA: 
sequence not available in the databases.  
 
The amino acids residues considered hot spot sites for mutations in humans as 
R132 for IDH1, R140 and R170 for IDH2, G12 and Q61 for NRAS and G12 for 
KRAS were recognized in dog. Since in humans TET2 mutations occur almost all 
over the sequence, all the corresponding canine coding exons were amplified; the two 
sequences shared the 84% of amino acid identity (Table 2). On the other hand, the 
canine SRSF2 partial sequence obtained in this study differed, either in exons and 
introns, from NCBI release. Anyway, the analog of human hot spot site (P95) was 
conserved also in dog. The updated partial sequence was submitted to NCBI with the 
following accession number: KT072629. 
 
6.4.2 Target gene mutational status in MCTs samples 
All genes were successfully amplified in all the 75 samples except for SRSF2, 
that was amplifiable in only 37 samples cause of its complexity and GC-richness. 
In our MCT cohort, surprisingly, no mutations were ever found analyzing 
sequencing results of IDH1, IDH2, NRAS, KRAS, SF3B1 and SRSF2 genes (data 
not shown). 
Among samples, some intronic variants not related with splicing sites were 
detected in the target genes. These alterations, with the relative allelic frequencies and 
population distribution, are collected in Table 3. 
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Gene Intron/Exon Variation Population Frequency Allelic frequencies 
TET2 exon 3 c.732G>A p. = 3/75 (4%) G : 0.98, A : 0.02 
TET2 exon 3 c. 2315G>A: p.Gly772Asp 4/75 (5.3%) G : 0.97, A : 0.03 
TET2 intron 3 c.3439+75del 6/75 (8%) T : 0.96, delT : 0.04 
TET2 intron 8 c.4075-38del 5/75 (6.67%) T : 0.97, delT : 0.03 
TET2 intron 10 c.4212+63_4212+65insCAG 62/75 (82.7%) WT : 0.31, insCAG : 0.69 
TET2 intron 10 c.4568-65C>T 6/75 (8%) C : 0.95, T : 0.05 
TET2 exon 11 c.4914T>C:p= 58/75 (77.3%) T : 0.41, C : 0.59 
TET2 exon 11 c.5213A>G: p.Asn1728Ser 57/75 (76%) G : 0.41, A : 0.59 
TET2 exon 11 c.5278G>A: p.Ala1760Thr 1/75 (1.33%) G : 0.01, A : 0.99 
IDH1 intron 2 c. 292+37T>C 3/75 (4%) T : 0.98, C : 0.02 
NRAS intron 2 c. 290+44C>T 18/75 (24%) C : 0.87, T : 0.13 
KRAS intron 1 c. 93+104A>T 8/75 (10.67%) A : 0.95, T : 0.05 
KRAS intron 1 c. 93+139T>C 8/75 (10.67%) T : 0.95, C : 0.05 
SRSF2 intron 1 362+59_362+62dup 21/37 (58%) WT : 0.64, Dup : 0.36 
Table 3. List of genetic variations grouped for gene, relative population frequency and 
allelic frequencies in the MCT cohort of samples. 
 
6.4.3 TET2 mutational status in dog MCT 
In canine TET2 only two samples evidenced the presence of mutation in their 
coding sequence: one sample showed a heterozygous non-synonymous substitution 
(c.491A>G: p. Asp164Gly) in exon 3 while another sample was homozygous for a 
complete codon deletion (c.2226-2228del: p. His742del) always in exon 3. Both 
MCTs were histologically classified as Patnaik grade II. As regards to c-KIT 
mutations, the former had a wild-type sequence, while the second one had an internal 
tandem duplication occurring in exon 11 (ITD
572-583
). Since the frequency of TET2 
mutations was low (2.7%), a correlation between TET2 and c-KIT mutational status 
and/or MCT histological grading, was not possible. 
Also for TET2 gene, some intronic variants not related with splicing sites, and 
single nucleotide polymorphisms (SNPs) in the coding sequence were detected in the 
samples. These alterations, with the relative allelic frequencies and population 
distribution, are collected in Table 3. 
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Deepening in sequence analysis, other genetic variations were detected, in two 
specific regions of the gene. The protein database Uniprot (http://www.uniprot.org/) 
recognized them as polyglutamine rich-regions because they are rich in glutamine 
residues: one is located in exon 3 and another one in exon 11. The alignment of 
canine sequence with the same human, cat, mouse and rat sequence portion showed 
that poly-glutamines residues were quite conserved among species and dog possessed 
the highest number of glutamine repetitions (Figure 1).  
 
 
Figure 1. Sequence alignment between dog, cat, human, mouse and rat specific 
glutamine-rich regions located in exon 3 and 11 of TET2 gene. The image was 
obtained using the tool ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
 
In details, in canine exon 3, 65 out of 75 MCTs (86,66%) showed the deletion 
of glutamine 753 (c. 2250_2252del; p.Gln753del). In exon 11, different 
rearrangements in the number of glutamine repetitions were detected among samples. 
All variations observed in our cohort of samples with relative frequencies in the 
group are listed in Table 4. Performing a Pearson χ2 analysis between the number of 
glutamine repetitions in each sample and the presence of c-KIT mutations, no 
statistical correlations were evident (P=0.3427). Furthermore, the number of 
glutamine repetitions in exon 3 and 11 did not correlate with the histologic grade 
(Fisher exact test, P= 0.5808 and Pearson χ2, P= 0.2308, respectively). 
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Variation Population Frequency Glutamine repetitions 
Wild-type sequence 59/75 12 
c. 4682insGCA; p. 1562insQ 5/75 13 
c.4686_4697del; p. 1564_1567del 4/75 8 
c.4686_4694del; p. 1564_1566del 3/75 9 
c.4698_4700del; p.1568del 4/75 11 
 
Table 4. List of genetic variations detected in the glutamine rich region of TET2 
exon 11 with relative population frequency and total glutamine residues number in 
the 75 MCT samples. 
 
Afterwards, to better understand if these sequence rearrangements might have a 
correlation with the onset of the disease, we screened the DNA from 39 healthy dogs 
for the same polyglutamine region in TET2 exon 11. Subsequently, considering as the 
wild-type phenotype the 12 glutamine repetitions presented in the reference NCBI 
sequence (XM_535678-4) we categorized all samples (healthy and pathologic) in 
three groups: samples that evidenced less than 12 glutamines (Q<12), wild-type dogs 
and samples with more than 12 glutamines (Q>12). From the contingency table and 
the Pearson χ2 test, no significant correlation emerged between the number of 
glutamine repetitions and the risk to develop mast cell tumor (Figure 2). 
 
Figure 2. Association 
between the number of 
glutamine (Gln) 
repetitions and 
healthy/pathologic state 
in 114 canine blood and 
MCT samples. Pearson 
χ2 test (p = 0.3454; not 
significant). 
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6.5 DISCUSSION 
Mast cells (MCs) neoplastic disorders occur in both canine and human species 
sharing many but not all biological and clinical features. Spontaneous MCT has been 
proposed as a model to study biological and therapeutic approach for human 
neoplastic MCs diseases, i. e. mastocytosis (Ranieri et al., 2015). At the same time, 
due to the implications of c-KIT aberrations in the development of MCs tumors, 
canine MCT could represent a useful model to study human c-KIT driven 
malignancies and TKIs, targeting c-kit. Therefore, comparative studies of MCs 
disorders may represent an opportunity to improve our knowledge on both 
mastocytosis and c-KIT driven tumors for diagnosis in case of c-KIT wild type state 
and/or with the aim to develop novel treatment options that can be translated in 
human patients.  
In this respect, starting from a list of genes that showed recurrent somatic 
mutations in human myeloproliferative diseases and mastocytosis, we screened a 
cohort of 75 canine MCTs for hot-spot mutations sites. 
No mutations were identified in IDH1 and IDH2 genes in our cohort of MCTs 
while, in SM, IDH2 mutations occurred for 6.9% of cases (Hanssens et al., 2014). To 
the best of our knowledge, only one study has been published in dog (Reitman et al., 
2010) where no mutations in both these genes were found in canine gliomas. 
Considering the high percentage of mutations in the human analog tumor ( ̴ 80% in 
grades II-III) these results were surprising and might suggest a minor role of these 
genes in the pathogenesis of canine gliomas and MCT.  
In SM, two genes involved in spliceosome machinery, SRSF2 and SF3B1, 
showed a mutation occurrence of 24% and 5.6% respectively (Hanssens et al., 2014). 
However, no mutations were detected in canine MCT. No data about the relevance of 
these genes and their mutational status in canine oncology are actually available; 
therefore, present results, are the first data ever published so far. 
On the other hand, more information are available about NRAS and KRAS, in 
dog cancer. Present results showing the absence of mutations obtained in our MCTs 
samples are consistent with a number of previously published studies in which RAS 
mutations have been shown to be extremely rare in the most common types of canine 
tumor such as mammary tumors, soft-tissue tumors (included MCTs), melanomas 
and lymphoproliferative disorders (Watzinger et al., 2001; Terragni et al., 2014). In 
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contrast, higher mutational frequencies of RAS genes have been obtained in human 
lung, pancreatic, gastrointestinal, brain and liver tumor, in acute myelogenous 
leukemia, in follicular and undifferentiated papillary thyroid tumors (Richter et al., 
2005). Therefore and likewise to IDH1/2 we might hypothesized that RAS mutations 
do not play a major role in the pathogenesis of canine MCT and this supposition is in 
line with previously published data (Watzinger et al., 2001). 
About TET2, the high percentage of mutations found in aggressive form of 
human mastocytosis (20.8%) was not confirmed in canine MCT (2.7%). Moreover, 
the typical frame-shift mutations observed in humans and coding for a truncated 
protein with consequently loss of function, was never observed. These results 
surprised the authors and, until this moment, represented the first attempt, in 
veterinary medicine, to investigate the role of TET2 mutations in a canine tumor 
since no information are available in previous published studies. 
Noteworthy, a frequent rearrangement was observed in a glutamine-rich region 
of TET2 exon 11, resulting in variations of the number of glutamine repetitions (from 
8 to 13) among cases. Very little information are actually published in human 
oncology about a possible relationship between length of polyglutamine regions in 
some genes and the risk to develop cancer. The number of CAG repetitions in 
androgen receptor seems to be correlated with the risk of occurrence of prostate 
cancer; furthermore polymorphisms in glutamine regions of nuclear receptor 
coactivator 3 (NCOA3 also known as AIB1) seems to play a role in the susceptibility 
of some type of breast cancer (Ingles et al., 1997; Kadouri et al., 2004; Yoo et al., 
2014). The sequencing analysis conducted in a little group of healthy dogs and 
matched statistically with results of MCT samples did not reveal any significant 
relationship between number of glutamine repetitions and the risk of MCT 
development.  
In conclusion, this preliminary study aimed to investigate, in canine MCT, the 
mutational status of genes known to be involved in human myeloproliferative 
disorders. The study was undertaken in a relatively small cohort of canine samples, 
and only human analogue hot-spot sites for mutation were took into consideration. 
Further investigations are needed to better characterize the pathogenic pathways 
involved in both diseases. Among these ones, to sequence the entire IDH1, IDH2, 
NRAS, KRAS, SRSF2 and SF3B1 genes and, subsequently, to analyze interesting 
genes that were excluded from this preliminary study (i. e. Additional Sex Combs 
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Like 1 alias ASXL1, Janus Kinase 2 alias JAK2). Clearly, the advent of deep 
sequencing methods might be more useful in this sense, giving a more wide 
observation on genome modifications and allowing the identification of new hot-spot 
mutation sites in canine genes. This approach will permit to clarify the possible value 
of canine MCT as a comparative animal model for human SM. 
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7. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The c-KIT gain of function mutations and overexpression are driven events in 
several highly malignant human (GIST, AML, melanoma) and canine tumors (MCT, 
melanoma). Tyrosine kinase inhibitors are a class of anti-cancer drugs inhibiting the 
phospho-activation of c-kit protein, but despite their use is directly linked to tumor 
regression, the onset of resistance is likely to occur, sometimes after several years of 
therapy, in most patients. The heterogeneity of patterns of mutations in the protein 
and in the resistance mechanisms suggests that the clinical challenges of resistance 
still remain to be overcome (Gunaratnam et al., 2009). 
The first part of this thesis described an alternative approach to inhibit human c-
KIT by using an anthraquinone derivative (AQ1). The compound was previously 
selected among a library of putative G4 ligands by the Department of Pharmaceutical 
Sciences. In this work, AQ1 blocked the proliferation of multiple cancer in vitro 
models. It also decreased c-KIT expression in human cancer cells with an inhibition 
rate that is, to the best of our knowledge, one of the highest ever noticed. 
Contextualizing this study in the G4 research field, one of its merits stands in the use 
of multiple cancer cell lines to test AQ1 in different cancer types. Also the two-
variants statistical approach represented an innovation aspect in these types of 
complex studies that could provide more robust results. Moreover the use, for the first 
time, of in vitro model engineered for expressing a promoter free from G4 could be 
an helpful tool to check deeper the specificity of ligands. Actually, a major 
impediment to the validation of G4 DNA as a new anti-cancer drug target is the lack 
of small molecules that bind to G4 DNA with high affinity (Kd<1 nM) and high 
specificity (Luedtke et al., 2009). However, the potentialities of G4 compounds as 
alternative to the current TKIs therapies (imatinib) were evidenced in the treatment of 
c-KIT mutated cells comparing to the wild type.  
In the past decades, the domestic dog has gained increasing interest as one of 
the most suitable animal model for comparative oncologic studies on tumor 
molecular mechanisms as well as for the identification and validation of new 
therapeutic targets. The lack of information about G4 presence in dogs, prompt us to 
investigate canine c-KIT promoter. Two putative G4 sequences were identified; these 
ones comprise a putative Sp1 transcriptional binding site and mimic the situation 
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present in the human DNA (Da Ros et al., 2014). The treatment of a canine MCT cell 
line with the same ligands used for human cells evidenced two putative efficient c-
KIT inhibitors, suggesting that differences in the G-strands base composition can 
affect affinity and, consequently, the ligand binding. 
Besides this encouraging results in both species, further experiments are needed 
to confirm the validity of these ligands as possible therapeutic tools. For example, 
gene reporter assays should be performed to verify whether ligands inhibit gene 
transcription through a specific binding to G4 conformations in both human and 
canine cells. Particularly in dogs, transcription regulatory elements found in c-KIT 
promoter are still undefined; moreover, the Sp1 domain, comprised between the two 
G4 regions, has not yet been characterized. Further studies, aiming to investigate the 
c-KIT downstream activation pathways, should also be undertaken to clarify which 
type of cellular damage occur following the exposure to AQ1 and AN6. 
Results exposed in chapter 5 represented the first investigation in veterinary 
medicine about the c-KIT mutational status in mast cell tumor and relative 
metastases. In our study, the perfect concordance between primary lesion and relative 
metastases was detected, and it has important clinical implications; both matrices can 
be sampled by veterinarians for the mutational screening analysis and, the eventual c-
KIT targeted therapeutic approach should be successful also against metastases. The 
small cohort of samples could represent a limit of this study and also the 
heterogeneity in the treatment protocols used. In this respect, future perspectives 
might be the analysis of an increased number of MCTs that underwent the same 
treatment. Furthermore, distal metastases should be inserted in the investigation as 
well as the multicentric MCTs to ascertain whether multiple masses are likely to 
present the same c-KIT mutational profile.  
In general, further efforts should be spent to better understand MCT molecular 
biology; in this respect, the last study here presented offered an insight about the 
possible involvement of common genes in the pathogenesis of human systemic 
mastocytosis and canine MCT. The absence of mutations in genes considered as 
hotspots for SM suggest that the two diseases might differ in terms of gene-related 
pathogenetic pathways. From a comparative point of view, data obtained suggest 
researchers to be cautious in assuming canine MCT as a model for SM. A limit of the 
present work consist in the screening of only a restricted number of genes; as a matter 
of fact, the use of high-throughput methodologies, such as next generation 
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sequencing techniques, might give a wider view of cell pathways involved in tumor 
progression. Worth mentioning, a full, in-depth characterization of canine MCT 
transcriptome has only recently been considered (Giantin et al., 2014; Giantin et al., 
submitted); nevertheless, most of molecular mechanisms involved in tumoral onset 
and progression are still unknown and need more efforts to be spent for their 
characterization.  
In conclusions, the research activities conducted in the three-years of Ph.D. 
program allowed to clarify some scientific gaps about c-KIT, and other related genes, 
in specific tumors, and identify new targets and strategies for canine and human 
anticancer chemotherapy. This work could lay the foundations of deeper 
investigations about the therapeutic usefulness of the c-KIT G4 ligands AQ1 and 
AN6, as well as the reliability of canine MCT as a model for other human c-KIT 
dependent tumors. 
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